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Abstract
Neurodegenerative tauopathies are characterized by the abnormal accumulation of tau protein inside
neural cells. The most common neurodegenerative disease, Alzheimer’s disease (AD), is one such
tauopathy, in which tau tangles contribute to both the neurodegeneration and clinical progression of the
disease. In other tauopathies like corticobasal degeneration (CBD) and progressive supranuclear palsy
(PSP), tau inclusions are the most prominent neuropathological feature, solely contributing to the clinical
symptoms and disease progression in those patients. Yet, tauopathies are highly diverse, with distinct
clinical features and neuropathological lesions, despite the common aggregation of tau protein. One
hypothesis that has emerged in the field is that misfolded tau protein can acquire multiple different
structural conformations, known as tau strains, which differentiate unique tauopathies. This dissertation
will test the hypothesis that tau strains derived from human tauopathy brains underlie the diversity of
tauopathies. First, I describe a novel mouse model utilizing human post-mortem brain-derived tau
aggregates to seed tau pathology in nontransgenic (nonTg) mouse brain (Chapter 2). Then I describe
using this nonTg mouse model to show tau strains derived from different human tauopathy brains have
distinct seeding potencies and cell-type specificities that recapitulate the diversity of tauopathies
(Chapter 3). From this study, I found a unique spatiotemporal transmission of glial tau pathology
following injection of certain tau strains. Therefore, I examine the novel relationships between neuronal
and glial tau in seeding and spreading tau pathology in the mouse brain in Chapter 4. This dissertation
demonstrates tau strains do exist in human tauopathy brains, and they play a key role in generating the
unique neuropathologies of different tauopathies.
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ABSTRACT
THE ROLE OF TAU STRAINS IN GENERATING THE DIVERSITY OF HUMAN
TAUOPATHIES
Sneha Narasimhan
Virginia Man-Yee Lee
Neurodegenerative tauopathies are characterized by the abnormal accumulation
of tau protein inside neural cells. The most common neurodegenerative disease,
Alzheimer’s disease (AD), is one such tauopathy, in which tau tangles contribute to both
the neurodegeneration and clinical progression of the disease. In other tauopathies like
corticobasal degeneration (CBD) and progressive supranuclear palsy (PSP), tau
inclusions are the most prominent neuropathological feature, solely contributing to the
clinical symptoms and disease progression in those patients. Yet, tauopathies are highly
diverse, with distinct clinical features and neuropathological lesions, despite the common
aggregation of tau protein. One hypothesis that has emerged in the field is that
misfolded tau protein can acquire multiple different structural conformations, known as
tau strains, which differentiate unique tauopathies. This dissertation will test the
hypothesis that tau strains derived from human tauopathy brains underlie the diversity of
tauopathies. First, I describe a novel mouse model utilizing human post-mortem brainderived tau aggregates to seed tau pathology in nontransgenic (nonTg) mouse brain
(Chapter 2). Then I describe using this nonTg mouse model to show tau strains derived
from different human tauopathy brains have distinct seeding potencies and cell-type
specificities that recapitulate the diversity of tauopathies (Chapter 3). From this study, I
found a unique spatiotemporal transmission of glial tau pathology following injection of
certain tau strains. Therefore, I examine the novel relationships between neuronal and
v

glial tau in seeding and spreading tau pathology in the mouse brain in Chapter 4. This
dissertation demonstrates tau strains do exist in human tauopathy brains, and they play
a key role in generating the unique neuropathologies of different tauopathies.
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CHAPTER 1: INTRODUCTION
1.1 Tau protein structure and function
Tau is a microtubule-binding protein primarily expressed in the axons of neurons
where it promotes the assembly and stability of microtubules (Cleveland et al., 1977;
Drechsel et al., 1992). The tau protein is encoded by a single gene with 16 exons found
on chromosome 17q21 (MAPT gene), whereby the full-length tau protein consists of 441
amino acids. The tau protein can be divided into four domains: the N-terminal acidic
projection domain (1-150 amino acids), the proline-rich domain (151-243 amino acids),
the microtubule binding domain (244-369 amino acids), and the C-terminal tail (370-441
amino acids) (Guo et al., 2017). The microtubule-binding region of tau contains the 4
repeat regions, while the projection domain interacts with other cytoskeletal proteins and
the plasma membrane (Buee et al., 2000).
However, the single tau gene is alternatively spliced at the mRNA level to
produce six different isoforms of tau, ranging from 352 to 441 amino acids (Lee et al.,
2001). In particular, exon 10 of MAPT found within the microtubule-binding region codes
for 1 of the 4 repeats in this region; the splicing in of exon 10 results in tau protein with 4
repeats, known as 4R tau, while the splicing out of exon 10 results in 3 repeats or 3R tau
(Goedert et al., 1989). These different tau isoforms can be separated on a SDS-PAGE
gel between the molecular weights of 48 to 67 kDA (Guo et al., 2017). The alternative
splicing of tau is developmentally regulated such that only the shortest tau isoform
(3R/0N) is expressed in fetal brain, while all six isoforms are expressed in the adult
human brain. The 3R and 4R tau isoforms are equally expressed in adult human brain.

1

Furthermore, adult mouse brain only expresses the 4R tau (three out of the six isoforms)
(Lee et al., 2001).
Tau is normally a natively unfolded protein, giving it a highly flexible conformation
without well-defined secondary or tertiary structures (Guo et al., 2017). Nonetheless,
local folding of tau has been described, including differences when tau is bound to
microtubules versus in the free state in the cytoplasm. The microtubule-binding domain
of tau binds to microtubules near the C terminus of the protein, while the N terminus
projects away from the microtubules. However, in the unbound state, it has been
proposed that tau acquires a “paperclip” formation whereby the N and C terminus
interact with each other, causing the tau protein to fold over (Guo et al., 2017). These
interactions may become important during tau misfolding and aggregation in disease.
More recently, it has been suggested tau may undergo liquid-liquid phase separation,
thereby forming membrane-less compartments in which it could interact with other tau
molecules and increase its propensity for aggregation (Ambadipudi et al., 2017).
While tau has many well-defined functions, its most notable role is to stabilize
microtubules and promote microtubule assembly. The binding of tau to microtubules is a
complex process regulated by many factors. For example, 4R tau isoforms have higher
binding affinity to microtubules than 3R tau isoforms, and thereby promote microtubule
assembly more efficiently (Lee et al., 2001). More importantly, tau phosphorylation plays
a key role in both its normal function and in disease. Out of 79 potential phosphorylation
sites on serine and threonine residues of tau, approximately 30 have been reported in
normal tau protein (Buee et al., 2000). Fetal tau is more phosphorylated than in adult
human brain, and tau phosphorylation declines with age. Most of the phosphorylation
sites are found in the regions of the protein surrounding the microtubule-binding region,
2

and it is now well-known that tau phosphorylation decreases its affinity for binding to
microtubules (Lee et al., 2001). The role of phosphorylation on specific sites in
microtubule-binding regulation is still being investigated, but sites both around the
microtubule-binding domain and in other regions of the protein such as the proline-rich
domain have been implicated in this regulation. It is important to note that while
phosphorylation is involved in the normal function of tau, in disease, tau becomes
abnormally hyperphosphorylated (Lee et al., 2001).
Several in vitro studies have implicated various protein kinases that regulate tau
phosphorylation, including glycogen synthase kinase 3 (GSK-3), cyclin-dependent
kinase 2 (cdk2), cdk5, mitogen-activated protein kinase (MAPK), cAMP-dependent
protein kinase, CA2+/calmodulin-dependent protein kinase II, and MT-affinity regulating
kinase (Buee et al., 2000). However, since most of these studies were conducted in
vitro, the role of these kinases in vivo is still poorly understood. Two of the kinases,
GSK-3 and cdk5, have also been studied in vivo to show they regulate tau
phosphorylation and microtubule stability, implicating them in a significant role in tau
function (Lee et al., 2001). Similarly, several phosphatases have been implicated in tau
dephosphorylation, including PP1, PP2A, PP2B, and PP2C (Buee et al., 2000).
Other reported functions of tau include synaptic plasticity in hippocampal
neurons, tau membrane interactions with roles in neurite development and intracellular
signaling cascades, DNA stability, and epigenetic regulation, although many of these are
less well characterized (Guo et al., 2017). Embryonic knockout (TauKO mice) of tau
does not lead to an overt phenotype, likely due to compensation by other microtubuleassociated proteins (Lee et al., 2001). However, some groups have reported subtle
changes with TauKO mice particularly with age, including behavioral abnormalities such
3

as muscle weakness and hyperexcitability, decreased hippocampal neurogenesis, and
decreased neuronal hyperexcitability or susceptibility to seizures (Ikegami et al., 2000;
Roberson et al., 2007).
1.2 The role of tau protein in neurodegenerative diseases
Although tau is normally highly soluble, it can abnormally misfold and assemble
into highly ordered paired helical filaments (PHFs), one of the key pathological hallmarks
of Alzheimer’s disease (AD) (Lee et al., 1991). Tau aggregates in a group of
neurodegenerative diseases collectively known as tauopathies, with AD as the most
common tauopathy. The exact mechanism by which tau forms pathological aggregates
and causes neurodegeneration is unknown, yet several lines of evidence support the
causative role of tau in neurodegenerative tauopathies (Ballatore et al., 2007b).
The most direct evidence of tau’s causative role in neurodegenerative disease is
the discovery of genetic mutations in MAPT associated with frontotemporal dementia
with parkinsonism linked to chromosome 17 (FTDP-17) cases (Ballatore et al., 2007b).
All cases of FTDP-17 contain tau aggregates only, thereby showing tau alone can cause
neurodegenerative disease. The exonic tau mutations have since been shown to
predispose tau to fibrillize, increase tau’s propensity for phosphorylation, or impair tau
binding to microtubules (Dayanandan et al., 1999; Nacharaju et al., 1999; von Bergen et
al., 2001; Alonso Adel et al., 2004; Goedert and Jakes, 2005). Furthermore, intronic
mutations as well as mutations in exon 10 of MAPT have been shown to affect the
splicing in or out of exon 10, thereby changing the ratio of 4R:3R tau isoforms and
increasing the aggregative potential of tau.
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While genetic mutations identified in the MAPT gene have been causally linked
to neurodegeneration, the majority of tauopathies are sporadic (no known genetic
mutation); in particular, no known tau mutations have been linked to Alzheimer’s
disease. In sporadic disease, some unknown event causes the initial misfolding of tau,
including the hyperphosphorylation of tau or other covalent modifications of tau. As
already described, several known kinases and phosphatases are involved in
physiological tau phosphorylation and dephosphorylation. However, some of these
proteins have also been implicated in the hyperphosphorylation of tau in disease,
including GSK3, CDK5, MARK, PP1, PP2A, PP2B, and PP2C.
It is thought that early deposits of tau, known as pretangles, contain aggregated
hyperphosphorylated tau without enriched β-sheet structures. The hyperphosphorylation
of tau decreases its binding to microtubules and thereby increases soluble cytosolic tau
concentrations. This allows for tau to aggregate in the cytosol, and eventually mature
from pretangles into β-sheet-rich PHFs. The loss of tau binding to microtubules
decreases microtubule stability, and the formation of NFTs may disrupt normal cellular
functions, leading to compromised axonal transport, synaptic dysfunction and eventually
neuron death. However, this is only one of many potential mechanisms hypothesized in
the field. The progression of tau pathology can be studied using various anti-tau
antibodies, including AT8 (pSer202/205), PHF-1 (pSer396/Ser404), and AT180
(pThr231) for hyperphosphorylated tau in pretangles, MC1 and TG3 for aggregated tau
in a more mature state (conformationally-specific antibodies), and Thioflavine S to bind
β-sheets in mature tau tangles (Ballatore et al., 2007a).
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1.3 Prion-like propagation of pathological tau
Some of the earliest studies investigating the pathogenesis of AD showed that
tau aggregates appear in different brain regions in a stereotypical manner over time
(Braak and Braak, 1991; Braak et al., 2011; Braak and Del Tredici, 2012). Earliest tau
aggregates were found in the locus coeruleus of the brainstem in normal aged brains
and even brains from young adults. Over the progression of AD, tau accumulated in the
transentorhinal cortex (Braak stage I-II), then spread to the hippocampus and medial
temporal lobe (Braak stage III-IV), and then finally into neocortical areas at the end stage
of disease (Braak stage V-VI). It was initially thought this stereotypical progression was
due to the selective vulnerability of particular regions to forming tau tangles; however,
collective evidence from our lab and others have now shown pathological tau may
propagate from neuron to neuron in a prion-like manner, accounting for the stereotypic
spread of NFTs through anatomically connected regions (see Table 1-1).
Several published studies, including those from our lab, have now shown that
misfolded tau can “seed” endogenous tau to form pathological tau aggregates in cell
culture models (Frost et al., 2009; Nonaka et al., 2010; Guo and Lee, 2011; Kfoury et al.,
2012; Guo and Lee, 2013; Holmes et al., 2013; Ahmed et al., 2014; Sanders et al.,
2014b; Takahashi et al., 2015; Usenovic et al., 2015; Guo et al., 2016). Although the
exact mechanism underlying this transmission is unknown, it is thought that normal tau
protein becomes misfolded and aggregates into fibrils to form NFTs, which then release
seeds (small fibrillar species from the larger aggregate) from one neuron into the
extracellular space. A neighboring neuron then takes up the released seeds, which then
recruit endogenous tau into a pathological conformation, whereby the endogenous tau of
the recipient neuron aggregates into fibrils and perpetuates this process (called seeded
6

fibrillization) (Figure 1-1). There is now some evidence that tau fibrils are released by
cells in culture (Kfoury et al., 2012), taken up by neighboring cells through fluid-phase
endocytosis (Frost et al., 2009; Guo and Lee, 2011), and induce fibrillization of native tau
protein through direct protein-protein interactions (Kfoury et al., 2012).
However, the most convincing evidence in support of the transmission
hypothesis comes from studies using mouse models of tauopathies. Almost all of the
studies describing tau transmission in vivo have used transgenic mouse models that
overexpress different forms of human tau, often with a MAPT (tau) mutation (Table 1-1).
The most common transgenic mice used include the PS19 mouse model developed in
our lab (1N4R human tau overexpression with P301S mutation), and the Alz17 mouse
model (2N4R human wild-type tau overexpression). While some of these transgenic
mouse models develop tau aggregates on their own over long periods of time,
intracerebral injection of pathological tau seeds hasten the formation and spreading of
tau aggregates in the mouse brain (Clavaguera et al., 2009; Clavaguera et al., 2013; Iba
et al., 2013; Ahmed et al., 2014; Holmes et al., 2014; Sanders et al., 2014b; Boluda et
al., 2015; Falcon et al., 2015; Iba et al., 2015; Peeraer et al., 2015; Stancu et al., 2015;
Hu et al., 2016; Jackson et al., 2016; Kaufman et al., 2016; Polanco et al., 2016).
Studies have used different sources of tau seeds, including synthetic tau preformed
fibrils, extracts from transgenic mouse brains, or extracts from human tauopathy brains,
all with reasonable success in seeding tau pathology in transgenic mice.
Another model of tau transmission uses restricted overexpression of human tau
in one specific brain region and describes the spread of tau aggregates to other regions

7

Figure 1-1: Schematic of cell-to-cell transmission of pathological tau. Diagram shows two
neurons, the yellow neuron on the left initiated tau fibrillization. Small misfolded seeds (red) are
released from yellow neuron via 3 potential mechanisms: (1) native release; (2) exosomes; (3)
nanotubes. Then the misfolded seed is internalized via native uptake, endocytosis, or tunneling
nanotube, whereby it gains access to normal tau monomers in the blue neuron (black) to
perpetuate the seeded fibrillization process.

over time. The most prominent model for this is the rTgTauEC mouse, which restricts
expression of human tau with the P301L mutation to the entorhinal cortex, but shows tau
aggregates forming in anatomically connected regions as the mouse ages (de Calignon
et al., 2012; Pooler et al., 2015; Wegmann et al., 2015). Injection of AAV virus
overexpressing human 2N4R tau with the P301L mutation into specific brain regions has
also been used to study tau propagation over time (Asai et al., 2015).
All of these studies collectively suggest tau aggregates spread from one brain
region to another via the neuronal anatomical connectome, similar to what is observed in
the human disease (Guo and Lee, 2014). However, there is still some selective
vulnerability of certain regions to develop tau pathology in these models, as not every
8

region that is anatomically connected to the initiation site develops pathology (Iba et al.,
2013; Iba et al., 2015). This mirrors what occurs in human AD, as the stereotypical
Braak progression of tau tangles does not target every anatomically connected region
from each site. The properties that make certain regions vulnerable to tau aggregates
and neurodegeneration are still unknown.
1.4 Clinical and neuropathological variation in tauopathies
Tauopathies vary greatly in clinical symptoms and in the neuropathological
distribution of tau pathology. AD is clinically characterized by early memory loss and
eventual dementia (Lee et al., 2001). As previously described, tau deposits in AD are
initially found in the hippocampus and entorhinal cortex, and eventually spread into the
medial temporal lobe and neocortical areas (Braak and Braak, 1991; Braak et al., 2011;
Braak and Del Tredici, 2012). In AD and some other tauopathies, tau aggregates are
composed of all six isoforms of tau (both 3R and 4R tau) primarily in neuronal cell bodies
(neurofibrillary tangles or NFTs) and in axons (neuropil threads) (Lee et al., 2001).
In contrast, corticobasal degeneration (CBD) and progressive supranuclear palsy
(PSP) patients have an earlier onset and shorter duration of disease than AD patients,
and primarily show motor dysfunction (Lee et al., 2001). CBD patients exhibit motor
deficits such as ataxia, tremors, stiffness, and akinesia, while PSP patients classically
have a downward gaze palsy, in addition to rigidity and postural instability. In CBD, tau
aggregates are found in the cerebral cortex, basal ganglia, deep cerebellar nuclei, and
substantia nigra. They are composed primarily of 4R tau isoforms in both neurons and
glia in CBD, including astrocytic plaques and oligodendroglial coiled bodies (Lee et al.,
2001). Classical PSP is characterized by tau aggregates in primarily subcortical regions,
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such as midbrain and basal ganglia (Williams and Lees, 2009). Similar to CBD, PSP tau
aggregates are composed of 4R tau isoforms in both neurons and glia, including tufted
astrocytes and oligodendroglial coiled bodies (Lee et al, 2001). The mechanism
underlying this clinical and neuropathological diversity of tauopathies is unknown.
1.5 Pathological tau strains and the heterogeneity of tauopathies
The prion protein can misfold into different structural conformations from the
same native protein, known as prion strains, which give rise to phenotypically diverse
prion diseases (including Creutzfeldt-Jakob disease (CJD), bovine spongiform
encephalopathy (BSE), and transmissible mink encephalopathy (TME)). These prion
diseases can arise sporadically, inherited as autosomal dominant diseases, or acquired
by infection. The prion strains are not determined by the primary protein sequence, as
they can be developed in mice with the exact same PrP (prion) gene, suggesting the
strains are determined by their secondary or tertiary structures (Collinge and Clarke,
2007). Indeed, these prion strains have different biochemical properties, including
different fragment sizes after limited proteolysis, thermal or chemical denaturation
curves, conformation-dependent immunoassay, infrared spectroscopy and metal
binding. These biochemical properties are maintained as the prion strain is passaged in
intermediate species with similar or different PrP primary structures (i.e., mouse brain).
By definition, the biochemical properties of prions strains must determine the
molecular basis of prion disease diversity by imposing their characteristics on a recipient
PrP protein from the same or different species. This has been extensively studied
through transmission studies of human prion strains in nontransgenic mice, showing
distinct incubation periods and patterns of neuropathology as in the unique prion
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diseases. The recapitulation of features of the human prion diseases in mouse models
via propagation of the prion protein has been critical in understanding how different prion
strains cause these heterogeneous diseases (Collinge and Clarke, 2007).
In parallel, it has been proposed that diverse tau strains may account for the
heterogeneity of sporadic tauopathies described above (Figure 1-2). A few prior studies
began to investigate the existence of tau strains and their role in the diversity of
tauopathies. One study showed seeding HEK293 cells overexpressing the microtubulebinding domain of tau (RD domain) with different tau fibrils in resulted in different
patterns of intracellular inclusions (Sanders et al., 2014a). They described these different
patterns of cellular inclusions as distinct tau strains, which were shown to propagate
indefinitely in culture. Similar to prion strains, they showed by limited proteolysis that
these tau strains have different protease-resistant banding patterns, suggestive of
different structural tau conformations. Furthermore, they showed these tau strains
derived in culture could induce different patterns of tau aggregates in the PS19 mouse
model, and that these patterns could be serially propagated in mice via intracerebral
injection of a strain derived from one mouse brain into another. More recently, the same
group showed these artificially-derived tau strains could dictate rate of progression,
cellular distribution, and regional selectivity of tau aggregate formation in the PS19
mouse model (Kaufman et al., 2016). Yet, the caveat of this study was the use of
artificially-derived tau strains from HEK293 cells, which may not recapitulate tau strains
found in human tauopathies.
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Figure 1-2: Schematic of the formation of different tau strains. Normal tau monomer (in black) can
misfold to form different structural conformations or strains (red, aqua, and yellow). These specific strains
can continue to recruit more normal tau monomer to misfold in the same conformation, perpetuating the
fibrillization of distinct strains.

In contrast, another study extracted pathological tau from human tauopathy
brains and injected each lysate into the Alz17 mouse brain (overexpressing wild-type
human tau) (Clavaguera et al., 2013). They showed different cell-type specificity of each
tauopathy lysate corresponding to the human neuropathology: for example, injections of
AD lysate resulted in neuronal tau pathology, whereas injection of CBD or PSP lysate
resulted in glial tau pathology. Yet, when they injected the same lysates into wild-type
(nonTg) mice, they needed to incubate the mice for a very long period of time (12-18
months), and still only observed the induction of tau aggregates in a few cells. While this
was the first study to suggest pathological tau from different human tauopathy brains can
seed different patterns of tau pathology in mouse brain, they did not further characterize
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this pathological tau to show they are bona fide tau strains. Furthermore, they were
unable to describe any differences between the patterns of tau pathology beyond the
cell-type specificity of different tauopathy lysates.
One final study showed differences in C-terminal tau fragments following
protease digestion of sarkosyl-insoluble tau from AD, CBD, and PSP brains, similar to
what is observed for different prion strains (Taniguchi-Watanabe et al., 2016). This was
the first piece of evidence to suggest tau aggregates derived from human brain may
form distinct structural conformations. Taken together, these studies suggest tau strains
may exist in different tauopathies, and they may account for some of the heterogeneity
observed in these diseases. However, given that the previous studies investigating the
transmission of tau strains primarily used transgenic mice, the overarching goal of this
thesis was to develop a sporadic tauopathy model using nontransgenic (nonTg) mice to
study the unique properties of human tau strains. Then, this novel sporadic tauopathy
model can be used to understand how the different properties of human tau strains give
rise to neuropathological variation in these tauopathies.
1.6 TABLES
Table 1-1: Tau transmission studies using transgenic mouse models
Transgenic
Tau
References
Mode of
Type of seeds
mouse line
Expression
transmission

Alz17

2N4R human
WT tau

(Clavaguera et
al., 2009)

Intracerebral
injection

Brain extract
from P301S
transgenic
mouse

(Clavaguera et
al., 2013)

Intracerebral
injection

Human
tauopathy brain
lysate
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(Iba et al.,
2013; Iba et
al., 2015;
Stancu et al.,
2015)

PS19

(Holmes et al.,
2014; Sanders
et al., 2014b;
1N4R human Kaufman et al.,
tau with P301S
2016)
mutation
(Boluda et al.,
2015)
(Ahmed et al.,
2014; Falcon
et al., 2015;
Jackson et al.,
2016)

Intracerebral
injection

Preformed
fibrils (PFFs)
from
recombinant
tau

Intracerebral
injection

Lysates from
HEK293 cells
with tau
aggregates

Intracerebral
injection

Human
tauopathy brain
lysate

Intracerebral
injection

Mouse brain
lysate

P301L

2N4R human
tau with P301L
mutation

(Peeraer et al.,
2015)

Intracerebral
injection

Preformed
fibrils (PFFs)
from
recombinant
tau

rTg4510

Inducible
0N4R human
tau with P301L
mutation

(Polanco et al.,
2016)

Intracerebral
injection

Exosomes
from same
transgenic
mouse brains

Htau

All six human
tau isoforms
with mouse tau
KO

(Hu et al.,
2016)

Intracerebral
injection

Human AD
brain lysate

rTgTauEC

Entorhinalcortex specific
expression of
human tau
with P301L
mutation

(de Calignon
et al., 2012;
Pooler et al.,
2015;
Wegmann et
al., 2015)

Restricted
expression of
tau

Endogenously
expressed
human tau

AAV
overexpression
of human tau

AAV with
human 2N4R
tau with P301L
mutations

(Asai et al.,
2015)

Restricted
expression of
tau

AAV expressed
human tau

*Reprinted with permission from Narasimhan and Lee (2017) The use of mouse models
to study cell-to-cell transmission of pathological tau. Methods in Cell Biology.
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CHAPTER 2: DEVELOPING A NOVEL SPORADIC TAUOPATHY MOUSE
MODEL
This research was originally published in Journal of Experimental Medicine and reprinted
here with permission: Guo JL, Narasimhan S, Changolkar L, He Z, Stieber A, Zhang B,
Gathagan RJ, Iba M, McBride JD, Trojanowski JQ, Lee VM (2016) Unique pathological
tau conformers from Alzheimer's brains transmit tau pathology in nontransgenic mice.
The Journal of experimental medicine 213:2635-2654
2.1 ABSTRACT
Filamentous tau aggregates are hallmark lesions in numerous neurodegenerative
diseases, including Alzheimer’s disease (AD). Cell culture and animal studies showed
that tau fibrils can undergo cell-to-cell transmission and seed aggregation of soluble tau,
but this phenomenon was only robustly demonstrated in models overexpressing tau.
Here we found that intracerebral inoculation of tau fibrils purified from AD brains (ADtau), but not synthetic tau fibrils, resulted in the formation of abundant tau inclusions in
anatomically connected brain regions in nontransgenic (nonTg) mice. Recombinant
human tau seeded by AD-tau revealed unique conformational features that are distinct
from synthetic tau fibrils, which could underlie the differential potency in seeding
physiological levels of tau to aggregate. Therefore, our study establishes a mouse model
of sporadic tauopathies and points to important differences between tau fibrils that are
generated artificially and authentic ones that develop in AD brains.
2.2 INTRODUCTION
Neurofibrillary tangles (NFTs), the cytoplasmic filamentous accumulations of tau
protein, are hallmark lesions of Alzheimer’s disease (AD) and other age-related
neurodegenerative diseases, collectively termed tauopathies (Lee et al., 2001). These
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pathological tau aggregates are believed to play critical roles in neuronal dysfunction
and neurodegeneration. Increasing evidence suggests filamentous tau aggregates are
self-perpetuating entities capable of undergoing cell-to-cell transmission, whereby
extracellular tau fibrils enter cells through endocytosis and seed the recruitment of
soluble tau into growing aggregates, some of which get released and taken up by
healthy cells to induce another cycle of seeded fibrillization (Frost et al., 2009; Guo and
Lee, 2011, 2013; Kfoury et al., 2012; Wu et al., 2013). Importantly, a single intracerebral
inoculation of synthetic tau fibrils assembled from recombinant tau (rTau) protein or tau
aggregate–containing brain homogenates into transgenic (Tg) mice overexpressing tau
was shown to induce and propagate NFT-like tau pathology to anatomically connected
brain regions (Clavaguera et al., 2009, 2013; Iba et al., 2013). This connectomedependent transmission of pathological tau is proposed to underlie the stereotypical
spatiotemporal progression of NFTs in AD brains (Guo and Lee, 2014; Walker and
Jucker, 2015).
While transgenic mouse models have been used widely to study pathological tau
transmission, they have inherent limitations: they use heterologous promoters to drive
tau overexpression, making it difficult to understand how tau pathology spreads in the
human brain; furthermore, they use the overexpression of human tau, and with familial
tau mutations, which does not fully recapitulate the more common sporadic tauopathies.
Despite the widespread use of these transgenic models, there has yet to be a diseasemodifying therapy for tauopathies in clinical practice. It has been challenging to develop
a nontransgenic (nonTg) mouse model of tau propagation that fully recapitulates the
phenotypes of tauopathies. A few studies have tried to intracerebrally inject different tau
seeds into a nonTg mouse brain, but with limited success in developing a few
endogenous tau aggregates, and only after long periods of incubation (Lasagna-Reeves
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et al., 2012; Clavaguera et al., 2013a). While one of those studies used human
tauopathy brain lysates, they used a crude homogenate with no quantification of the
amount of pathological tau in their lysate; thus, low amounts of tau seeds likely account
for their limited ability to induce tau pathology in nonTg mice (Clavaguera et al., 2013b).
Recent studies have shown that different structural conformations of tau exist,
known as tau strains, and these tau strains may underlie the phenotypic diversity of
tauopathies (Sanders et al., 2014b; Boluda et al., 2015; Kaufman et al., 2016). We
hypothesize the different strains of tau seeds account for why it has been challenging to
develop a nonTg mouse model of tau transmission. In particular, we hypothesize tau
fibrils derived from human brains will be much more potent than those derived from
recombinant tau. To test this hypothesize, we describe here the development of a novel
sporadic tauopathy model using AD-brain derived pathological tau.
2.3 MATERIALS AND METHODS
Animals
C57BL6, C57BL6/C3H F1 and CD1 mice were purchased from Charles River.
Two to three month old C57BL6 and C57BL6/C3H F1 mice were used for intracerebral
inoculation of different tau fibrils. 15-19 mo old C57BL6 mice were also used for AD-tau
injection. Embryos from pregnant CD1 mice were used to obtain primary hippocampal or
cortical neurons. All animal care and experimental protocols were approved by the
University of Pennsylvania’s Institutional Animal Care and Use Committee.

Purification of Tau PHFs from AD brains
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Human brain tissues from 3 sporadic AD patients with abundant tau pathology
qualified for AD, and 2 normal controls were used in this study (see Table 2-S1). All
cases used were histologically confirmed. The use of postmortem brain tissues for
research was approved by the University of Pennsylvania’s Institutional Review Board
with informed consent from patients or their families. For each purification, 6-14 g of
frontal cortical gray matter was homogenized using a Dounce Homogenizer in 9 volumes
(v/w) of high-salt buffer (10 mM Tris-HCl at pH7.4, 0.8 M NaCl, 1 mM EDTA, 2 mM DTT,
with protease inhibitor cocktail, phosphatase inhibitor and PMSF) with 0.1% Sarkosyl
and 10% sucrose added, and centrifuged at 10,000 g for 10 min at 4°C. Pellets were reextracted once or twice using the same buffer conditions as the starting materials and
the supernatants from all 2-3 initial extractions were filtered and pooled. Additional
sarkosyl was added to the pooled low-speed supernatant to reach 1%. Following 1 hr
rotation at RT, samples were centrifuged again at 300,000 g for 60 min at 4°C. The
resulted 1% sarkosyl-insoluble pellets, which contain pathological tau, were washed
once in PBS and then resuspended in PBS (~100 µl/g gray matter) by passing through
27 G ½ inch needles. The resuspended sarkosyl-insoluble pellets were further purified
by a brief sonication (20 pulses at ~0.5 sec/pulse) using a hand-held probe (QSonica)
followed by centrifugation at 100,000 g for 30 min at 4°C, whereby the majority of protein
contaminants were partitioned into the supernatant while 60-70% of tau remained in the
pellet fraction. The pellets were resuspended in PBS at 1/2 to 1/5 of the precentrifugation volume, sonicated with 20-60 short pulses (~0.5 sec/pulse) and spun at
10,000 g for 30 min at 4°C to remove large debris. The final supernatants which contain
enriched AD PHFs were used in the study and referred to as “AD-tau”. The same
purification protocol was used to prepare brain extracts from the 2 normal controls. The
different fractions from PHF purification were characterized by Ponceau S staining,
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western blotting (refer to Table 2-S3 for antibodies), and sandwich ELISA for tau. The
final supernatant fraction was further analyzed by transmission EM, BCA assay (Fisher),
silver staining (SilverQuest™ Silver Staining Kit, Pierce), and sandwich ELISA for Aβ 140, Aβ 1-42 and α-syn.

Sandwich ELISA
The concentrations of tau, Aβ 1-40 and Aβ 1-42 in AD-tau preparations were
measured using sandwich ELISA as previously described (Lee et al., 2003; Guo and
Lee, 2011) with the following combinations of capture/reporting antibodies:
Tau5/BT2+HT7 for tau, Ban50/BA27 for Aβ 1-40, and Ban50/BC05 for Aβ 1-42. For
measuring α-syn concentrations, a 384-well NuncTM MaxisorpTM clear plate was coated
with monoclonal antibody 9027 in Takeda buffer overnight at 4°C, washed, and blocked
with Block AceTM solution (AbD Serotec) overnight at 4°C. AD-tau preparations were
diluted at 1:100 for loading onto the plate, with serially diluted recombinant α-syn
monomers used as standards. Following overnight incubation at 4°C, the plate was
washed and incubated with monoclonal rabbit antibody MJF-R1 for overnight at 4°C.
After washing and incubation with HRP-conjugated goat-anti-rabbit secondary antibody
for 1hr at 37°C, the plate was developed using 1-Step Ultra TMB-ELISATM Substrate
Solution (Fisher Scientific) for 10-15 min, quenched with 10% phosphoric acid and read
at 450 nm on a Spectramax M5TM plate reader.

Immunodepletion of Tau from AD-tau Preparations
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Monoclonal anti-tau antibody Tau5 (IgG1) was covalently conjugated to
Dynabeads® M-280 Tosylactivated (Fisher Scientific) per manufacturer's instructions.
Immunodepletion of tau was performed by incubating 200 µl of diluted AD-tau
preparations containing 2 µg tau with Tau5/bead complex containing 20 µg Tau 5
overnight at 4°C with rotation. The unbound fraction was separated from the
antibody/bead complex using a magnet, while the bound fraction was boiled with SDSsample buffer for 10 min to elute proteins from the beads. Mock immunodepletion was
performed using a control mouse IgG1 antibody that does not recognize tau.

Recombinant Tau Purification and in Vitro Fibrillization
Different isoforms of recombinant tau protein used in the study were expressed in
BL21 (DE3) RIL cells and purified by cationic exchange using a Fast Protein Liquid
Chromatography (FPLC) as previously described (Li and Lee, 2006). For heparininduced fibrillization, 40 µM recombinant T40 (4R2N tau) monomers were mixed with 10
µM or 40 µM low-molecular-weight heparin and 2mM DTT in Dulbecco’s PBS (DPBS)
without Ca2+ and Mg2+ (Cellgro, Mediatech Inc; pH adjusted to 7.0) and incubated at
37°C for 5-7 days with constant agitation at 1,000 rpm. To minimize the amount of
heparin added to neurons or injected into mice, fibrillization mixtures were centrifuged at
100,000 g for 30 min at 22°C with the resulted pellet resuspended into DPBS without
heparin and DTT. Repetitive self-seeding of tau was conducted as previously described
for α-syn (Guo and Lee, 2013a). Cofactor-free de novo fibrillization of T40 was carried
out under the same conditions as heparin-induced fibrillization except for the exclusion
of heparin from the reaction, and the resulted samples were termed passage 1 (P1). P2
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reactions were set up at 40 µM total tau, with 90% fresh monomers and 10% tau from
P1 that had been sonicated with a hand-held probe, and incubated at 37°C for 5-7 days
with constant agitation at 1,000 rpm. This process was repeated for later passages.
Sedimentation test was performed by centrifuging fibrillization products at 100,000 g for
30 min at 22°C, and equal volumes of supernatant and pellet fractions were analyzed on
SDS-PAGE followed by Coomassie blue staining. Stained gels were scanned using
ODY-2816 Imager (Li-Cor Biosciences). Repetitive self-seeded fibrillization always led to
the emergence of tau recovered in the pellet fraction at later passages, although the XT40 variant that is seeding-competent was only stochastically generated in a subset of
the self-seeding series.

Transmission EM
Negative staining EM was performed as previously described (Guo and Lee,
2011) for the different variants of tau fibrils. For double-labeling immuno-EM, samples
were absorbed onto carbon/formvar-coated copper grids for 5 min, washed 3 times for 5
min each by floating the grids on drops of PBS, and blocked for 5 min by floating on
blocking buffer containing 10% BSA, 1% fish gelatin and 0.02% sodium azide in PBS.
The grids were then incubated with two primary antibodies for 1-2 hr followed by 3 times
of 5 min wash on PBS drops and 5 min on blocking buffer. After further incubation with
anti-mouse and anti-rabbit secondary antibodies conjugated to 6 nm or 12 nm colloidal
gold (Jackson Immunoresearch) for 1-2 hr, the grids were negatively stained using 1%
uranyl acetate following 3 PBS washes and 2 distilled water washes. To rule out nonspecific binding of secondary antibodies, some experiments were performed with a
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single primary antibody but both secondary antibodies. All antibodies were diluted in
blocking buffer. Antibody solutions, blocking buffer and PBS wash solution were all
filtered through 0.2 µm syringe filters before use. All EM pictures were taken with a Joel
1010 electron microscope.

Generation of Mouse Tau-Specific Polyclonal Antibody
Polyclonal antibody R2295 was generated by immunizing rabbits with
recombinant 2N4R mouse tau (Covance Research Products Inc., Denver). The serum
was first affinity purified against human tau by passing through a NHS-activated agarose
column (Pierce) coupled to recombinant 2N4R human tau. This processed was
performed twice, whereby the eluates were collected as the fraction of antibodies
recognizing both human and mouse tau (see Figure 2-2I and J) and the flow-through
from the second pass was affinity purified using a NHS-activated agarose column
coupled to recombinant 4R2N mouse tau. The eluates from the mouse tau-coupled
column were verified to be specific to mouse tau by western blotting of recombinant tau
and immunostaining of cells expressing mouse or human tau.

Primary Neuron Culture and Fibril Treatment
Primary neuron cultures were prepared from E16-E18 embryos from pregnant
CD1 mice. Dissociated hippocampal or cortical tissues were digested with papain
(Worthington Biochemical Corp.), triturated and strained into single neurons using
FalconTM Cell Strainer (BD Biosciences), and plated onto coverslips or plates pre-coated
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with poly-D-lysine (Sigma) diluted in borate buffer (0.05 M boric acid at pH 8.5) at
100,000 cells per coverslip on 24-well plates for immunocytochemistry or 375,000 cells
per well on 12-well plates for biochemistry. Neurons were treated with tau fibrils that had
been sonicated with 60 pulses by a hand-held probe on 6 or 7 days in vitro. The amount
of tau added per coverslip/well were indicated in the figure legends. For the heparin
inhibition experiment, 50 nM heparin was added to neurons together with tau fibrils.
Immunocytochemistry or biochemical extraction was performed at 15 or 19 days after
fibril treatment.

Immunocytochemistry
Neurons were fixed with pre-chilled methanol at -20°C for 15 min or with ice-cold
4% paraformaldehyde (PFA) containing 1% Triton-X100 at RT for 15 min to remove
soluble tau. Normal tau staining was performed on neurons fixed with 4% PFA and
permeabilized with 0.1% Triton-X100. After blocking with 3% BSA and 3% FBS for at
least 1 hr at RT, cells were incubated with specific primary antibodies (see Table 2-S3)
overnight at 4°C followed by staining with appropriate Alexa fluor 594- or 488-conjugated
secondary antibodies (Invitrogen) for 2 hr at RT. Coverslips were mounted using
Fluoromount-G containing DAPI (SouthernBiotech) to label cell nuclei.
Immunofluorescence images were acquired using Olympus BX 51 microscope equipped
with a digital camera DP71 and DP manager (Olympus). For the quantification of tau
pathology shown in Figures 2-2B, whole coverslips were scanned using LaminaTM
Multilabel Slide Scanner (PerkinElmer) and quantified using the image analysis platform
HALOTM (Indica labs).
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Biochemical Extraction of Neurons and Western Blotting
To investigate the expression profile of tau isoform in cultured nonTg neurons,
cells were lysed with RIPA buffer (50 mM Tris at pH 8.0, 150 mM NaCl, 1% NP-40, 5
mM EDTA, 0.5% sodium deoxycholate, 0.1% SDS) containing protease inhibitor
cocktail, sonicated, and centrifuged at 100,000 g for 30 min at 4°C with the supernatants
saved for analysis. To confirm the induction of insoluble tau aggregates, neurons in 12well plates were scraped into 1% sarkosyl lysis buffer (1% sarkosyl in 50 mM Tris, 150
mM NaCl, pH 7.6) containing protease inhibitor cocktail, sonicated, and centrifuged at
100,000 g for 30 min at 4°C. The supernatants were saved as the “sarkosyl-soluble”
fraction, whereas pellets were re-sonicated in 1% sarkosyl lysis buffer and centrifuged
again at 100,000 g for 30 min at 4°C. The resulted pellets were resuspended in DPBS at
1/3 of the initial volume and sonicated to clear the solution, which were saved as the
“sarkosyl-insoluble” fraction. Protein concentrations in the RIPA extracts or “sarkosylsoluble” fraction were determined using BCA assay. Ten to twenty micrograms of
proteins from these fractions and equal volume of corresponding insoluble fraction were
loaded per lane on SDS-PAGE, transferred to nitrocellulose membranes, and blocked in
Odyssey blocking buffer (Li-Cor Biosciences) or 5% milk diluted in TBS before being
immunoblotted with specific primary antibodies (see Table S3). The blots were further
incubated with IRDye-labeled secondary antibodies and scanned using ODY-2816
Imager.

Stereotaxic Surgery on NonTg Mice
24

Two to three month old C57BL6 or C57BL6/C3H F1 mice, or 15-19 mo old
C57BL6 mice were deeply anesthetized with ketamine/xylazine/acepromazine and
immobilized in a stereotaxic frame (David Kopf Instruments) installed with both a
stereotaxic robot and a microinjection robot (Neurostar, Germany) for motorized,
computer-controlled injections. Animals were aseptically inoculated with synthetic tau
fibrils or human brain extracts in the dorsal hippocampus and overlying cortex of one
hemisphere (bregma: -2.5 mm; lateral: +2 mm; depth: -2.4 mm and -1.4 mm from the
skull) using a Hamilton syringe. Each of the two injection sites received 2.5 µl of
inoculum, with the synthetic tau fibrils (both Hep-T40 and X-T40 fibrils) prepared at 1.8
µg tau/µl (4.5 µg tau/site) and AD-tau prepared at 1.6 µg tau/µl (4 µg tau/site) or 0.4 µg
tau/µl (1 µg tau/site). Materials were injected into the hippocampus first (-2.4 mm from
the skull) before the needle was pulled vertically upwards to the cortical injection site (1.4 mm from the skull). We noted that the majority of the injected materials were
deposited at the dorsal hilus of hippocampus (see Figure 2-5A and B). The number and
strain of mice used for each experimental condition is summarized in Table S4.

Histology and Immunohistochemistry
Inoculated mice were sacrificed and analyzed as previously described (Iba et al.,
2013a). Briefly, animals were perfused at different time points after stereotaxic surgery
(summarized in Table 2-S4). Their brains were fixed in formalin, embedded in paraffin,
and sectioned into 6 µm thickness. Following deparaffinization and rehydration, the brain
sections were immunostained with different antibodies (see Table 2-S3) and developed
using a polymer horseradish peroxidase detection system (Biogenex) with hematoxylin
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counterstaining. ThS and AT8 double-labeling immunofluorescence was conducted to
visualize mature tangle-like tau inclusions as follows: slides were stained with 0.0125%
ThS, differentiated in 50% Ethanol/50% PBS for 30 min, and incubated overnight with
AT8 for immunofluorescence; the slides were dipped in Sudan black for 1 min before
mounting to reduce autofluorescence. For quantification of tau pathology shown in
Figures 2-3F, 2-4B and 2-4E-G as well as neuronal counts shown in Figures 2-3G and
2-4C, 2-3 brain sections containing the region of interest were selected from each
mouse, stained with AT8 for tau pathology or with an anti-NeuN antibody for neuronal
count, scanned using LaminaTM Multilabel Slide Scanner and quantified using the image
analysis platform HALOTM. Semi-quantitative analyses on the distribution of tau
pathology induced by 8 µg AD-tau/mouse injection were performed as previously
described (Iba et al., 2013), whereby the extent of AT8-positive pathology induced at 3
and 6 months p.i. was examined for every 20th of coronal sections and graded as 0-3 (0:
no pathology; 3: high pathology) for 6 coronal sections (Bregma 0.98 mm, -2.18 mm, 2.92 mm, -3.52 mm, -4.96 and -5.52 mm) that capture all affected brain structures.
Averaged scores from the 4 mice at each time point were imported into a customized
software to create heat maps of pathology distribution (Figure 2-6A).

Statistical Analyses
For data shown in Figures 2-3F-G and 2-4B-C, one-way ANOVA was performed
with Tukey’s post hoc test. For all the other statistical analyses, two-tailed unpaired
Student’s t-test was conducted for selected comparisons described in the figure legends.
Differences with p values less than 0.05 are considered significant.
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2.4 RESULTS
Generating different variants of tau fibrils with distinct seeding patterns in nonTg
neurons
To generate different variants of tau fibrils (i.e., tau strains), we performed
repetitive self-seeded fibrillization of recombinant T40 (2N4R human tau) in vitro, similar
to previous methods we used to generate different variants of α-synuclein fibrils (Guo et
al., 2013). While de novo fibrillization of T40 did not result in any insoluble tau with any
cofactors (passage 1 or P1), repetitive seeding of T40 monomers with the fibrils from the
previous passage led to an increase in insoluble tau by P4-6 (Figure 2-1A-C). The
seeded fibrillization yielded true fibrils as imaged by transmission EM (Figure 2-1C).
We then developed a sequential extraction protocol to purify insoluble tau PHFs
from human AD brains (Figure 2-1 D-F; Table 2-S1). Compared to traditional
purification methods previously developed in our lab (Lee et al., 1999), our new method
yielded higher amount of PHF-tau with high purity (hereto referred to as AD-tau; 15-30
µg tau per g of gray matter using our new protocol vs. 1-5 µg tau per g of gray matter
using the traditional protocol). Further characterization using bicinchoninic acid (BCA)
assay and sandwich ELISA showed 10-28% purity of our AD-tau preps, which also
contain minimal Aβ and α-syn (Table S2). Silver staining revealed the dominant protein
bands as tau at 50-75 kDa, and western blot for different anti-tau antibodies showed the
presence of both 3R and 4R tau isoforms in the final insoluble tau fraction (Figure 21G). Negative stain EM revealed numerous filaments of tau (Figure 2-1H).
The seeding capacity of self-seeded T40 fibrils (hereafter referred to as X-T40
fibrils) and AD-tau were compared with heparin-induced T40 (Hep-T40) fibrils in nonTg
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Figure 2-1. Preparation of different variants of tau fibrils. (A) Sedimentation test for passages 1 to 6 of
repetitively self-seeded T40 fibrillization without heparin. Supernatant (S) and pellet (P) fractions were
resolved on SDS-PAGE and stained by Coomassie blue. (B) Sedimentation test for T40 fibrils induced with
and without heparin. The heparin-free fibrils were from passage 9 or 10 of repetitively self-seeded
fibrillization as shown in (A). (C) Negative staining EM images for T40 fibrils induced with and without
heparin after sonication. Scale bar: 100 nm. (D) A schematic diagram summarizing the main steps of tau
PHF purification from AD brains. (E) and (F) Different fractions from PHF purification (refer to the schematic
in D) were immunoblotted with 17025 (a polyclonal pan-tau antibody) and PHF-1 (a monoclonal antibody
specific for tau phosphorylated at S396/S404). Ponceau S staining for the final purification steps (F)
revealed further removal of contaminants from sarkosyl pellet (SP). The final supernatant (fraction 3, red in
D) is the fraction used in the study and referred to as AD-tau. (G) Silver staining of AD-tau shows prominent
bands between 50 and 75 kDa, recognized by a panel of tau antibodies, including T14 (a monoclonal
antibody specific for human tau), 17025, PHF-1, RD3 (a 3R tau-specific monoclonal antibody) and an anti-
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4R tau polyclonal antibody. Representative preparations from the frontal cortices of 3 AD cases were shown
(1a and 1b are 2 different preparations from the same case). (H) Negative staining EM images for AD-tau
with (+) and without (-) sonication. Scale bar: 100 nm.

primary hippocampal neurons. Consistent with our previous study (Guo and Lee,
2013b), treatment with Hep-T40 fibrils resulted in limited aggregation of endogenous
mouse tau, manifested as rare puncta labeled by a mouse tau-specific antibody (T49) in
methanol-fixed neurons (Figure 2-2A and C). In contrast, the X-T40 fibrils seeded
profuse thread-like mouse tau aggregates, as did the AD-tau in nonTg neurons (Figure
2-2A and B). For both strains, the widespread mouse tau pathology mostly stayed in the
axons, although occasional perikaryal depositions occurred with X-T40 treatment
(Figure 2-2D).
To determine whether contaminating proteins in AD-tau affected the
accumulation of endogenous tau aggregates in these neurons, we immunodepleted tau
from the AD-tau preps, which abolished the seeding activity in neurons (Figure 2-2E
and F). Furthermore, when we added AD-tau immunodepleted of tau to synthetic tau
fibrils and seeded nonTg with this preparation, there was no enhancement of seeding
activity with Hep-T40 or X-T40 fibrils (Figure 2-2G and 2-2H compared with Figure 22A). This suggests extrinsic factors present in AD-tau do not directly influence the
seeding properties of these tau fibrils.
We biochemically confirmed the differential seeding activity of Hep-T40, XoT40,
and AD-tau fibrils by immunoblotting the sarkosyl soluble and insoluble fractions from
treated neurons (Figure 2-2K). Cultured nonTg neurons express both 3R and 4R mouse
tau over days in vitro (Figure 2-2I and J). While Hep-T40 did not seed any insoluble tau
biochemically, consistent with the previous immunocytochemistry results, small number
of tau X-T40 fibrils recruited only 4R tau into the insoluble fraction, while both 3R and 4R
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Figure 2-2. Different variants of tau fibrils differentially seed tau pathology in nonTg neurons. (A)
Induction of endogenous mouse tau pathology in nonTg neurons treated with the different variants of tau
fibrils (amount of tau per coverslip: 4.5 µg for Hep-T40 and X-T40, 1.5 µg for AD-tau). Neurons were
immunostained with T49, a mouse tau-specific monoclonal antibody (green). Scale bar: 100 µm. (B)
Quantification of the area occupied by mouse tau pathology normalized to total cell count, shown as mean +
SEM. (C) Immunostaining of mouse tau (T49, green) and MAP2 (polyclonal antibody 17028, red) in dPBStreated nonTg neurons fixed with 4% PFA or with cold methanol. Scale bar: 50 µm. D) The thread-like
neuritic tau aggregates induced by both X-T40 and AD-tau fibrils rarely colocalized with MAP2 staining,
suggesting their axonal location. X-T40 but not AD-tau fibrils induced tau aggregation in a subset of
neuronal cell bodies (shown by * in the top panels). Scale bar: 50 µm. (E) and (F) Mouse tau pathology
induced by AD-tau preparations after a mock immunodepletion using control mouse IgG (E) or after
immunodepletion of tau using Tau 5 (F). The volume of unbound fraction added per coverslip contained 0.2
μg of AD-tau prior to immunodepletion. (G) and (H) Mouse tau pathology induced by 4.5 µg Hep-T40 fibrils
(G) or 1.5 µg X-T40 fibrils (H) that had been mixed with tau-immunodepleted AD-tau preparations. Scale
bar: 100 µm. (I) RIPA-extracted lysates from nonTg neurons that were 6-, 10-, 15-, and 20 days in vitro
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(DIV) were probed for 3R and 4R tau expression using isoform-specific monoclonal antibodies RD3 and
RD4, respectively. Total tau was shown by K9JA (a polyclonal antibody recognizing residues 243-441 of tau)
or R2295 h&mTau. (J) Dephosphorylation of neuronal lysates showed that the 2 predominant isoforms of
mouse tau expressed in culture are the shortest ones (i.e. 3R0N and 4R0N) when aligned to the 6 isoforms
of human tau (the lane marked by *). (K) Supernatant (S) and pellet (P) fractions from 1% sarkosyl
extraction of treated nonTg neurons were immunoblotted with mouse tau-specific antibodies (R2295 and
T49). Black and red arrows indicate 4R and 3R mouse tau, respectively. *: a non-specific band detected by
R2295.

tau was recruited by AD-tau (Figure 2-2K).

AD-tau induces and propagates robust tau pathology in nonTg mice
We next tested whether these different tau fibril strains transmit tau pathology in
young nonTg mice (2-3mo). We injected Hep-T40 (9 µg), X-T40 (9 µg), and AD-tau (2 or
8 µg) into the dorsal hippocampus and overlying cortex (Figure 2-3A). Consistent with
the poor seeding in neurons, Hep-T40 fibrils failed to seed any appreciable tau
pathology in nonTg mice up to 24 mo post-injection (p.i.) (Figure 2-3B and C). While
there was variability among injected animals, X-T40 fibrils overall seeded inclusions as
detected by phosphor-tau antibody AT8 in the ipsilateral hippocampus 9 mo p.i. (Figure
2-3B and D). In contrast, inoculation of 2 or 8 µg of AD-tau seeded many AT8-positive
tau aggregates in several brain regions as early as 3 mo p.i. (Figure 2-3B and 4A). This
result was confirmed with injection of 2 µg of AD-tau prepared from 2 additional AD
cases (data not shown; see Table 2-S4).
To detect any residual AD-tau in the injected mice, we used both AT8 and
human-tau specific antibody HT7 at 2 and 7 days p.i. We found visible AT8-positive and
HT7-positive immunoreactivities around the injection site at 2 d p.i. but not 7 d p.i.
(Figure 2-5A and B), suggesting the AT8-positive inclusions detected at 3 mo p.i. must
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Figure 2-3. AD-tau is a more potent seed for tau aggregation in nonTg mice. (A) Schematics showing
injection sites in the dorsal hippocampus and overlying cortex indicated by red dots (B) Differential induction
of tau pathology recognized by AT8 (a monoclonal antibody specific for tau phosphorylated at S202/T205) in
nonTg mice at 3 mo p.i. of different tau fibrils. Amount of tau injected per mouse: 9 µg for Hep-T40 (4 mice)
and X-T40 fibrils (6 mice), 8 µg for AD-tau (4 mice). (C) AT8 immunostaining at 24 mo p.i. of Hep-T40 fibrils
(9 μg/mouse, 2 mice). (D) AT8 immunostaining at 9 mo p.i. of X-T40 fibrils (9 μg/mouse, 3 mice). (E) AT8
immunostaining at 3-, 6-, and 9 mo p.i. of AD-tau (8 μg/mouse; 4 mice per time point). Scale bars: 100 m.
(F) Quantification of % area occupied by AT8-positive tau pathology developed in the ventral hippocampal
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hilus with 8 μg AD-tau injection (4 mice per time point; each dot represents one mouse). One-way ANOVA
was performed across different time points for ipsilateral and contralateral pathology separately. Significant
differences were found for ipsilateral pathology and Tukey’s multiple comparison test identified a significant
difference between 3 mo p.i. and 9 mo p.i. (*: p < 0.05). (G) AD-tau inoculation (8 μg/mouse) did not lead to
significant neuron loss in the ventral hippocampal hilus region as compared to mice injected with control
brain extracts (Ctrl). Data are shown as mean + SEM. One-way ANOVA found no significant differences
among the groups. Data shown in this figure were obtained from injections performed all on 2-3 mo old
nonTg mice (C57BL6 or C57BL6/C3H F1).

be the recruitment of endogenous mouse tau by injected human AD-tau. This was
confirmed by labeling of the tau inclusions by mouse tau-specific antibody R2295
(Figure 2-5E). Moreover, injection of control brain lysates containing equivalent
concentrations of total proteins but little abnormal tau into nonTg mouse brain did not
result in any tau pathology (Tables 2-S1 and 2; Figure 2-5F), thus excluding any nonspecific induction of tau aggregation by injection-associated brain damage or by
exposure to human brain materials.
Interestingly, only some neuropil accumulations of tau developed near the
injection sites (Figure 2-5C and D), whereas the abundant perikaryal inclusions
accumulated in brain regions distant from, but anatomically connected to the injection
site, such as the hilus of the ventral dentate gyrus (ipsilateral and contralateral sides),
raphe nucleus, and the mammillary area (Figure 2-3B; Figure 2-4A). With injection of 8
µg of tau, tau pathology persisted in the abovementioned regions, with significantly more
pathology at 9 mo p.i. compared to 3mo p.i. in the ipsilateral ventral hilus (Figures 2-3F
and 2-4B). Meanwhile, new tau inclusions emerged at 6 mo p.i. in a few distal sites,
such as the locus coeruleus (Figures 2-3E and 2-4A; Figure 2-6A). In contrast,
injection of 2 µg of tau led to a trend in decline of tau pathology (although not statistically
significant) from 3 mo to 9 mo p.i. (Figure 2-4A and B). Together, these results provide
evidence for retrograde (and possibly anterograde) transmission of pathological tau and
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Figure 2-4. Propagation of tau pathology following inoculation of a lower dose of AD-tau into young
and aged nonTg mice. (A) AT8 immunostaining for various brain regions following a lower dose of AD-tau
inoculation (2 μg/mouse) into the dorsal hippocampus and overlying cortex of 2-3 mo old nonTg mice
(C57BL6). (B) Quantification of % area occupied by AT8-positive tau pathology developed in the ventral
hippocampal hilus with 2 μg AD-tau injection (3-4 mice per time point; each dot represents one mouse). (C)
Quantification of NeuN+ cells in the ventral hippocampal hilus region with 2 μg AD-tau injection. Data are
shown as mean + SEM. One-way ANOVA for both (B) and (C) showed no significant differences among
groups. (D) Comparisons of AT8-positive tau pathology developed in the ipsilateral entorhinal cortex,
ipsilateral fimbria and corpus callosum at 6 mo p.i. of AD-tau into young (2-3 mo) versus aged (15-19 mo)
nonTg mice (2 μg/mouse, 4 young and 3 aged mice at 6 mo p.i. with each dot representing one mouse, all
C57BL6). Scale bars: 100 μm. (E) – (G) Quantification of % area occupied by AT8 immunoreactivities in
regions shown in (D) followed by Student’s t-test indicated that aged mice developed significantly more
pathology in the ipsilateral entorhinal cortex (*: p <0.05) and a trend of more abundant pathology in the
ipsilateral fimbria and corpus callosum.

selective vulnerability of different neuronal populations to the development of tau
pathology in nonTg mice (Figure 2-6B).
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Furthermore, other markers of tau pathology (AT180, TG3, MC1) displayed
increased immunoreactivities over time in the 8 µg AD-tau injected mice, with a subset of
tau inclusions turning ThS-positive, indicating time-dependent maturation of pre-tangles
into NFT-like aggregates (Figure 2-6C and D). However, no overt neuron loss was ever
detected up to 9 mo p.i. (Figures 2-3G and 4C). We also injected AD-tau into aged (1519 mo) nonTg mice. Interestingly, while inoculation of 2 µg AD-tau led to minimal
pathology in the ipsilateral entorhinal cortex of young nonTg mice (Figure 2-3B), the
same low dose of AD-tau resulted in more pathology in the ipsilateral entorhinal cortex of
mice injected at 15-19 mo old (Figure 2-4D and E). There was also more neuropil tau
accumulation in the aged mice at 6 mo p.i. in white matter regions such as the fimbria
and corpus callosum (although not statistically significant) (Figure 2-4D, F and G).
Therefore, the age of mice appears to have a modifying effect on the spreading of ADtau-induced mouse tau pathology.
2.5 DISCUSSION
Over the past several years, a large body of literature has shown that the
hypothesis that cell-to-cell transmission of pathological protein aggregates underlies the
progression of many neurodegenerative diseases (Guo and Lee, 2014; Walker and
Jucker, 2015). While studies thus far have shown PrPSc and α-syn can seed the
induction and propagation of endogenous protein in nonTg mice (Weissmann et al.,
2002; Luk et al., 2012b; Masuda-Suzukake et al., 2013; Paumier et al., 2015), similar
results have never been robustly demonstrated without overexpression of tau protein
(Guo and Lee, 2014). This questions the validity of experimental evidence supporting the
transmission hypothesis for tau, particularly since tau protein is almost never
upregulated in human disease.
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Figure 2-5. Pathology developed after AD-tau inoculation is composed of endogenous mouse tau
and cannot be induced by control brain extracts. (A) and (B) IHC of the injection site with AT8 and
human tau-specific antibody HT7 at 2- and 7 d p.i. (2 μg/mouse, 2 mice per time point). (C) and (D) AT8positive neuropil staining, presumably due to endogenous mouse tau accumulations, was observed near the
injection site at 3- and 6 mo p.i. (2 μg/mouse for C, 8 μg/mouse for D); 4 mice per condition except for 3
mice at 3 mo p.i. of 2 μg/mouse. (E) IHC with mouse tau-specific R2295 confirms recruitment of endogenous
mouse tau into aggregates formed in the ipsilateral ventral hippocampus (Ventral HP Ipsi) and raphe
nucleus at 3 mo p.i. (8 μg/mouse, 4 mice). (F) Lack of AT8 immunoreactivity throughout the brains following
injections of extracts from control brains prepared the same way as AD-tau. Scale bars: 200 μm for (A)-(D),
100 μm for (E) and (F).

Studies from us and others showed that amyloid aggregates composed of one
single protein can exhibit different conformations, or tau strains (Petkova et al., 2005;
Furukawa et al., 2011; Guo et al., 2013; Sanders et al., 2014a; Peelaerts et al., 2015).
We hypothesized those differences in seeding capabilities of different tau strains
account for previous challenges in generating significant tau pathology in nonTg mice.
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While heparin-induced recombinant tau fibrils have been used extensively to propagate
tau pathology in transgenic mice overexpressing mutant tau (Iba et al., 2013b; Iba et al.,
2015; Peeraer et al., 2015; Stancu et al., 2015), they are inefficient in seeding nonoverexpressed wild-type tau (Guo and Lee, 2013b).
Here we demonstrate that tau fibrils purified from AD brains (AD-tau) are more
potent than synthetic tau fibrils generated with or without heparin in seeding
physiological levels of endogenous mouse tau in vivo. Although two previous studies
showed a few tau inclusions with injection of synthetic tau fibrils or AD brain extracts in
nonTg, the extent of tau pathology induced in the brains of those mice was much lower
than what we described here (Lasagna-Reeves et al., 2012; Clavaguera et al., 2013b).
Our study shows convincingly for the first time that abundant tau inclusions were
induced in multiple brain regions that are anatomically connected following intracerebral
injection of AD-tau. This observation provides the strongest support thus far for the
pathophysiological relevance of tau transmission to human tauopathies.
Parallel with our findings of higher seeding activity of human brain-derived tau
fibrils than synthetic tau fibrils, tau aggregates formed in tau Tg mice were shown to
seed more efficiently than heparin-induced tau fibrils in cultured cells overexpressing
mutant tau (Falcon et al., 2015). A similar discrepancy between synthetic and brainderived protein aggregates has been observed for other disease-associated proteins,
including prion, Aβ, and α-syn (Colby and Prusiner, 2011; Luk et al., 2012a; Stohr et al.,
2012). We speculate that this phenomenon could be explained by the formation of
different tau strains, with three possible mechanisms.
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Figure 2-6. Spreading and maturation of tau pathology induced by AD-tau inoculation in nonTg mice.
(A) Heat maps showing semi-quantitative analyses of tau pathology based on AT8 immunostaining (0: no
pathology, gray; 3: maximum pathology, red) at 3- and 6 mo p.i. of AD-tau (8 μg/mouse; 4 mice per time
point). Six coronal planes were shown from left to right: Bregma 0.98 mm, -2.18 mm, -2.92 mm, -3.52 mm, 4.96 and -5.52 mm. HP = hippocampus; Ctx = cortex; Ipsi = ipsilateral; Contra = contralateral. (B) A
schematic showing various brain regions connected to the dorsal hippocampus, the primary site receiving
inoculums (see Figure 2-5A and B), with both afferents and efferents indicated by directional arrows. Brain
regions with tau aggregate formation following AD-tau injections are marked in red. The diagram was
created based on data from the Allen Brain Atlas C57Bl/6 mouse connectivity studies (Oh et al., 2014). (C)
Brain sections were immunostained with antibodies AT180 (recognizing tau phosphorylated at T231), MC1
(recognizing a pathological conformation of tau found in the AD brains), and TG3 (recognizing
conformationally altered tau phosphorylated at T231), which all demonstrated increased immunoreactivities
over time after AD-tau inoculation (8 μg/mouse, 4 mice per time point). Double-labeling immunofluorescence
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using AT8 (red) and ThS (green) shows a subset of pretangles matured into β-sheet rich tangle-like
aggregates starting 6 mo p.i.. (D) AT8 and ThS double-labeling of the ipsilateral ventral hippocampus at 9
mo p.i. of AD-tau (8 μg/mouse, 4 mice). Scale bars: 100 μm.

First, in vitro reactions cannot recreate the cellular milieu required for generating
potent seeding conformers, including a lack of certain cofactors. Our study shows that
even direct seeding by AD-tau cannot efficiently impart AD-tau conformation to
recombinant tau in vitro (Figure 2-2). Although heparin is a potent inducer of tau
fibrillization in vitro, it is unlikely the intrinsic cofactor that initiates NFT formation,
considering the low transmissibility of heparin-induced tau fibrils and their conformational
difference from AD-tau in our model. Heparin was previously shown to interfere with
propagation of the AD-tau conformation to recombinant tau (Morozova et al., 2013).
Second, many different conformations of protein aggregates may arise in human
brains, but the particular strains that dominate diseased brains are likely those that are
kinetically favored, more resistant to degradation and/or more readily transmitted than
other misfolded conformers. In this regard, the emergence of such pathogenic tau
conformers would be less likely to occur during in vitro fibrillization. The unexpectedly
low seeding activity of X-T40 fibrils in vivo could be due to the lack of certain properties
that are important for in vivo pathogenicity. In particular, since X-T40 fibrils and AD-tau
had similar seeding properties in cultured neurons, it is possible the tau strain properties
necessary for in vitro transmission are different from in vivo transmission.
Third, post-translational modifications of tau that are found in vivo are absent in
recombinant tau. Tau is highly phosphorylated in AD brains as previously described, but
the role of specific phosphorylation sites in the development of unique AD-tau
conformers is still unknown. Furthermore, other post-translation modifications have also
been implicated in the formation of tau fibrils in AD (including acetylated, glycosylation,
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ubiquitination, glycation, prolyl-isomerization, polyamination, oxidation, nitration and
sumoylation). The role of these post-translational modifications in creating specific tau
conformations will be need to be characterized more extensively in future studies.
Notably, despite the abundance of tau inclusions developed in select brain
regions interconnected with the injection site, the tau pathology in vivo does not spread
to all interconnected regions (see Figure 2-6A and B), which may indicate selective
vulnerability of different brain regions to the development of tau aggregation. In fact, only
a small number of brain regions had newly emerged tau inclusions between 3 and 6 mo
p.i. with no further spreading occurring from 6 to 9 mo p.i. These results suggest that,
even with injection of AD-tau, the propagation of tau aggregates alone is insufficient to
fully recapitulate the extent of NFT progression observed in AD brains. We speculate
that other factors may contribute to the continued propagation of pathological tau in the
human brain, including aging, disease duration, and the presence of Aβ plaques (Gotz et
al., 2001; Lewis et al., 2001; Pooler et al., 2015).
Interestingly, our study shows that the age of nonTg mice inoculated with AD-tau
has a modulatory effect on the spreading of tau pathology, possibly due to impaired
protein quality control systems in aged mice. One can imagine an even more
pronounced effect of aging in human brains, given the much longer lifespan of human,
consistent with aging being the greatest risk factor for AD and other neurodegenerative
diseases. Nonetheless, we did not observe any overt neuron loss in these mice even up
to 9 mo p.i., despite tau-mediated neurodegeneration being a key feature of AD. This
lack of neurodegeneration could have several possible explanations, including
incubation time, the effect of aging, and other modifying factors (i.e., neuroinflammation).
It is possible with longer incubation times, and in aged mice, we would observe more
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neuron loss, consistent with long disease duration in human AD. However, future studies
can now use our new mouse model to interrogate these other factors modulating AD
pathogenesis.
In summary, our study suggests that AD-tau represents a unique conformational
variant of tau fibrils that are distinct from synthetic tau fibrils, including the commonly
used heparin-induced fibrils. The higher seeding potency of AD-tau, coupled with our
improved protocol of isolating large quantities of enriched PHFs, allowed us to
demonstrate in vivo transmission of pathological tau in nonTg mice, thus establishing a
physiologically relevant mouse model of sporadic tauopathies amenable to mechanistic
and therapeutic investigations.
2.6 SUPPLEMENTARY MATERIALS
Table 2-S1. Demographics of human cases used in the study.

Case No.
1
2
3
4
8
9

Neuropathological
Diagnosis
AD
AD
AD
AD
Normal
Normal

Gender
F
F
M
F
M
M

Age at death
68
59
66
81
59
62

PMI (hr)
9
14
4
5
17
16

Table 2-S2. Characterization of final supernatant fraction from human brain
extractions.

Preparatio
n No.

Concentr
ation of
tau by
ELISA
(µg/ml)

Total
protein
concentr
ation by
BCA
assay
(mg/ml)

Purity
(tau/t
otal
protei
n, %)
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Concentr
ation of
Aβ 1-40
by ELISA
(µg/ml)

Concentr
ation of
Aβ 1-42
by ELISA
(µg/ml)

Concentr
ation of
α-syn by
ELISA
(µg/ml)

AD1
AD2
AD3

1800
1600
1500

6.5
9.7
10

27.7
16.5
15.0

AD4
AD5
AD6
AD7

1270
1360
1650
2300

8.3
12.5
10.6
12.6

15.3
10.9
15.6
18.3

AD8

1500

7.2

0.030
0.019
0.056
not
detected
0.054
0.114
0.071
not
detected
not
detected

0.468
0.349
0.324

1.22
1.08
1.01

0.262
0.261
0.416
0.069

0.88
0.95
0.92
4.95

20.8
0.066
0.86
0.049
Control 1
5
10.3
%
0.004
5.80
0.016
Control 2
2
12.2
%
0.002
0.010
7.60
This table shows protein composition of representative final supernatant fractions
following our purification protocol.

Table 2-S3. Antibodies used in this study.
Antibody
Name

Specificity

Host
Species

Dilutions

T49
R2295
mTau

mouse tau
mouse tau

mouse
monoclonal
rabbit
polyclonal

R2295
h&mTau

human and mouse
tau

rabbit
polyclonal

AT8

p-tau
(phosphorylated at
Ser202 and Thr 205)

mouse
monoclonal

1:1000 (WB)
1:500 (ICC),
1:1000 (WB),
1:10000 (IHC),
1:5000 (IF)

17025

raised against
recombinant
human tau

rabbit
polyclonal

1:1000 (WB)

T14

PHF-1

Tau5

human tau (aa 141178)
p-tau
(phosphorylated at
Ser396 and Ser404)

tau (aa 210-230)

mouse
monoclonal

1:1000 (ICC, WB)
1:1000 (ICC, WB)

mouse
monoclonal

1:1000 (WB)
1:1000 (WB),
1:200 (immunoEM)

mouse
monoclonal

1:1000 (WB), 2.5
µg/ml as capture
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Source
In-house
(Kosik et
al., 1988)
Newly
generated
Newly
generated

Innogenet
ics
In-house
(Ishihara
et al.,
1999)
In-house
(Kosik et
al., 1988)
Gift from
Dr. Peter
Davies
Gift from
Dr. Lester
Binder

antibody in tau
ELISA
mouse
monoclonal
rabbit
polyclonal
rabbit
polyclonal
mouse
monoclonal
mouse
monoclonal

T46

tau (aa 401-441)

K9JA

tau (aa 243-441)

Anti-4R tau

4R tau

RD3

3R tau

RD4

HT7

4R tau
tau in the
pathological
conformation
p-tau
(phosphorylated at
Thr231)
conformational
specific p-tau
(phosphorylated at
Thr 231)
human tau (aa 159163)

Biotinylated
BT2

tau (aa 194-198)

mouse
monoclonal

Biotinylated
HT7

tau (aa 159-163)

mouse
monoclonal

Myc 9E10

Myc tag

Anti-c-Myc

Myc tag

HA

HA tag

mouse
monoclonal
rabbit
polyclonal
rabbit
polyclonal

HA tag

mouse
monoclonal

MC1

AT180

TG3

Anti-HA

1:1000 (WB)
1:5000 (WB)

In-house
(Kosik et
al., 1988)

1:5000 (WB)

Dako
Cosmo
Bio USA

1:1000 (WB)

Millipore

1:500 (WB)

mouse
monoclonal

1:2000 (IHC)

Millipore
Gift from
Dr. Peter
Davies

mouse
monoclonal

1:1000 (IHC)

Pierce

1:250 (IHC)

Gift from
Dr. Peter
Davies

mouse
monoclonal
mouse
monoclonal
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1:500 (IHC)
31.25 ng/ml as
reporting
antibody in tau
ELISA
together with HT7
62.5 ng/ml as
reporting
antibody in tau
ELISA
together with BT2

1:1000 (WB)
1:500 (immunoEM)
1:1000 (WB, EM)
1:500 (immunoEM)

Pierce

Pierce

Pierce
Developm
ental
Studies
Hybridom
a
Bank
Sigma
Covance
Berkeley
Antibody
Company

HA (12CA5)
GAPDH
(6C5)

HA tag
Glyceraldehyde-3phosphate
dehydrogenase

17028

MAP2

NeuN(A60)

NeuN

mouse
monoclonal

1:500 (immunoEM)

mouse
monoclonal

1:3000 (WB)

rabbit
polyclonal
mouse
monoclonal

Roche
Advanced
Immunoc
hemical
In-house
(VolpicelliDaley et
al., 2011)

1:5000 (ICC)

1:500 (IHC)
3.3 µg/ml as
mouse
capture antibody
9027
α-syn (aa 130-140)
monoclonal
for α-syn ELISA
0.5425 µg/ml as
rabbit
reporting antibody
MJF-R1
α-syn (aa 118-123)
monoclonal
for α-syn ELISA
10 µg/ml as
capture antibody
mouse
for Aβ1-40 and 1Ban50
Aβ (aa 1-10)
monoclonal
42 ELISA
reporting antibody
for Aβ1-40 ELISA
HRP(concentration not
labeled
mouse
determined after
BA27
Aβ1-40
monoclonal
HRP labeling)
reporting antibody
for Aβ1-42 ELISA
HRP(concentration not
labeled
mouse
determined after
BC05
Aβ1-42
monoclonal
HRP labeling)
Abbreviations: ICC - immunocytochemistry; WB - western blotting; IHC immunohistochemistry; IF – immunofluorescence.

Millipore

In-house

Abcam
Takeda
Pharmace
utical

Takeda
Pharmace
utical

Takeda
Pharmace
utical

Table 2-S4. Summary of inoculated mice analyzed for IHC.

INCUBA
TION
TIME

HEPT40 (9
µG/MO
USE)

X-T40
(9
µG/MO
USE)

AD-TAU
CASE 1
(8
µG/MO
USE)

AD-TAU
CASE 1
(2
µG/MO
USE)

AD-TAU
CASE 2
(2
µG/MO
USE)

AD-TAU
CASE 3
(2
µG/MO
USE)

CONTR
OL
BRAIN
EXTRA
CTS

2D

-

-

-

2

-

-

-
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7D

-

-

-

2

-

-

-

1 MO

-

-

-

3 + 2#

-

-

-

3 MO

4

4 + 2*

4

3+ 3#

3

3

3

6 MO

2*

3*

4

4+ 3#

2

2

-

9 MO

-

3*

4

3

-

-

2

12 MO

2*

-

-

-

-

-

-

18 MO

2*

-

-

-

-

-

-

24 MO

2*

-

-

-

-

-

-

This table summarizes the number of mice sacrificed at different time points after the
injection of different tau fibrils.
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CHAPTER 3: PATHOLOGICAL TAU STRAINS FROM HUMAN BRAINS
RECAPITULATE THE DIVERSITY OF TAUOPATHIES IN NONTRANSGENIC
MOUSE BRAIN
***This chapter has been published in the Journal of Neuroscience and reprinted here
with permission: Narasimhan S, Guo JL, Changolkar L, Stieber A, McBride JD, Silva LV,
He Z, Zhang B, Gathagan RJ, Trojanowski JQ, Lee VMY (2017) Pathological tau strains
from human brains recapitulate the diversity of tauopathies in nontransgenic mouse
brain. Journal of Neuroscience. 37:11406-11423. Copyright©2017 the authors***

3.1 ABSTRACT
Pathological tau aggregates occur in Alzheimer’s disease (AD) and other
neurodegenerative tauopathies. It is not clearly understood why tauopathies vary greatly
in the neuroanatomical and histopathological patterns of tau aggregation, which
contribute to clinical heterogeneity in these disorders. Recent studies have shown that
tau aggregates may form distinct structural conformations, known as tau strains, similar
to prion protein strains. Here, we developed a novel model to test the hypothesis that
cell-to-cell transmission of different tau strains occurs in nontransgenic (nonTg) mice,
and to investigate whether there are strain-specific differences in the pattern of tau
transmission. By injecting pathological tau extracted from postmortem brains of AD (ADtau), progressive supranuclear palsy (PSP-tau) and corticobasal degeneration (CBD-tau)
patients into different brain regions of female nonTg mice, we demonstrated the
induction and propagation of endogenous mouse tau aggregates. Specifically, we
identified differences in tau strain potency between AD-tau, CBD-tau, and PSP-tau in
nonTg mice. Moreover, differences in cell-type specificity of tau aggregate transmission
were observed between tau strains such that only PSP-tau and CBD-tau strains induce
astroglial and oligodendroglial tau inclusions, recapitulating the diversity of
neuropathology in human tauopathies. Furthermore, CBD-tau and PSP-tau-injected
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mice showed spatiotemporal transmission of glial tau pathology, suggesting glial tau
transmission contributes to the progression of tauopathies. Finally, we demonstrated the
neuronal connectome, but not the tau strain, determines which brain regions develop tau
pathology. Taken together, our data suggest that different tau strains determine seeding
potency and cell-type specificity of tau aggregation that underlie the diversity of human
tauopathies.

3.2 INTRODUCTION
Alzheimer’s disease (AD) and other neurodegenerative tauopathies are all
characterized by the pathological aggregation of tau protein (Lee et al., 2001). Tau is
normally a highly soluble protein, which in tauopathies becomes hyperphosphorylated
and misfolded, forming larger aggregates as intracellular inclusions. In AD, the burden of
tau aggregates correlates closely with neuron death and cognitive decline, and tau
aggregates alone cause neurodegeneration in other tauopathies (Arriagada et al., 1992;
GomezIsla et al., 1997; Giannakopoulos et al., 2003). Tau PET imaging studies also
show tau burden correlates with clinical symptoms and neurodegeneration in human AD
(Cho et al., 2016a; Wang et al., 2016; Xia et al., 2017). Taken together, these studies
show tau plays a key role in neurodegeneration.
Tauopathies vary greatly in clinical symptoms and in the neuropathological
distribution of tau pathology. Thus, despite the fact that the tau protein forms aggregates
in all tauopathies, the molecular basis of this heterogeneity is still unknown. AD is
clinically characterized by early memory loss and eventual dementia (Lee et al., 2001).
In AD, tau aggregates deposit in a stereotypical manner along anatomically connected
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networks from the transentorhinal cortex to neocortical areas (Braak and Braak, 1991;
Braak et al., 2011; Braak and Del Tredici, 2012; Cho et al., 2016b). In AD and several
other tauopathies, tau aggregates are composed of all six isoforms of tau (both 3R and
4R tau) primarily in neuronal cell bodies (neurofibrillary tangles or NFTs) and in axons
(neuropil threads) (Lee et al., 2001).
In contrast, corticobasal degeneration (CBD) and progressive supranuclear palsy
(PSP) patients have an earlier onset and shorter duration of disease than AD patients,
and primarily show motor dysfunction (Lee et al., 2001). In CBD, tau aggregates are
found in the cerebral cortex, basal ganglia, deep cerebellar nuclei, and substantia nigra.
They are composed primarily of 4R tau isoforms in both neurons and glia in CBD,
including astrocytic plaques and oligodendroglial coiled bodies (Lee et al., 2001).
Classical PSP is characterized by tau aggregates in primarily subcortical regions, such
as midbrain and basal ganglia. (Williams and Lees, 2009). Similar to CBD, PSP tau
aggregates are composed of 4R tau isoforms in both neurons and glia, including tufted
astrocytes and oligodendroglial coiled bodies (Lee et al, 2001). While PSP was initially
described as a single syndrome, recent evidence suggests PSP may constitute multiple
clinical subtypes (Williams and Lees, 2009). There is also some overlap in the
manifestations of CBD and PSP (Sha et al., 2006).
Several recent studies, including those from our laboratory, have shown that preexisting tau aggregates can “seed” the aggregation of soluble tau, and the resulting
pathological tau aggregates can propagate from cell-to-cell through transmission of
these proteopathic tau seeds (Clavaguera et al., 2009; Frost et al., 2009; Clavaguera et
al., 2013; Guo and Lee, 2013; Iba et al., 2013; Sanders et al., 2014; Boluda et al., 2015;
Falcon et al., 2015; Iba et al., 2015; Guo et al., 2016b; Kaufman et al., 2016). It has also
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been proposed that similar to the prion protein, proteopathic tau seeds form structural
conformations that constitute distinct tau strains, which may account for the
heterogeneity of tauopathies (Clavaguera et al., 2013; Sanders et al., 2014; Boluda et
al., 2015; Irwin et al., 2015; Guo et al., 2016a; Kaufman et al., 2016; TaniguchiWatanabe et al., 2016).
We recently developed a novel model of sporadic AD tauopathy by injecting
enriched pathological tau from human AD brains (AD-tau) into nonTg mouse brains (Guo
et al., 2016a). Using the same paradigm, we injected enriched pathological tau strains
from AD (AD-tau), CBD (CBD-tau), and PSP (PSP-tau) human brains into nonTg mouse
brain to test the hypothesis that different tauopathies comprised of unique tau strains will
seed different types of tau aggregates in vivo. We show differences in seeding potency
and cell-type specificity between the tau strains represented by AD-tau, PSP-tau and
CBD-tau, thereby recapitulating the diversity of these human tauopathies.

3.3 MATERIALS AND METHODS
Purification of Insoluble Tau from AD, CBD, and PSP brains
Human brain tissues from 3 AD cases, 3 CBD cases, and 2 PSP cases (all cases
from the CNDR brain bank except one PSP case generously donated from Mayo Clinic)
with abundant frontal cortical tau pathology were selected for this study (see Figure 3-1
and Table 3-1). 3 additional PSP cases from the CNDR brain bank with abundant
lentiform tau pathology were also selected for extraction (Figure 3-1 and Table 3-1). All
cases were diagnosed based on accepted neuropathology criteria (Irwin et al., 2015;
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Montine et al., 2016). Purification of pathological, insoluble tau from the frontal cortex of
these cases was performed as previously described (Guo et al., 2016a).
Table 3-1 Demographics of human cases used for study: Table shows all human
tauopathy cases used in the study, gender, age of death, PMI (in hours), and disease
duration (in years).
Neuropathological
Disease
Case No. Diagnosis
Gender
Age at death PMI (hr)
Duration
1
AD
F
68
9
8
2

AD

F

59

14

9

3

AD

M

66

4

11

1

CBD

M

44

7

unknown

2

CBD

M

52

8

4

3

CBD

M

56

15

6

1

PSP

F

63

6.5

5

2

PSP

M

74

Unknown

3

PSP

M

65

13

10

4

PSP

M

78

23

9

5

PSP

M

71

14

unknown

unknown

Table 3-2 Final supernatant characterization of all cases used: Characterization of
final supernatants (referred to as AD-tau, CBD-tau, and PSP-tau in text) with
concentration of tau by ELISA, protein concentration by BCA, purity of tau, and
concentration of Aβ 1-40 and 1-42 by ELISA. n.d. = not detectable
Total
protein
Concentrat Concentr
Concentra concentrati Purity
ion of Aβ
ation of
tion of tau on by BCA (tau/total
1-40 by
Aβ 1-42
by ELISA
assay
protein,
ELISA
by ELISA
Preparation No. (µg/ml)
(mg/ml)
%)
(µg/ml)
(µg/ml)
AD1 10/6/14

1800

6.5

28

0.02989

0.4683

AD1 12/9/14

1500

10

15

0.05586

0.3241

AD2 2/17/15

1270

8.3

15

n.d.

0.2618
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AD3 2/17/15

1360

12.5

11

0.05387

0.2610

AD1 5/17/16

1960

9.42

21

0.0158

0.0379

CBD1 10/14/14

400

17.1

2

n.d.

0.00481

CBD3 4/14/15

172

17.3

1

0.00947

0.05321

CBD2 3/18/15

560

21.5

3

n.d.

0.0097

CBD1 5/11/16

240

40

0.6

n.d.

n.d.

PSP1 11/10/14

360

19.2

2

0.01238

0.1828

PSP2 4/20/15

30

15

0.002

0.0051

0.01892

PSP2 3/28/16

91

5.12

2

n.d.

n.d.

PSP1 3/17/16

141

9.24

2

n.d.

0.0041

PSP1 5/12/16

270

23

1.7

n.d.

0.0689

PSP1 7/8/14
lentiform

---

---

31.9

15.3

0.002

PSP 3 7/8/14
lentiform

---

---

5

3.059561

0.002

PSP 4 8/11/14
lentiform

---

---

5

19.98607

0.0002

PSP 5 3/16/16
lentiform

---

---

7

22.23

0.031

Briefly, for the purification of AD-tau and PSP-tau, 6-14 g of frontal cortical gray
matter was homogenized in 9 volumes (v/w) of high-salt buffer (10 mM Tris with 0.8 M
NaCl, pH7.4) with 0.1% Sarkosyl and 10% sucrose added, and centrifuged at 10,000xg
for 10 min at 4°C. For CBD cases, both gray and white matter was homogenized in the
high-salt buffer. Pellets were re-extracted twice using the same high-salt buffer and the
supernatants from all 3 extractions were filtered and pooled. Additional sarkosyl was
added to the pooled supernatants to reach 1% and the samples were rotated for 1 hr at
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RT. The samples were centrifuged at 300,000xg for 60 min at 4°C and the resulted 1%
sarkosyl-insoluble pellets containing pathological tau were re-suspended in PBS. The resuspended sarkosyl-insoluble pellets were further purified by a brief sonication using a
hand-held probe (QSonica), followed by centrifugation at 100,000xg for 30 min at 4°C.
The pellets were re-suspended in PBS at 1/2 to 1/5 of the pre-centrifugation volume,
sonicated, and spun at 10,000xg for 30 min at 4°C to remove large debris (Guo et al.,
2016a).
The final purified supernatants contained insoluble, pathological tau, and are
identified as AD-tau, CBD-tau, and PSP-tau in subsequent experiments. The different
fractions from each purification were analyzed by western blotting, silver staining, and
sandwich ELISA for tau as previously described (see Figure 3-1 and Table 3-2) (Guo et
al., 2016a). The sandwich ELISA and western blotting for tau in the final supernatant
were used for estimates of tau concentration. The final supernatants were also analyzed
by bicinchoninic acid (BCA) assay (Fisher) for total protein concentration, and sandwich
ELISA for Aβ 1-40 and Aβ 1-42 levels, as previously described (Guo et al., 2016a; see
Table 2).

Western blotting
Samples were loaded on 7.5% SDS-PAGE, transferred to 0.2 µm nitrocellulose
membranes, and blocked in Odyssey blocking buffer (Li-Cor Biosciences) or 5% milk
diluted in TBS. Blots were incubated in appropriate primary antibodies overnight as
indicated in each figure (see Table 3-3 for details), and then incubated with IRDyelabeled secondary antibodies and scanned using ODY-2816 Imager.
53

Table 3-3 Antibodies used in this study: Description of all antibodies used in this
study, including specific proteins/epitopes they recognize, concentrations used, and how
they were procured.
Antibody
Host
Name
Specificity
Species
Dilutions
Source
mouse
1:1000 (ICC,
In-house (Kosik et
T49
mouse tau
monoclonal WB)
al., 1988)
R2295
mTau

mouse tau

rabbit
polyclonal

1:1000 (ICC,
WB)

(Guo et al., 2016a)

AT8

Tau
phosphorylation
at Ser202 and
Thr 205

mouse
monoclonal

1:10000 (IHC),
1:5000 (IF),
1:2000 (EM)

Thermo Scientific
(RRID:
AB_223647)

17025

raised against
recombinant
human tau

rabbit
polyclonal

1:1000

In-house (Ishihara
et al., 1999) RRID:
AB_2315435

mouse
monoclonal

0.05 μg/μl (IP),
2.5 µg/ml in tau
ELISA

Gift from Dr. Lester
Binder; RRID:
AB_663326

Tau5

tau (aa 210-230)

PHF-1

Tau
phosphorylation
at Ser396 and
Ser404

mouse
monoclonal

1:1000 (WB),
1:2000 (IHC)

Davies (Greenberg
et al., 1992) RRID:
AB_2313687

Anti-4R tau

4R tau

rabbit
polyclonal

1:5000

Cosmo Bio USA

RD3

3R tau

mouse
monoclonal

1:1000

Millipore RRID:
AB_310013

MC1

tau in the
pathological
conformation

mouse
monoclonal

1:1000 (IHC)

Gift from Dr. Peter
Davies (Jicha et al.,
1997a) RRID:
AB_2314773

AT180

Tau
phosphorylation
at Thr231

mouse
monoclonal

TG3

conformational
specific tau
phosphorylation
at Thr231

Gift from Dr. Peter

Thermo Fisher
1:1000 (IHC)

RRID: AB_223649
Gift from Dr. Peter

mouse
monoclonal
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1:250 (IHC)

Davies (Jicha et al.,
1997b)

GAPDH
(6C5)

Glyceraldehyde3-phosphate
dehydrogenase

mouse
monoclonal

GFAP

Glial fibrillary
acidic protein
(astrocytes)

Rat
polyclonal

Olig-2

Oligodendrocyte
marker

Rabbit
polyclonal

MAP2

rabbit
polyclonal

17028

Advanced
1:3000

Immunochemical

1:1000 (IF)

In-house (Lee et
al., 1984)
Millipore

1:500 (IF)

RRID: AB_570666

1:5000 (ICC)

In-house
(Volpicelli-Daley et
al., 2011)

Transmission Electron Microscopy (EM) for tau fibrils
Immuno-EM for PHF-1 (kindly donated by Peter Davies; RRID: AB_2313687)
was performed as previously described ((Guo et al., 2016a)). Briefly, samples were
adsorbed onto carbon/formvar-coated copper grids for 5 min, then washed three times
for 5 min each by floating the grids on drops of PBS. Samples were blocked for 5 min by
floating on blocking buffer containing 10% BSA, 1% fish gelatin, and 0.02% sodium
azide in PBS. The grids were incubated with PHF-1 (1:300, diluted in blocking buffer) for
1–2 h, followed by three times of 5 min wash on PBS drops and 5 min on blocking
buffer. The grids were incubated with anti–mouse secondary antibody conjugated to 6
nm colloidal gold (Jackson ImmunoResearch Laboratories, Inc.) for 1–2 h, and then the
grids were negatively stained using 2% uranyl acetate. All EM pictures were taken with a
JEOL1010 electron microscope.

GuHCl Denaturation assay
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250 ng of AD-tau, CBD-tau, and PSP-tau were denatured with the following
concentrations of GuHCl for 30 minutes at 37 °C: 0 M, 1 M, 1.5 M, 2 M, and 3 M. The
samples were diluted 1:3 and then digested with 1g/l of proteinase K for 30 minutes at
37 °C, followed by centrifugation at 45,000 rpm for 30 min. The pellets were resuspended in 20 μl of sample buffer and run on 12% Bis-Tris gels, followed by western
blotting for tau phosphorylated at serine 396/401 with PHF-1. The PHF-1 signal was
quantified using LiCor ImageStudio software.

Primary neuron cultures
E16-E18 embryos from pregnant CD1 mice were used to generate primary
neuron cultures. Dissociated hippocampal tissues were digested with papain
(Worthington Biochemical Corp.), triturated, and strained into single neurons using
FalconTM Cell Strainer (BD Biosciences). They were then plated onto coverslips precoated with poly-D-lysine (Sigma) diluted in borate buffer (0.05 M boric acid, pH 8.5) at
100,000 cells per coverslip on 24-well plates or 375,000 cells per well on 12-well plates
for biochemistry. Neurons on day 6 or 7 in vitro were treated with tau fibrils from AD-tau,
CBD-tau, or PSP-tau that had been sonicated for 60 pulses with a handheld probe.
Immunocytochemistry and/or biochemical extractions were performed at 15 or 19 days
after fibril treatment.

Immunocytochemistry
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Neurons were fixed with either cold 100% methanol or 4% paraformaldehyde
(PFA) with 1% Triton-X100 for 15 min to remove soluble tau. Tau staining was
performed with the primary tau antibodies described in each figure overnight (see Table
3 for details), followed by incubation with appropriate Alexa fluor-conjugated secondary
antibodies the next day. Coverslips were mounted using Fluoromount-G containing DAPI
(Southern Biotech) to label cell nuclei. An Olympus BX 51 microscope equipped with a
digital camera DP71 and DP manager (Olympus) was used to acquire
immunofluorescence images. For the quantification of the tau pathology, whole
coverslips were scanned using a Lamina Multilabel Slide scanner (PerkinElmer) and
quantified using the image analysis platform HALO (Indica Laboratories).

Extraction of Neurons for Biochemistry
To investigate the tau composition of insoluble tau in neurons seeded with ADtau, CBD-tau, or PSP-tau, neurons in 12-well plates were scraped into 1% sarkosyl lysis
buffer (1% sarkosyl in 50 mM Tris, 150 mM NaCl, pH 7.6) and centrifuged at 100,000xg
for 30 min at 4°C. The supernatants were the sarkosyl-soluble fraction (Figure 3-2C;
“sup”), whereas pellets were re-sonicated in 1% sarkosyl lysis buffer and centrifuged at
100,000x g for 30 min at 4°C. The pellets were re-suspended and sonicated in DPBS at
1/3 of the initial volume, as the sarkosyl-insoluble fraction (Figure 3-2C; “pel”). Protein
concentration in the “sarkosyl-soluble” fractions were determined using BCA assay, and
western blots were loaded with equal total protein concentration.

Immunodepletion of tau from PSP lysates
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Immunodepletion of tau from PSP and CBD lysates was performed as previously
describe (Guo et al., 2016a). Briefly, anti-tau monoclonal antibody Tau5 (Giasson et al.,
2003) or anti-tau polyclonal antibody 17025 was conjugated covalently to Protein G
Dynabeads (Invitrogen) by incubating 10 g of Tau5 or 17025 with dynabeads for 1 hr at
RT with rotation. 200 ng of PSP-tau or 500ng of CBD-tau in 200 l dPBS each was
incubated with the Tau5/bead (PSP-tau) or 17025/bead (CBD-tau) complex overnight at
4°C with rotation. Mock immunodepletion was performed with a mouse IgG1 antibody in
a similar manner as above. The unbound fraction was separated from the
antibody/beads using a magnet, and the bound fraction was boiled in SDS sample buffer
for 10 min to separate the proteins from the beads. Primary nonTg neurons were treated
with initial sample containing 20 ng of PSP-tau or 100ng CBD-tau, unbound fraction of
the Tau5 or 17025 sample (immunodepleted of tau), and the unbound fraction of the
IgG1 sample (mock immunodepletion) for 15 days. Immunocytochemistry for
endogenous mouse tau using the mouse tau-specific mAb T49 was performed as
described above.

Animals
CD1 and C57Bl/6 mice were purchased from Charles River. Embryos from
pregnant CD1 females were used to generate primary hippocampal neurons. Two to
three-month-old female C57Bl/6 mice (nonTg) were used for intracerebral inoculation of
AD-tau, CBD-tau, or PSP-tau human brain lysates. The University of Pennsylvania’s
Institutional Animal Care and Use Committee (IACUC) approved all animal protocols.
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Stereotaxic Surgery on Mice
Stereotaxic surgery on nonTg mice was performed as previously described (Iba
et al., 2013). Briefly, two to three-month-old nonTg mice were deeply anesthetized with
ketamine/xylazine/acepromazine and immobilized in a stereotaxic frame. The mice were
aseptically inoculated with human brain extracts in the dorsal hippocampus and
overlying cortex of one hemisphere (bregma: -2.5 mm; lateral: +2 mm; depth: -2.4 mm
and -1.4 mm from the skull) or the thalamus (bregma: -2.5 mm; lateral: +2 mm; depth: 3.4 mm from the skull) (see Figure 3-8). For the hippocampus and cortex injections,
each site received 2.5 µl of inoculum, and the thalamus injection received 4 µl of
inoculum. Concentrations of tau per injection site for AD-tau, CBD-tau and PSP-tau are
described for each figure.

Immunohistochemistry and Immunofluorescence
Injected mice were sacrificed and analyzed via immunohistochemistry (IHC) and
immunofluorescence (IF) as previously described (Iba et al., 2013). In brief, mice were
intracardially perfused at 1, 3, 6, or 9 months post-injection, with brains and spinal cords
fixed in 10% neutral buffered formalin (NBF) overnight. Brains and spinal cords were
then embedded in paraffin and microtome sectioned at 6 µm, followed by IHC for various
anti-tau primary antibodies (see figure legends and Table 3 for details). The next day,
the sections were developed using a polymer horseradish peroxidase detection system
(Biogenex) with counterstaining for hematoxylin. Stained slides were scanned using the
LaminaTM Multilabel Slide Scanner (PerkinElmer) to obtain images. Double-labeling IF
was performed with two primary antibodies incubated on tissue sections overnight,
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followed by incubation with secondary antibodies conjugated to Alexa fluor (anti-mouse,
anti-rabbit, or anti-rat based on primary antibody; see Table 3-3). Thioflavin S (ThS)
amyloid binding dye and AT8 IF for double-labeling for tau amyloid deposits were
performed as previously described (Guo et al., 2016a). Coverslips were mounted with
Fluoromount-G containing DAPI, and images were acquired using Nikon Eclipse
DSQi1MC microscope.
Semi-quantitative analysis was performed as previously described (Guo et al.,
2016a), with AT8-positive pathology scored on a scale of 0-3 (0: no pathology; 3: high
pathology) at 6 coronal sections (Bregma 0.98 mm, -2.18 mm, -2.92 mm, -3.52 mm, 4.96 mm and -5.52 mm) for each mouse. Scores were averaged across all mice at each
time point and then imported into a customized software to generate color-coded
heatmaps of the spatial distribution of pathology. Quantitative analysis was performed
using Halo software, with stereological cell counts for AT8-positive neuronal and glial
pathology in brain regions as described in each figure.

Experimental design and statistical analysis
For the GuHCl assay, independent experiments of 2 to 3 batches of AD-tau from
n=3 cases, 2 to 3 batches of CBD-tau from n=3 cases, and 2 to 3 batches of PSP-tau
from n=2 cases were conducted. Data are plotted as mean ± SEM of independent
experiments (2 to 3 batches) of n=3 AD cases, n=3 CBD cases, and n=2 PSP cases
(plotted separately). Two-way ANOVA with Bonferroni post-hoc test was performed
comparing PSP case 1 to all other groups with Graph-Pad Prism 4.0 software
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(GraphPad software, San Diego, CA; RRID: SCR_002798) (see Figure 3-1 for details).
P values less than 0.05 were considered statistically significant.
For the seeding of primary nonTg neuron cultures, 2 batches of n=3 cases of AD,
2 batches of n=3 cases of CBD, and 2 batches of n=1 case of PSP were tested, and
data are plotted as mean ± SEM across batches of all cases (see Figure 3-2 for details).
One-way ANOVA with Tukey post-hoc test was performed comparing all groups with
Graph-Pad Prism. P values less than 0.05 were considered statistically significant.
The number of mice used for all in vivo experiments is described in Table 3-4.
For quantification of IHC, 2 to 3 sections per mouse per region were quantified for AT8+
cells as specified in each figure. Total number of AT8+ cells per mouse per region were
plotted as mean ± SEM. IHC quantification results were analyzed across mice using
one-way ANOVA with Tukey or Bonferroni post-hoc tests or linear regression with
Graph-Pad Prism, with each statistical test described per figure. P values less than 0.05
were considered statistically significant.
Table 3-4 Number of mice used in injection experiments: Number of mice injected
with each tauopathy case (extracted from different brain regions) at different time points.
HP= hippocampus, Ctx= cortex.
Tauopathy Extraction Injection 1 month
3
6
9
case
Brain
Brain
p.i.
months
months
months
Region
Region
p.i.
p.i.
p.i.
AD case 1
Frontal
HP/Ctx
3
3
4
3
AD case 1

Frontal

Thalamus

---

---

3

---

AD case 2

Frontal

HP/Ctx

---

3

---

---

AD case 3

Frontal

HP/Ctx

---

3

---

---

CBD case 1

Frontal

HP/Ctx

2

4

4

4

CBD case 1

Frontal

Thalamus

---

---

3

---
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CBD case 2

Frontal

HP/Ctx

---

3

---

---

CBD case 3

Frontal

HP/Ctx

---

3

---

---

PSP case 1

Frontal

HP/Ctx

2

4

4

3

PSP case 1

Frontal

Thalamus

---

---

3

---

PSP case 1

Thalamus

HP/Ctx

---

4

---

---

PSP case 1

Lentiform

HP/Ctx

---

3

---

---

PSP case 2

Frontal

HP/Ctx

---

4

---

---

3.4 RESULTS
Biochemical differences between tau strains from human brains
Cases of AD, CBD, and PSP with abundant frontal cortical pathology were
identified as brain tissue sources for the preparation of tau extracts (Figure 3-1A). Of
note, the two PSP cases selected for pathological tau extraction from the frontal cortex
were unusual for their high abundance of cortical tau pathology. The frontal cortex was
selected for extraction from all cases so that sufficient brain material is available to
enrich for enough pathological tau in the final lysate to perform multiple experiments.
The cortical samples underwent sequential extraction to enrich for insoluble, pathological
AD-tau, PSP-tau, and CBD-tau ((Guo et al., 2016a) Table 3-1 & 3-2). Previous work
from our lab showed by Western blots that tau protein isoforms are the most dominant
immunobands in the AD-tau preps (Guo et al., 2016a); in contrast, CBD-tau and PSPtau have lower tau purity in the final supernatant (1-3%; Table 3-2).
As previously shown (Guo et al., 2016a), AD-tau contains all six isoforms of tau
with 3 prominent bands (17025 red; Figure 3-1B) comprised of both 3R and 4R tau
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Figure 3-1 Biochemical characterization of tau strains from human tauopathy brains: A) IHC was
conducted on sections of mid-frontal cortex with anti-tau mAb PHF-1 on all AD and CBD cases as well as
PSP case 1, and with mAb CP13 in PSP case 2. Scale bar 50 m. B) Western blots were performed using
anti-tau antibodies 17025 (red), PHF-1 (green), anti-4R tau from CosmoBio (red), and RD3 (green), plus
silver staining, on final supernatants from sequential extraction of 3 AD, 3 CBD and 2 PSP cases from part
A. C) IHC of the lentiform nucleus for PHF-1 from PSP cases. Scale bar 50 m D) Western blots for 17025
(red) and PHF-1 (green) on final supernatants from sequential extraction of the lentiform nucleus of PSP
cases from part C. E) Immuno-EM for PHF-1 (1:300) on AD-tau fibrils (AD case 3, 0.9 µg/µl), CBD-tau fibrils
(CBD case 2, 0.55 µg/µl), and PSP-tau fibrils (PSP case 1, 0.625 µg/µl) before (-) and after (+) sonication.
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Scale bar 100 nm F) Representative western blots for PHF-1 (green) on the GuHCl denaturation assay for 1
AD, 1 CBD, and 2 PSP cases. G) Whole lane quantification of the PHF-1 signals for each concentration of
GuHCl as a percentage of the initial sample (0M GuHCl) is plotted as % PK resistance for each case. Twoway ANOVA with Bonferroni post-hoc test was performed comparing PSP case 1 to all other groups H) The
2 cases of PSP were considered separately as they exhibited different properties using this assay. Whole
lane quantification of the PHF-1 signals for each concentration of GuHCl as a percentage of the initial
sample (0M GuHCl) is plotted as % PK resistance for two to three replicates of each PSP case. Statistics
are the same as described in part F.

(Figure 3-1B). In contrast, CBD-tau and PSP-tau contain primarily 4R tau isoforms with
2 prominent bands (17025 red; Figure 3-1B). Consistent with prior studies (Lee et al.,
2001), pathological tau from all cases was hyperphosphorylated as indicated by
prominent PHF-1 immunoreactivity (green). The three CBD cases used here contained
insoluble tau composed primarily of 4R tau with varying levels of 3R tau, as indicated by
Western blotting for 4R and 3R tau specific antibodies (Figure 3-1B). This phenomenon
has been described in the literature and could be due to overlapping AD pathology in the
frontal cortex of these CBD cases (Forman et al., 2002; Yoshida, 2006; Uchihara et al.,
2011). Given that abundant frontal cortical pathology is not common in PSP, we
extracted sarkosyl-insoluble pathological tau (without further purification) from the
lentiform nucleus (representing the putamen and globus pallidus) of 4 PSP cases, as tau
pathology is nearly always abundant in this region in PSP (Figure 3-1C). Western blots
show two prominent tau bands in the insoluble sarkosyl pellet from the lentiform nucleus
of all PSP cases (17025 red), with hyperphosphorylation of tau (PHF-1 green) (Figure 31D) although the concentration of tau in the sarkosyl pellet from the lentiform nucleus is
much lower than from the frontal cortex (Table 3-2). Immuno-EM for PHF-1 on AD-tau,
CBD-tau, and PSP-tau fibrils before and after sonication shows shorter and more
numerous fibrils after sonication as previously shown (Guo et al., 2016a).
In the prion literature, different strains are characterized by various biochemical
studies, including limited proteolysis and conformational stability assays using different
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concentrations of GuHCl (Collinge and Clarke, 2007). A previous study showed
differences in C-terminal tau fragments following protease digestion of sarkosyl-insoluble
tau from AD, CBD, and PSP brains, similar to what is observed for different prion strains
(Taniguchi-Watanabe et al., 2016), Here, we performed a conformational stability assay
using GuHCl as previously described (Legname et al., 2006). Specifically, we incubated
AD-tau, CBD-tau and PSP-tau in increasing concentrations of GuHCl, then performed
proteinase K (PK) digestion followed by Western blotting for PHF-1 to determine the
presence of protease-resistant bands at each concentration (Figure 3-1F).
Interestingly, AD-tau, CBD-tau, and PSP-tau showed different banding patterns
after PK digestion without GuHCl (Figure 3-1F; lane 0M GuHCl). AD-tau had smaller tau
fragments ranging from 15-20 kDa, while CBD-tau and PSP-tau had larger tau
fragments around 25 kDa (AD-tau and CBD-tau are representative images of n=3 AD
cases and n=3 CBD cases, respectively). We then plotted the percent (%) PK resistance
for each tau strain as a function of the GuHCl concentration, normalizing the PHF-1
signal in each lane to the sample with GuHCl-free digestion (lane 0 M GuHCl). A steeper
decline in % PK resistance suggests higher susceptibility of the tau aggregates to
denaturation by GuHCl.
AD-tau, CBD-tau, and PSP-tau showed different structural stabilities in this
GuHCl denaturation assay based on curves shown in Figure 3-1G (two-way ANOVA
with Bonferroni post-hoc test, F=3.739, p=0.0002). All cases of CBD-tau were the least
stable (Figure 3-1G red line; steepest decline), while all cases of AD-tau showed
intermediate stability in this assay (Figure 3-1G; black line). PSP-tau from case 1
showed the highest stability in GuHCl (Figure 3-1G; blue line). However, PSP-tau from
case 2 showed much less stability than PSP-tau case 2, suggesting the existence of
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different PSP-tau conformations in these two cases (Figure 3-1H). Nonetheless, both
PSP case 1 and 2 had similar banding patterns after PK digestion, suggesting they
share some strain properties and not others. Taken together, our data show different
biochemical properties of AD-tau, CBD-tau, and PSP-tau indicative of different strains of
pathological tau among AD, CBD and PSP tauopathies.
Tau strain seeding in primary nonTg neuronal cultures
To determine the biological activity of the different tau strains, AD-tau, CBD-tau
and PSP-tau were used to seed the aggregation of endogenous mouse tau in nonTg
primary hippocampal neurons, which initially express 3R tau and subsequently express
4R tau with differentiation in culture, as previously described (Guo et al., 2016a). We
found phenotypic differences in the subcellular localization of seeded tau aggregates
(recognized by mouse-tau specific T49 antibody after extraction of soluble tau with 4%
PFA and 1% Triton X-100) in these neurons corresponding to each tau strain: AD-tau
induced thread-like immunoreactivity mostly in axons with rare perikaryal inclusions,
while CBD-tau induced frequent perikaryal inclusions apart from axonal pathology
(Figure 3-2A). Strikingly, PSP-tau from case 1 was the most potent, inducing much
more abundant axonal and perikaryal inclusions at the same concentrations as AD-tau
and CBD-tau. In fact, PSP-tau from this case was about 300-times more potent than ADtau or CBD-tau (Figure 3-2B; one-way ANOVA with Tukey post-hoc test, F=86.49).
Tau aggregates formed in neurons were sarkosyl-insoluble and recruited tau
isoforms corresponding to the original human cases. For example, AD-tau treated
neurons recruited both 3R and 4R tau into the insoluble fraction, and PSP-tau treated
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Figure 3-2 Human tauopathy lysates seeding endogenous mouse tau in primary nonTg neurons: A)
Left Top: Representative images from immunocytochemistry studies for anti-mouse tau specific MAb T49
(green) on primary nonTg hippocampal neurons treated with pathological tau from AD, CBD, and PSP cases
Left Bottom: Images from ICC for T49 (green) and MAP2 (red) overlay from AD-tau, CBD-tau and PSP-tau
treated neurons. Scale bar 100 m. B) Quantification of % area occupied by T49 signal/DAPI signal from ICC
of neurons treated with AD-tau from 3 cases of AD (2 replicates), CBD-tau from 3 cases of CBD (2 replicates),
and PSP-tau from 1 case of PSP (case 1; 2 replicates) at different tau concentrations. One-way ANOVA with
Tukey post-hoc test comparing all groups was performed (*p<0.05, **p<0.01, **p<0.001). C) Western blot for
T49 on sarkosyl-soluble supernatants (sup) and sarkosyl-insoluble pellets (pel) extracted from neurons treated
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with AD-tau, CBD-tau or PSP-tau. Western blot for GAPDH as loading control. D) Representative images from
ICC for T49 (green) on primary nonTg hippocampal neurons treated with PSP-tau from 5 different PSP cases.
PSP cases 1, 3, 4 and 5 were used to treat neurons with 15 ng of sarkosyl pellet from the lentiform nuclei, and
PSP case 2 was used to treat neurons with 150 ng of final supernatant from frontal cortex. Scale bar 100 m.
E) Top: Images are shown here of ICC for T49 from primary nonTg hippocampal neurons treated with 200 ng
of PSP-tau, or Tau5-immunodepleted PSP-tau from case 1, or mock IgG-treated PSP-tau from case 1.
Bottom: Representative images are shown here of ICC for T49 from primary nonTg hippocampal neurons
treated with 100 ng of CBD-tau from n=3 cases, or 17025-immunodepleted CBD-tau, or mock IgG-treated
CBD-tau. Scale bar 100 m.

neurons recruited only 4R tau. Two cases of CBD-tau with primarily 4R tau in the final
human supernatant recruited only 4R tau in the insoluble fraction, while one case of
CBD-tau with more 3R tau in the final supernatant recruited both 4R and 3R tau (Figure
3-2C). Interestingly, not all cases of PSP were highly potent in vitro, as PSP case 2 with
tau extracted from the frontal cortex and other PSP cases with tau extracted from the
lentiform nucleus failed to induce significant tau pathology in primary neurons (Figure 32D). Thus, our data suggest tau from different PSP brains may contain different tau
strains, including the highly potent one described above.
To confirm that it is human tau that is accountable for inducing mouse tau
pathology in cultured neurons, we immunodepleted tau from our potent PSP-tau prep
(PSP case 1), and showed a dramatic loss of seeding activity in nonTg neurons (Figure
3-2E; top). Similarly, we immunodepleted tau from 3 cases of CBD-tau, and showed a
reduction in seeding activity in nonTg neurons. Therefore, we conclude insoluble human
tau in the final supernatant is necessary for seeding endogenous mouse tau in nonTg
neurons.

Seeding potency and cell-type specificity of human pathological tau in nonTg
mice
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To test whether different tau strains would lead to different patterns of
endogenous mouse tau aggregation in vivo, comparable concentrations of AD-tau, CBDtau, and PSP-tau were injected into the dorsal hippocampus and overlying neocortex of
nonTg mice (Figure 3-3A). Following post-injection (p.i.) survival intervals of 3 months,
we observed differences in seeding potency between the different pathological tau
strains in vivo. The unusual PSP-tau strain (case 1) was most potent in propagating
neuronal tau aggregates to several different brain regions at 3 months p.i. (Figure 3-3A).
Replicate studies using AD-tau, CBD-tau, and PSP-tau extracts obtained from different
cases resulted in a similar neuroanatomical distribution and density of tau pathology
(Figure 3-3B). Interestingly, the second PSP case with abundant frontal cortical
pathology also showed high potency in vivo (case 2; Figure 3-3B), suggesting
pathological tau purified from PSP-tau cases with extensive frontal cortical tau pathology
are potent seeds in vivo.
In contrast, all AD-tau and CBD-tau cases induced less extensive tau pathology
than the PSP-tau cases at 3 months p.i. (Figure 3-3A-B). CBD-tau seeded fewer
neuronal tau aggregates than PSP-tau in the same brain regions (n=3 CBD cases),
while AD-tau was the least potent, only eliciting tau aggregates in a subset of neurons in
select brain regions (n=3 AD cases). Both PSP-tau and CBD-tau seeded tau aggregates
in more neuronal subtypes in the hippocampus (i.e. dentate granule, hilar neurons and
CA3 neurons) than AD-tau (which primarily induced tau pathology in hilar neurons)
(Figure 3-3A-B).
All three tau strains also maintained cell-type specificity for neurons or glia as in
their corresponding human disease. Thus, AD-tau induced tau aggregates only in
neurons, while both PSP-tau and CBD-tau induced tau aggregates in oligodendrocytes
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Figure 3-3 Different seeding potencies and cell-type specificity of human tau strains in nonTg mice:
A) Upper Left: Schematic coronal and sagittal sections of the mouse brain showing injection sites in dorsal
hippocampus and overlying cortex Right: Representative images from IHC for anti-tau MAb AT8
(pS202/T205) for AD-tau case 1 (1 μg/site, n=3 mice), CBD-tau case 1 (1 μg/site, n=4 mice), and PSP-tau
case 1 (0.7 μg/site, n=4 mice) injected nonTg mice 3 months p.i. Black boxes with insets indicate neuronal
tau pathology and red boxes with insets indicate glial tau pathology. Panel scale bar 100 m. Inset scale bar
10 m B) Representative images of IHC for AT8 on 2 cases of AD-tau injections (each injection at 1 μg/site,
n=3 mice each), 2 cases of CBD-tau injections (case 2: 0.43 μg/site n=3 mice, case 3: 0.9 μg/site n=3 mice),
and 1 case of PSP-tau injections (case 2: 0.21 μg/site n=4 mice) into nonTg mice at 3 months p.i.
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Quantification performed on 2 sections for each region on 3 AD cases (n=9 mice), 3 CBD cases (n=10 mice)
and 2 PSP cases (n=8 mice total). One-way ANOVA with Tukey post-hoc analysis was performed for each
region (*p<0.05, **p<0.01, ***p<0.001). Panel scale bar 100 m. Inset scale bar 10m C) Left:
Representative images of IHC for AT8 or double-labeling IF for AT8 (red) and anti-oligodendrocyte specific
marker Olig-2 (green) from CBD-tau and PSP-tau injected mice 3 months p.i. Panel scale bar 50 m. Inset
scale bar 10 m. Right: Representative images of IHC for AT8 or double-labeling IF for AT8 (green) and
anti-astrocyte specific marker GFAP (red) from CBD-tau and PSP-tau injected mice 3 months p.i. Panel
scale bar 50 m. Inset scale bar 20 m. Hipp = hippocampus, Ctx = cortex, Ipsi= ipsilateral, Contra=
contralateral, DG= dentate gyrus.

and astrocytes, in addition to neurons (Figure 3-3A & C). The glial tau inclusions in
nonTg mice recapitulated the corresponding human tau neuropathology: oligodendroglial
inclusions occurred in white matter tracts such as the fimbria and corpus callosum and
resembled oligodendroglial coiled bodies of human CBD and PSP (Figure 3-3C left
panel; co-labeling AT8 and Olig-2). Astrocytic tau inclusions in CBD-injected mice
resembled astrocytic plaques of human CBD, while most of the astrocytic tau pathology
in PSP-injected mice resembled tufted astrocytes of human PSP (Figure 3-3C right
panel; co-labeling AT8 and GFAP). However, the PSP-tau-injected mice showed a
range of astrocytic tau pathologies ranging from astrocytic plaque-like profiles to tuftedastrocyte-like tau inclusions (Figure 3-3B), thereby showing some overlap with CBD as
described previously (Sha et al., 2006; Yoshida, 2014).

Rate of propagation and maturation of tau aggregates in nonTg mice
Since one of our PSP-tau strains induced highly extensive tau pathology at 3
months p.i., we hypothesized it more efficiently seeded tau pathology than AD-tau at
earlier time points. Indeed, more neuronal tau aggregates were observed at 1 month p.i.
of PSP-tau in the ventral hilus of the hippocampus than following injections of AD-tau at
the same time interval (Figure 3-4A; black boxes). In fact, both CBD-tau and PSP-tau
induced glial tau aggregates in astrocytes and oligodendrocytes at 1 month p.i., thereby
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Figure 3-4 Early recruitment and maturation of tau aggregates in nonTg mice: A) Representative
images from IHC for AT8 for AD-tau (1 μg/site, n=3 mice), CBD-tau (0.4 μg/site, n=2 mice), and PSP-tau
(0.7 μg/site, n=2 mice) injected nonTg at 1 month p.i. (hippocampus/cortex). Black boxes with insets indicate
neuronal tau pathology and red boxes with insets indicate glial tau pathology. Panel scale bar 100 m. Inset
scale bar 10 m B) Representative IHC images for AT8 near injection site and R2295 (mouse tau-specific
antibody) for AD-tau (1 μg/site, n=3 mice), CBD-tau (1 μg/site, n=4 mice), and PSP-tau (0.7 μg/site, n=4
mice) injected nonTg mice 3 months p.i. Scale bar 50 m C) R2295 also recognizes glial tau pathology in
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astrocytes and oligodendrocytes, indicating endogenous mouse tau is seeded in glial cells. Left panel:
Astrocytic plaque-like pathology from CBD-tau injected mice. Middle panel: Tufted astrocyte-like pathology
from PSP-tau injected mice. Right panel: Oligodendroglial coiled body-like pathology from PSP-tau injected
mice. Scale bar 20 m D) Representative images of IHC for anti-tau MAb AT180, MC1, and TG3 or IF for
AT8 and Thioflavin S (ThS) of the ventral hilus for the three AD cases injected into nonTg mice 3 months p.i.
Scale bar 5 0m E) Representative images of IHC for AT180, MC1, and TG3 or for AT8/ThS of the ventral
hilus for the three CBD cases injected into nonTg mice 3 months p.i. Scale bar 50 m F) Representative
images of IHC for AT180, MC1, and TG3 or for AT8/ThS of the ventral hilus for the two PSP cases injected
into nonTg mice 3 months p.i. Scale bar 50 m G) Representative images of IHC for AT180, MC1, and TG3
or for AT8/ThS of astrocytes (CBD-tau case 1 injected nonTg mice 3 months p.i.) or oligodendrocytes (PSPtau case 1 injected nonTg 3 months p.i.). Scale bar 20 m. Hipp = hippocampus, Ipsi= ipsilateral, Contra=
contralateral.

showing a fast rate of glial tau pathology formation for PSP-tau and CBD-tau strains
(Figure 3-4A; red boxes). Furthermore, the ventral hilus was the only brain region with
tau inclusions at 1 month p.i., confirming our previous findings that it may be selectively
vulnerable in this model (Guo et al., 2016a).
Since the injected human pathological tau is rapidly degraded by 7 days p.i. (Guo
et al., 2016a), we infer that the injected human material rapidly recruits endogenous
mouse tau (R2295, mouse-tau specific antibody) to form seeded aggregates for all three
tau strains (Figure 3-4B). Both the neuronal and glial tau pathology in PSP-tau and
CBD-tau-injected mice were positive for R2295, showing that endogenous mouse tau
had aggregated in neurons and glia in our model (Figure 3-4C).
We next investigated the differential recognition of the human tau strain-seeded
mouse tau aggregates by a panel of anti-tau antibodies. When tau becomes
hyperphosphorylated, it is recognized by phosphorylation-specific antibodies such as
AT8 (pSer202/Thr205) and AT180 (pThr231) (Ballatore et al., 2007). Then as tau
misfolds and aggregates, it is recognized by conformation-specific antibodies MC1
(misfolded conformation around interaction of N- and C-terminus of tau) and TG3
(misfolded conformation around pThr231 site) (Jicha et al., 1997a; Jicha et al., 1997b).
Finally, as tau aggregates mature into neurofibrillary tangles comprised of cross beta73

sheet structures, they are recognized by amyloid-binding dyes like Thioflavine S (ThS)
(Ballatore et al., 2007).
A small subset of AD-tau-seeded neuronal tau aggregates were weakly positive
for AT180, TG3, and MC1 at 3 months p.i.; however, none of them were ThS+ at this
time point (Figure 3-4E). This suggests AD-tau induced mouse tau aggregates are in a
prefibrillar, pretangle state at this time point. In contrast, CBD-tau-induced aggregates
were strongly AT180+, MC1+, and TG3+ at 3 months p.i., while only rare tau inclusions
were ThS+ (Figure 3-4F). PSP-tau induced the most mature neuronal tau tangles that
were AT180+, MC1+, TG3+, and ThS+ at 3 months p.i. (Figure 3-4G). The differential
recognition by anti-tau antibodies of the seeded pathology is indicative of unique and
diverse tau strains between AD-tau, CBD-tau, and PSP-tau. The astrocytic tau pathology
in CBD-tau-injected mice were AT180+ and mildly MC1+, while the oligodendroglial tau
inclusions were AT180+, MC1+ and TG3+ (Figure 3-4H). None of the glial tau
aggregates were ThS+.

Characterization of a uniquely aggressive PSP-tau strain
The high in vivo potency of both PSP cases with abundant frontal cortical
pathology suggests that either PSP-tau cases with extensive frontal cortical tau
pathology contain a highly potent tau strain in all brain regions with pathology, or that a
high potency strain is preferentially found in the frontal cortex of PSP cases. To test the
hypothesis that PSP cases with extensive frontal cortical pathology contain a highly
potent tau strain throughout the human brain, pathological tau was extracted from both
the thalamus and lentiform nucleus of one of the potent PSP cases (PSP case 1), and
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injected into the hippocampus and cortex of nonTg mice. At 3 months p.i., PSP-tau
extracted from the thalamus showed a transmission pattern in the mouse brain that was
nearly identical to PSP-tau from the frontal cortex, even with injection of a lower tau
concentration (Figure 3-5A; 0.7μg tau/site for frontal cortex compared to 0.35μg tau/site
for thalamus). A lower amount of PSP-tau from the lentiform was injected into nonTg
mice (0.0175μg tau/site), so PSP-tau from this region induced less pathology at 3
months p.i.; however, the induced tau aggregates still spread to the same brain regions,
and also were found in oligodendrocytes and astrocytes, in addition to neurons (Figure
3-5A; fimbria and hipp; red boxes). PSP-tau from all three brain regions induced mature,
ThS+ tau aggregates at 3 months p.i. (Figure 3-5B). Thus, this potent tau strain does
not appear to be restricted to the frontal cortex, but instead propagates throughout the
human PSP brain, just as we observed in the PSP-tau-injected mouse brains.

Spatiotemporal transmission of tau strains in nonTg mice
We had previously mapped out the neuronal connectome from our hippocampal
AD-tau-injected mice (Guo et al., 2016a). The neuronal tau pathology induced by the
three different tauopathy strains continued to increase and spread from 1 to 3 months
p.i. to other connected CNS regions from the ventral hilus (Figure 3-3A and 3-5A).
However, the seeded tau aggregates did not increase further from 6 to 9 months p.i.
(Figure 3-6A and B). In fact, while the number of neuronal tau aggregates remained
stable for PSP-tau from 3 to 9 months p.i., the extent of neuronal tau aggregates
declined for CBD-tau over these longer p.i. times in select brain regions (Figure 3-6A
and B; ventral hilus ipsi). A decline of AD-tau pathology was also observed over time
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Figure 3-5 PSP-tau from different brain regions have similar seeding potency in vivo: A)
Representative images of IHC of AT8 on PSP-tau extracted from either the frontal cortex (0.7 μg/site, n=4),
thalamus (0.35 μg/site, n=3), or lentiform nucleus (0.0175 μg/site, n=3) of case 1 injected into nonTg mice
hippocampus/cortex 3 months p.i . Red boxes with insets indicate glial tau pathology in either the fimbria
(oligodendrocytes) or hippocampus (astrocytes). Panel scale bar 100 m, inset scale bar 10 m. B) IHC
using other epitope specific anti-tau antibodies AT180, TG3, and MC1 on PSP-tau from the frontal cortex,
thalamus, or lentiform nucleus of case 1 injected into nonTg mice HP-Ctx 3 months p.i. Double-labeling IF
for AT8/ThS shows tau inclusions are ThS positive when seeded by PSP-tau extracted from any of the three
regions. Panel scale bar 100 m, inset scale bar 10 m. Hipp = hippocampus, Ctx = cortex, Ipsi= ipsilateral,
Contra= contralateral

(although this was not statistically significant), similar to what we previously reported
(Guo et al., 2016a). As in the prior study with AD-tau, we did not observe any significant
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neuron loss in CBD-tau- and PSP-tau-injected mice over the p.i. time intervals studied
here (data not shown). Notably, the PSP-tau strain retained more tau inclusions than the
AD-tau and CBD-tau strains in the ventral hilus at 9 months p.i. (Figure 3-6B). All three
tau strains also transmitted tau aggregates to the accessory olfactory bulb, a region not
directly anatomically connected to the sites of injection (Figure 3-6A). The observation
of seeded tau pathology in this region is consistent with trans-neuronal spreading of tau
pathology across neuronal circuits.
While all tau strains transmit neuronal tau aggregates to regions anatomically connected
to the sites of injection, PSP-tau- and CBD-tau-injected nonTg mice showed a wider
spatial distribution of tau pathology than AD-tau injected mice at 3 months p.i. (Figure 36C). In particular, PSP-tau- and CBD-tau-injected mice showed propagation of tau
inclusions to more cortical regions than AD-tau-injected mice, as visualized by the
heatmaps of tau pathology in each brain region (Figure 3-6C). Interestingly, the spatial
distribution of tau pathology between CBD-tau- and PSP-tau-injected mice were very
similar at 3 months p.i., suggesting that the CBD-tau and PSP-tau strains may share
seeding properties. At 6 and 9 months post-injection, we did not observe further
spreading of neuronal tau pathology in CBD-tau- and PSP-tau-injected mice. However,
we did find limited neuronal tau pathology in more cortical regions in AD-tau-injected
mice (Figure 6C). Thus, the spatial distribution of neuronal tau pathology for all three tau
strains was remarkably similar with longer p.i. times.
Transmission of glial tau pathology in nonTg mice
The seeding of glial tau inclusions in nonTg mice following injections of CBD-tau
and PSP-tau is especially remarkable given that it was widely believed that only neurons
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Figure 3-6 Spatiotemporal transmission patterns of seeded neuronal tau aggregates from three tau
strains: A) Left panel: Representative images from IHC for AT8 for AD-tau (1 μg/site, n=4 mice), CBD-tau
(1 μg/site, n=4 mice), and PSP-tau (0.7 μg/site, n=4 mice) injected nonTg mice 6 months p.i. Right panel:
Representative images from IHC for AT8 for AD-tau (1 μg/site, n=3 mice), CBD-tau (1 μg/site, n=4 mice),
and PSP-tau (0.7 μg/site, n=3 mice) injected nonTg mice 9 months p.i. Scale bar 100 m B) Quantification
of AT8+ neurons in ventral hilus region of AD (n=3 mice for 6 and 9 months), CBD (n=4 mice for 6 and 9
months p.i.) and PSP-tau (n=4 mice for 6 months p.i. and n=3 mice for 9 months p.i.). One-way ANOVA with
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Bonferroni post-hoc test was performed to compare groups (*p<0.05, **p<0.01, ***p<0.001. C) Semiquantitative analyses performed on a scale of 0 (gray) to 3 (red) for neuronal tau pathology and color coded
onto heatmaps. Scores were averaged between mice for each group at 3 months p.i. (n=3 for AD-tau, n=4
for CBD-tau, n=4 for PSP-tau), 6 months p.i. (n=4 for AD-tau, n=4 for CBD-tau, n=4 for PSP-tau), and 9
months p.i. (n=3 for AD-tau, n=4 for CBD-tau, n=3 for PSP-tau). Hipp = hippocampus, Ctx = cortex, Ipsi=
ipsilateral, Contra= contralateral.

express significant amounts of tau protein (Lee et al., 2001). However, recent evidence
suggests glial cells may also express tau, albeit at much lower levels than neurons,
which may provide enough endogenous tau for seeding by CBD-tau and PSP-tau strains
(Zhang et al., 2014). Interestingly, while the transmission of CBD-tau and PSP-tau
shared similar properties as described above, CBD-tau-injected mice developed more
astrocytic tau pathology, while PSP-tau-injected mice developed more oligodendroglial
tau inclusions (Figure 3-7). While we did not observe increased spreading of neuronal
tau pathology in CBD-tau- and PSP-tau-injected mice at 6 and 9 months p.i., we did
observe the continued spatiotemporal transmission of glial tau aggregates in these mice
(Figure 3-7).
Astrocytic tau pathology appeared to spread dramatically over time in CBD-tau
injected mice, from the ipsilateral ventral hippocampus at 3 months p.i. to the
contralateral hippocampus, as well as cortical regions, at 6 and 9 months p.i. (Figure 37A). In fact, the extent of astrocytic tau pathology inversely correlated with that of
neuronal tau pathology, with a decrease in the number of neuronal tau aggregates in
regions accompanied by a concomitant increase in astrocytic tau inclusions (Figure 37B). Although correlational at this point, we speculate that this finding may imply a
neuron-to-astrocyte mechanism of transmission that underlies the spreading of
astrocytic tau pathology. It is also possible there is an independent mechanism of
astrocytic tau spreading that occurs slower than neuronal tau spreading due to lower
endogenous tau expression in astrocytes.
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Moreover, there was also significant propagation of oligodendroglial tau
aggregates in PSP-tau-injected mice over time, particularly from the ipsilateral to
contralateral side of white matter tracts such as the fimbria and corpus callosum (Figure
3-7C and D). This result may be interpreted to signify that a glia-to-glia transmission
mechanism underlies the spreading of oligodendroglial tau inclusions; however, tau
pathology to oligodendrocytes may also spread through the axons of neurons in these
white matter tracts.

Regional selectivity of tau strains in nonTg mice
Our finding of similar spatial distributions of tau pathology at longer incubation
times after seeding with all three tau strains conflicts with the regional selectivity
observed in human tauopathies. However, it is possible that all tau strains are capable of
seeding neuronal tau aggregates in the same brain regions, and thus do not determine
the brain region specificity observed in different human tauopathies. We hypothesized
that the site of initiation and the neuronal connectome from the initiation site, rather than
the specific tau strain, determines the anatomical distribution or intraneuronal spread of
tau aggregates in tauopathies. To test this hypothesis, AD-tau, CBD-tau, and PSP-tau
were injected into a different brain region, the dorsal thalamus, of nonTg mice (Figure 38A). At 6 months p.i., differences between tau strains were observed that mimicked the
results with the hippocampus/cortex injections: PSP-tau was still the most potent tau
strain, and CBD-tau and PSP-tau induced glial tau pathology while AD-tau did not
(Figure 3-8B). Despite these quantitative differences in the abundance of neuronal tau
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Figure 3-7 Spatiotemporal transmission of seeded glial tau aggregates in CBD-tau and PSP-tau
injected mice: A) Left panel: Representative images of IHC for AT8 showing neuronal and astrocytic tau
pathology in CBD-tau injected nonTg mice at 3, 6, and 9 months p.i. (n=4 mice for each time point). Scale
bar 100 m Right panel: Semi-quantitative heatmaps of same CBD-tau injected mice shown in IHC images
on left. Neuronal tau pathology is color-coded per region (as in Figure 4). Astrocytic tau pathology was
counted for each coronal section and averaged across all mice in each group, then depicted schematically
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on the heatmaps as red stars (1 star per 3 tau-positive astrocytes). Oligodendroglial tau pathology was
counted similar to the astrocytic pathology, then represented similarly as above on heatmaps as purple
ovals (1 oval per 5 tau-positive oligodendrocytes). B) Quantification of AT8-positive neurons and astrocytes
of CBD-tau injected mice at 3, 6, and 9 months p.i. (n=4 mice at each time point; hippocampus/cortex)
based on stereological cell counts of 2 sections in each region. Linear regression was performed correlating
neuron tau pathology (y-axis) with astrocyte tau pathology (x-axis) in each region, with r2 and p-values noted
for each regression analysis in the graphs. C) Left panel: Representative images of IHC for AT8 showing
oligodendroglial tau pathology in PSP-tau injected mice at 3 months (n=4 mice), 6 months (n=4 mice), and 9
months (n=3 mice) p.i. Scale bar 100 m. Right panel: Semi-quantitative heatmaps of same CBD-tau
injected mice shown in IHC images on left. Neuronal tau pathology is color-coded per region (as in figure 4),
with astrocytic tau pathology in red stars and oligodendroglial tau pathology in purple circles as in part A. D)
Quantification of AT8-positive oligodendrocytes in PSP-tau injected mice at 3 months (n=4 mice), 6 months
(n=4 mice), and 9 months (n=3 mice) p.i. based on stereological counts of 3 sections in each region. Oneway ANOVA with Tukey post-hoc analysis was performed across the time points (*p<0.05, **p<0.01,
***p<0.001). Hipp = hippocampus, Ctx = cortex, Ipsi= ipsilateral, Contra= contralateral.

inclusions, the spatial distribution of neuronal tau aggregates was highly similar among
all three tau strains following injection in the thalamus (Figure 3-8C). Yet, the spatial
distribution of tau pathology following injection in the thalamus differed from the spatial
distribution of tau aggregates following injection in the hippocampus/cortex (Figure 3-6C
versus Figure 3-8C), supporting our hypothesis that the initiation site and neuronal
connectome from that site determines the brain region selectivity of different tau strains.
Finally, we also observed the spreading of astrocytic tau pathology in the same brain
regions as neuronal pathology from the thalamus of CBD-tau-injected mice, (Figure 38C), supporting our speculation that neuronal-to-astrocyte propagation of tau pathology
may be involved in the spread of astrocytic tau pathology.

3.5 DISCUSSION
In this study, we developed a sporadic tauopathy mouse model to interrogate the
mechanisms of neuropathological heterogeneity among human tauopathies. This model
was generated by enriching pathological tau from human AD, CBD, and PSP brains and
injecting these preparations into nonTg mouse brains. While other studies have
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Figure 3-8 Spatiotemporal transmission of tau pathology from additional injection site in nonTg
mice: A) Left: Schematic coronal and sagittal sections of the mouse brain showing dorsal thalamus
injection site. Right: Anatomical neuronal connectome showing anterograde and retrograde connections
from the dorsal hippocampus. Brain regions with seeded tau pathology are bolded. B) Representative
images from IHC for AT8 for AD-tau (6.4 μg/site, n=3 mice), CBD-tau (0.64 μg/site, n=3 mice), and PSP-tau
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(1.1 μg/site, n=3 mice) injected nonTg mice 6 months p.i. Panel scale bar 50 m, inset scale 10 m C) Semiquantitative heatmaps were created as described in Figure 4 and 7 on AD-tau, CBD-tau and PSP-tau
injected mice into the thalamus 6 months p.i.

investigated tau strains (Clavaguera et al., 2013; Sanders et al., 2014; Kaufman et al.,
2016), our work extends upon the current literature in several ways.
First, our study uses authentic pathological tau strains purified from human
tauopathy brains, and more carefully characterizes the human tau strains, including the
concentration of proteopathic tau seeds used, unlike previous studies using human
tauopathy brains (Clavaguera et al., 2013). Second, our study highlights the importance
of using nonTg mice as a sporadic tauopathy model. Since previous research studying
tau strains used transgenic mice with heterologous promoters controlling overexpression
of tau, it has been difficult to elucidate whether the properties of tau transmission are
due to intrinsic strain differences or due to the distribution of transgene overexpression.
Our model with only endogenous mouse tau expression develops tau aggregates that
recapitulate several features of each tauopathy following injections of AD-tau, CBD-tau,
or PSP-tau. While a previous study showed seeding of mouse tau pathology in nonTg
mice, they showed only a few cells with aggregates (Clavaguera et al., 2013), without
quantitation of the seeded tau inclusions or description of the spatiotemporal
transmission of tau pathology, as in our study. Finally, this is the first study, which
describes in detail the transmission of glial tau pathology.
We used the GuHCl/PK digestion assay as a biochemical readout to establish
that AD-tau, CBD-tau, and PSP-tau indeed are folded differently, consistent with the
notion that they represent unique tau strains. Other recent studies have shown
pathological tau can form different structural conformations using PK digestion (Kaufman
et al., 2016; Taniguchi-Watanabe et al., 2016). Taken together, these studies support
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the hypothesis that these tauopathies represent the manifestations of different tau
strains. It is important to consider that AD-tau contains both 3R and 4R tau isoforms,
while CBD-tau, PSP-tau, and adult nonTg mouse brain primarily contain 4R tau. It is
unclear whether both 3R and 4R tau isoforms in AD-tau are seeding endogenous mouse
4R tau, but given our previous finding that 3R and 4R tau isoforms incorporate randomly
into recombinant fibrils seeded by AD-tau (Guo et al., 2016a), we hypothesize that both
isoforms likely seed mouse tau.
Our enriched human tau strains had different potencies in seeding mouse tau in
primary hippocampal neurons. In particular, a distinct strain of PSP-tau was identified
that was 300-times more potent than AD-tau or CBD-tau in seeding neuronal tau
aggregates in vitro. This PSP-tau strain showed different seeding properties than other
PSP cases, thereby suggesting the existence of phenotypic diversity among PSP-tau
strains. A previous study showed pathological tau from PSP human brains have different
seeding properties in HEK293 cells overexpressing tau, supporting the heterogeneity
among PSP-tau strains (Sanders et al., 2014). It is important to note that while primary
neurons express both 3R and 4R tau isoforms with additional days in culture, only the
4R tau isoforms are expressed in adult mouse brain. While it is difficult to compare in
vitro and in vivo systems given their differences, they provide two independent systems
to interrogate different properties of human tau strains.
Notably, each tau strain induced a unique distribution of tau pathology in nonTg
mouse brains that recapitulated human tau neuropathology. PSP-tau isolated from the
frontal cortex from cases with abundant frontal cortical pathology was the most potent in
vivo, propagating more neuronal tau aggregates to anatomically connected brain regions
than the other strains. Given that abundant cortical pathology is not common in PSP, we
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hypothesized these PSP cases contained a unique tau strain that was especially
aggressive in promoting tau aggregates throughout the human brain. Indeed, PSP-tau
extracted from the thalamus and lentiform nucleus of one of these potent PSP cases
showed the same aggressive phenotype in the mouse brain as PSP-tau isolated from
the frontal cortex.
The clinical diversity in PSP has been noted in the literature. One study showed
there are three distinct clinical syndromes of PSP: Richardson’s syndrome (RS), PSPparkinsonism (PSP-P), and pure akinesia with gait freezing (PAGF) (Williams et al.,
2005). The same group showed RS patients had higher tau burdens in more cortical
regions than PSP-P patients, with an inverse correlation between higher tau burdens
and disease duration (Williams et al., 2007). It is possible PSP patients with abundant
cortical pathology contain a more potent tau strain that is aggressive enough to spread
faster and produce greater disease severity, similar to the highly potent PSP-tau strain
that we describe in this paper.
The observed differences of the human tau strains in the nonTg mouse brain
provide insights into the diversity of tauopathies. The increased potency of PSP-tau and
to a lesser extent, CBD-tau, could explain the shorter clinical course of PSP and CBD in
comparison to AD. We show tau aggregates develop more quickly with PSP-tau (by 1
month p.i.), and remain stable over long periods of time (up to 9 months p.i.). In contrast,
far fewer tau aggregates develop in AD-tau-injected mouse brains at early time points,
and show a trend to decline at 9 months p.i. Therefore, we hypothesize with increasing
age, tau aggregates slowly form in AD and accumulate over long periods of time. On the
other hand, PSP and CBD have a younger clinical onset than AD and a shorter time
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course for formation of tau pathology, suggesting the rapid propagation of tau pathology
in our model mimics a faster clinical course in human disease.
We showed the spatial distributions of neuronal pathology induced by all three
tau strains were very similar to each other at longer p.i. times following the
hippocampus/cortex and thalamus injections. This finding is in direct contrast to a recent
study using artificially-derived tau strains, in which their tau strains did show regional
selectivity up to 3 months p.i. (Kaufman et al., 2016). Such discrepancy is likely due to
their use of PS19 tau transgenic mice for injection with shorter p.i. times using
laboratory-generated tau strains versus our use of human brain-derived tau strains into
nonTg mice with longer p.i. times. Given that human tauopathies develop over many
years, the spatial distribution with longer incubations more closely resembles what
occurs in the human disease.
Our data are consistent with the hypothesis that all tau strains are capable of
inducing neuronal tau aggregates in the same brain regions, with the site of pathology
initiation and the neuronal connectome from that site determining which brain regions
are affected. In AD, Braak and colleagues proposed that the transentorhinal cortex is the
earliest site of tau pathology (Braak and Braak, 1991; Braak et al., 2011; Braak and Del
Tredici, 2012), whereas recent studies showed the striatum and prefrontal cortex as the
earliest sites in CBD (Ling et al., 2016), and the brainstem in PSP (Williams et al., 2007).
We speculate that these different sites of initiation lead to the development of unique tau
strains, in which distinct biochemical environments predispose the formation of unique
pathological conformers. These distinct tau strains then transmit to brain regions that are
anatomically connected via neuronal projections to the original site of pathology. In
particular, PSP-tau purified from different brain regions of the same case exhibited
87

similar seeding properties, suggesting this tau strain developed in an early site and then
spread to other regions in the human brain.
Our model also revealed remarkable spatiotemporal transmission of glial tau
pathology through the nonTg mouse brain following CBD-tau and PSP-tau injections.
The mechanism of glial tau pathology formation has always been a major question in the
field, but our findings suggest two mechanisms of pathogenesis. First, a significant
inverse correlation between neuronal and astrocytic tau pathology was observed in
select brain regions, suggesting there may be transmission of pathological tau seeds
from neurons to neighboring astrocytes. Alternatively, it is also possible that astrocytic
tau pathology spreads from one astrocyte to another, possibly through astrocytic gap
junction networks known to connect adjacent astrocytes across brain regions (Giaume et
al., 2010). In contrast, the transmission of oligodendroglial tau aggregates implies a gliato-glia mechanism through white matter tracts. While the exact mechanism of glial tau
transmission is still unknown, our model can now be used to study the role of neuron-glia
and glia-glia interactions in the transmission of tau aggregates.
In conclusion, we demonstrate different tau strains from human AD, CBD, and
PSP brains induce unique cellular distributions of tau pathology in nonTg mouse brains
that recapitulate the diversity of tauopathies. Furthermore, this model can now be used
to test new therapies to treat these devastating diseases. In light of the development of
anti-tau immunotherapy and other tau targeted therapies for AD (Khanna et al., 2016), it
will be important to test these therapies against all tau strains so they can be used for
the treatment of all tauopathies.
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CHAPTER 4: NOVEL INSIGHTS INTO THE INTERACTION BETWEEN
NEURONAL AND GLIAL TAU PATHOLOGY

This chapter is being prepared for publication as: Narasimhan S, Changolkar L, Riddle
DM, Kats A, Weitzman SA, Zhang B, Brown H, Olefumi M, Roberson E, Trojanowski JQ,
Lee VMY (2018) Novel insights into the interaction between neuronal and glial tau
pathology. In preparation
4.1 ABSTRACT
Tauopathies are characterized by the abnormal accumulation of tau protein in
neurons and glial cells. The most common tauopathy, Alzheimer’s disease (AD),
primarily forms tau aggregates in neurons, known as neurofibrillary tangles (NFTs).
However, in other tauopathies like corticobasal degeneration (CBD) and progressive
supranuclear palsy (PSP), astrocytic and oligodendroglial tau pathology feature
prominently. The mechanisms of glial tau pathology formation have thus far been poorly
understood. We previously demonstrated neuronal and glial tau aggregates can be
seeded in nonTg mouse brain by intracerebrally injecting human brain-derived tauopathy
lysates (i.e., CBD-tau and PSP-tau) (Narasimhan et al., 2017). In particular, we showed
glial tau pathology can spread across the mouse brain, from the initial site of injection to
distant brain regions, similar to the transmission of neuronal tau pathology. Yet, the
mechanism of glial tau transmission and its relationship to neuronal tau pathology was
still unknown. Here, we developed a novel mouse model using the Cre-Flox system to
selectively knockout tau in neurons, referred to as the TauKOn mice. We then
intracerebrally injected CBD-tau into the TauKOn mice, which still developed
oligodendroglial and astrocytic tau aggregates in the absence of neuronal tau pathology
at 3 months post-injection. Surprisingly, with longer incubation periods, the astrocytic tau
pathology did not spread in the TauKOn mice, while the oligodendroglial tau pathology
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did. Thus, we demonstrate the spreading, but not the initiation, of glial tau pathology
depends on neuronal tau pathology, defining novel interactions between neurons and
glia in the pathogenesis of tauopathies.

4.2 INTRODUCTION
Neurodegenerative tauopathies, the most common of which is Alzheimer’s
disease (AD), are characterized by the abnormal aggregation of tau protein in the human
brain (Lee et al., 2001). Tau is normally a highly soluble protein found primarily in
neuronal axons where it binds to and stabilizes microtubules. However, in tauopathies,
tau misfolds and aggregates into insoluble fibrils, which have been shown to correlate
with both neurodegeneration and clinical symptoms in patients (Arriagada et al., 1992;
GomezIsla et al., 1997; Giannakopoulos et al., 2003; Cho et al., 2016a; Wang et al.,
2016; Xia et al., 2017).
Tauopathies display a great deal of clinical and neuropathological heterogeneity,
despite the fact that tau aggregation is the key pathological hallmark (see Table 4.1; Lee
et al., 2001). For each tauopathy, patients present with different clinical symptoms
corresponding to different brain regions affected by tau aggregation and neuron loss.
Most interestingly, on neuropathological examination, tau forms aggregates in different
cell types for each disease: for example, in AD only neurons develop tau pathology, but
in CBD and PSP, astrocytes and oligodendrocytes also develop insoluble tau
aggregates (Table 4.1). The range of morphologies for each type of pathology widely
differs, from neurofibrillary tangles in neurons in AD and ballooning neurons in CBD and
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PSP, to astrocytic plaques in CBD versus tufted astrocytes in PSP, to oligodendroglial
coiled bodies in CBD and PSP and globular glial inclusions in GGT (Table 4.1).
Until recently, the mechanism underlying this diversity of clinical and pathological
findings in tauopathies was unknown. Now, findings from our lab and others have shown
that different structural conformations of the misfolded tau protein, known as tau strains,
underlies the heterogeneity of tauopathies (Clavaguera et al., 2013, Kaufman et al.,
2016, Narasimhan et al., 2017, Sanders et al., 2014). We have shown that misfolded tau
can indeed form different structural conformations known as strains, and these strains
are formed in human tauopathy brains (Kaufman et al., 2016, Narasimhan et al., 2017,
Sanders et al., 2014, Taniguchi-Watanabe et al., 2016). Furthermore, we recently
demonstrated human tau strains can seed different patterns of tau aggregation in
nontransgenic (nonTg) neurons in culture and nonTg mice, mimicking the same variation
in neuropathology observed in the human disease (Narasimhan et al., 2017).
Table 4-1 Clinical and neuropathological heterogeneity of tauopathies
Tauopat
hy

Age
of
onse
t

Diseas
e
Durati
on

Clinical
sympto
ms

Brain
regions
affected

Cell types
with tau
pathology

Tau
isofor
ms in
fibrils

Biochemic
al
Difference
s

Alzheime
r’s
disease
(AD)

~65
year
s old

~8-10
years

Early
memory
loss,
dementia
,
visuospat
ial
deficits

Locus
coeruleus,
Entorhinal
cortex,
hippocamp
us,
temporal,
frontal,
visual
cortices

Neurons

3R+4
R

Moderate
instability in
GuHCl

Progressi
ve
supranuc
lear palsy
(PSP)

~60
year
s old

~3-5
years

Vertical
gaze
palsy,
postural

Midbrain,
basal
ganglia,
deep

Neurons,
astrocytes,
oligodendrocyt
es

4R

Variable
instability in
GuHCl
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Corticoba
sal
degenera
tion
(CBD)

~60
year
s old

Pick’s
disease

~4060
year
s old

Globular
Glial
Tauopath
y (GGT)

~6080
year
s old

~6-8
years

~5-10
years

~3-10
years

instability
, rigidity

cerebellar
nuclei

Akinesia,
stiffness,
tremors,
ataxia

Frontal/mot
or cortex,
basal
ganglia,
deep
cerebellar
nuclei, and
substantia
nigra

Neurons,
astrocytes,
oligodendrocyt
es

4R

Low
instability in
GuHCl

Personali
ty and
behavior
al
changes,
language
impairme
nt

Hippocamp
us, limbic
regions,
anterior
frontal and
temporal
lobes,
medial
temporal
lobe

Neurons,
some
astrocytes and
oligodendrocyt
e

3R

Not tested

Behavior
al variant
FTD,
motor
symptom
s

Frontal and
temporal
lobes,
motor
cortex,
subiculum,
amygdala

Mostly
oligodendrocyt
es; neurons
and astrocytes

4R

Not tested

In particular, we observed the seeding of endogenous mouse tau in astrocytes
and oligodendrocytes when nonTg mice were intracerebrally injected with particular tau
strains extracted from CBD and PSP brains (referred to as CBD-tau and PSP-tau)
(Narasimhan et al., 2017). Most fascinatingly, we also described the spreading of glial
tau aggregates from the site of injection to different brain regions over time in CBD-tau
and PSP-tau injected mice (see Table 4.2). Since the spatiotemporal transmission of
glial tau aggregates had never been previously described, we further characterized this
finding to reveal an inverse correlation between neuronal and astrocytic tau pathology
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transmission over time. The oligodendroglial tau aggregates also appeared to propagate
through white matter tracts over time. However, from the correlational data, we could not
determine whether the formation of glial tau pathology depended on the formation of
neuronal tau pathology (Narasimhan et al., 2017).
The mechanisms underlying the formation of glial tau pathology in tauopathies
have always been poorly understood. While it was previously thought that glial cells do
not express significant amounts of tau protein, a growing body of literature suggests
there is some endogenous tau expression in glial cells (Zhang et al., 2014, Zhang et al.,
2016; LoPresti 2002; Seiberlich et al., 2015). Recent studies using RNAseq in FACSsorted glial cells from mouse brain show significant tau mRNA expression in both
astrocytes and oligodendrocytes in vivo (Zhang et al., 2014, Zhang et al., 2016; Figure
4.4A). Several studies have additionally shown oligodendrocytes in culture express a
significant amount of tau protein (LoPresti 2002; Seiberlich et al., 2015). However, based
on these studies, tau expression is still significantly higher in neurons than glial cells,
leading to the question of whether the formation of astrocytic and oligodendroglial tau
pathology in tauopathies depends on neuronal tau expression. We hypothesized that
glial tau aggregates form independently of neuronal tau pathology in these diseases. To
test this hypothesis, we seeded human tau strains in glial cell cultures, and in a novel
neuronal tau knockout (TauKOn) mouse model.
Table 4-2 Neuron and glial tau pathology in nonTg mice injected with AD-tau, CBD-tau,
and PSP-tau
Lysate
Cell type
1mpi
3mpi
6mpi
9mpi
Neuron

+/-

++

++

+

Astrocyte

-

-

-

-

AD-tau
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CBD-tau

PSP-tau

Oligodendrocyte

-

-

-

-

Neuron

+/-

++

+

+

Astrocyte

+/-

+

++

+++

Oligodendrocyte

+

++

++

++

Neuron

+

+++

+++

+++

Astrocyte

-

+

+

+

Oligodendrocyte

+

++

++

+++

4.3 MATERIALS AND METHODS
Purification of Insoluble Tau from AD, CBD, and PSP brains
Human brain tissues from 2 AD cases, 2 CBD cases, and 1 PSP case (all cases
from the CNDR brain bank) with abundant frontal cortical tau pathology were selected
for this study (Table 4.3). 1 control brain case with no tau pathology was also selected
for this study (Table 4.3). All cases were diagnosed based on accepted neuropathology
criteria (Irwin et al., 2015; Montine et al., 2016). Purification of pathological, insoluble tau
from the frontal cortex of these cases was performed as previously described (Guo et
al., 2016a, Narasimhan and Lee, 2017).
The final purified supernatants contained insoluble, pathological tau, and are
identified as AD-tau, CBD-tau, and PSP-tau in subsequent experiments. The different
fractions from each purification were analyzed by western blotting and sandwich ELISA
for tau as previously described (Guo et al., 2016a, Narasimhan and Lee., 2017). The
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sandwich ELISA and western blotting for tau in the final supernatant were used for
estimates of tau concentration. The final supernatants were also analyzed by
bicinchoninic acid (BCA) assay (Fisher) for total protein concentration.
Table 4-3 Demographics of human cases used for study: Table shows all human
tauopathy cases used in the study, gender, age of death, PMI (in hours), and disease
duration (in years).
Case
No.

Neuropathological
Diagnosis

Gender

Age at
death

PMI (hr)

Disease
Duration

1

AD

M

66

4

11

2

AD

M

62

12

n.d.

3

AD

F

68

9

8

1

CBD

M

52

8

4

2

CBD

M

56

15

6

3

CBD

F

76

14

10

1

PSP

F

63

6.5

5

1

Control

M

59

17

NA

Primary neuron cultures
E16-E18 embryos from pregnant CD1 mice were used to generate primary
neuron cultures. Dissociated hippocampal tissues were digested with papain
(Worthington Biochemical Corp.), triturated, and strained into single neurons using
FalconTM Cell Strainer (BD Biosciences). They were then plated onto coverslips precoated with poly-D-lysine (Sigma) diluted in borate buffer (0.05 M boric acid, pH 8.5) at
100,000 cells per coverslip on 24-well plates. Neurons on day 6 or 7 in vitro were treated
with AD-tau, CBD-tau, or PSP-tau that had been sonicated for 60 pulses with a handheld
probe. Immunocytochemistry was performed at 15 days after fibril treatment.
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Primary astrocyte and neuron-astrocyte cultures
The cortex was dissected out from P0-P2 pups from pregnant CD1 mice to
generate primary cortical astrocyte cultures. Tissue was triturated with a Pasteur pipet in
dissection media (DMEM with high glucose, 10% fetal bovine serum (FBS), 1%
penicillin/streptomycin, and 1% L-glutamine) and strained through 70 μm strainer into a
50 mL Falcon conical tube. Cells were centrifuged at 2000 rpm for 3 min at 4°C, then
washed in dissection media and centrifuged at 2000 rpm for 3 min at 4°C two more
times. Cells were seeded onto a T-25 flask (1 flask/cortex) and incubated for 2 to 3
weeks until confluent (fed with maintenance media: DMEM/1% FBS every two to three
days).
Once astrocytes formed confluent monolayer on T-25 flask, flasks were shaken
for 30 min at 180 rpm at 37°C and fresh media was added (to remove microglia). Then
flasks were shaken again for 6 hours at 37°C at 240 rpm, with fresh media added (to
remove oligodendrocytes). Cells were washed with versene, and 0.25% trypsin was
added to remove the astrocytes, and cells were resuspended in dissection media.
Astrocytes were centrifuged at 2000 rpm for 3 min at 4°C, resuspended in maintenance
media, and counted to plate 50,000 cells/coverslip on 24-well plate or 100,000 cells/well
on 12-well for biochemistry.
For neuron-astrocyte co-culture, astrocytes were prepared as described above
and plated on coverslips at 80,000 cells/coverslip (coated with 0.4 g/mL PDL in 50mM
borate buffer, then coated with 10 g/mL laminin). After washing, coverslips were
incubated with glia media (GM, DMEM with 10% FBS, 1% penicillin-streptomycin)).
Once the astrocytes were 70% confluent, 20 l of 1000X FDU (5-Fluorodeoxyuridine)
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was added to stop astrocyte growth before adding neurons. One day before the neurons
were plated, the astrocyte culture medium was changed to glia-neuron media (GNM; 1%
B27, 1% heat-inactivated FBS, 0.5 mM glutamax in Neurobasal A medium). Neurons
were prepared as described above and resuspended after centrifugation in GNM media.
Neurons were plated at 100,000 cells/coverslip (24-well plate) on top of astrocytes.
Primary astrocyte only or neuron-astrocyte co-cultures were seeded with CBD-tau or
AD-tau at 500ng/coverslip and incubated for 15 days post-seeding.
Primary oligodendrocyte and neuron-oligodendrocyte co-cultures
Cerebral hemispheres from P1 to P2 rat pups were dissected and suspended in
DMEM with 10% FBS. Tissue was triturated with Pasteur pipet and centrifuged at 800 g
for 5-10 min at room temperature (RT). Supernatant was aspirated and pellet was
resuspended in DMEM/10% FBS and plated onto T-75 flask (~1 rat brain per flask).
Flasks were not touched for four days to allow for neurons to die and astrocytes to
adhere; after four days, cells were fed twice a week until astrocytes formed confluent
monolayer on flasks, with microglia and oligodendrocyte precursor cells (OPCs) on top
(seven to 10 days).
Once astrocyte monolayer had formed, medium was changed completely with
fresh DMEM/10% FBS and incubated for 1 hour at 37°C. Flasks were first shaken for 2
hours at 200 rpm at 37°C, then media was aspirated (to remove microglia) and cells
were washed with PBS. Media was replaced and flasks were incubated for 1 hour at
37°C. Flasks were shaken again for 2 hours at 220 rpm at 37°C, then media was
replaced and flasks were incubated for 1 hour at 37°C (to remove microglia). Finally,
flasks were shaken for 24 hours at 240 rpm at 37°C. The supernatant containing OPCs
was removed and centrifuged at 500 g for 10min, with OPCs resuspended in
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DMEM/10% FBS and plated at 65,000 cells/coverslip (50 ug/mL PLL coated coverslips
in 24-well plate). Four hours after plating, media was replaced with oligodendrocyte
growth media (DMEM with insulin (5 μg/ml) transferrin (5μg/ml), and sodium selenite (25
ng/ml) supplement (Boehringer, Mannheim)). Once OPCs were confluent on coverslip
(3-4 days), oligodendrocyte growth media was replaced with long-term differentiation
media (Half DMEM/Half Neurobasal, 2% B27, 1% T3, 1% L-glutamine, 1% penicillinstreptomycin, 1% sodium pyruvate, 2.5mg/mL insulin, 1% DM supplement (containing
50mg/mL transferrin, 5.37 mg/mL purescene, 0.0015 mg/mL progesterone, 0.00264
mg/mL selenium dioxide), 10 ug/mL biotin, 1% BSA, 1X NAc, and 1X Cellgro Trace
elements B). Once oligodendrocytes matured for 7 days, they were directly seeded with
different tauopathy lysates and incubated for 15 days post-seeding (DIV 26 total).

Immunocytochemistry (ICC)
Neurons, oligodendrocytes, and astrocytes were fixed with 4% paraformaldehyde
(without extraction) or either cold 100% methanol or 4% paraformaldehyde (PFA) with
1% Triton-X100 to remove soluble tau (with extraction) for 15 min. ICC was performed
with the primary tau antibodies described in each figure overnight (see Table 4.4 for
details), followed by incubation with appropriate Alexa fluor-conjugated secondary
antibodies the next day. Coverslips were mounted using Fluoromount-G containing DAPI
(Southern Biotech) to label cell nuclei. A Nikon Eclipse DSQi1MC microscope was used
to acquire immunofluorescence images. For quantification of fluorescent signals, whole
coverslips were scanned using a Lamina Multilabel Slide scanner (PerkinElmer) and
quantified using the image analysis platform HALO (Indica Laboratories).
Extraction of astrocytes and oligodendrocytes for biochemistry
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To investigate tau expression in astrocytes, mouse astrocytes in 6-well plates
were scraped into 1% RIPA buffer and centrifuged at 100,000xg for 30 min at 4°C.
Similarly, rat oligodendrocytes in 6-well plates were scraped and 2 wells were pooled
into 1% sarkosyl lysis buffer (1% sarkosyl in 50 mM Tris, 150 mM NaCl, pH 7.6) and
centrifuged at 100,000xg for 30 min at 4°C. The supernatants from both extractions were
collected for soluble tau, and total protein concentration was determined by BCA assay
(Fisher).
Table 4-4: Antibodies used in this study: Description of all antibodies used in this
study, including specific proteins/epitopes they recognize, concentrations used, and how
they were procured.
Antibody
Name
Specificity
Host Species
Dilutions
Source
In-house
(Kosik et al.,
1988)

T49

mouse tau

mouse monoclonal

1:1000 (ICC,
WB)

R2295 mTau

mouse tau

rabbit polyclonal

1:1000 (ICC,
WB)

(Guo et al.,
2016a)

AT8

Tau
phosphoryla
tion at
Ser202 and
Thr 205

mouse monoclonal

1:10000
(IHC),
1:5000 (IF),
1:2000 (EM)

Thermo
Scientific
(RRID:
AB_223647)

rabbit polyclonal

1:1000

In-house
(Ishihara et al.,
1999) RRID:
AB_2315435

mouse monoclonal

0.05 μg/μl
(IP), 2.5
µg/ml as
capture
antibody in
tau ELISA

Gift from Dr.
Lester Binder;
RRID:
AB_663326

raised
against
recombinant
17025

Tau5

human tau

tau (aa 210230)

100

Anti-4R tau

4R tau

rabbit polyclonal

mouse monoclonal

1:5000

Cosmo Bio
USA

1:1000

Millipore
RRID:
AB_310013

RD3

3R tau

GAPDH (6C5)

Glyceraldeh
yde-3phosphate
dehydrogen
ase

mouse monoclonal

1:3000

Immunochemi
cal

GFAP

Glial
fibrillary
acidic
protein
(astrocytes)

Rat polyclonal

1:1000 (IF,
ICC)

In-house (Lee
et al., 1984)

Advanced

Millipore
Olig-2

Oligodendro
cyte marker

Rabbit polyclonal

1:500 (IF,
ICC)

RRID:
AB_570666

Iba-1

Microglial
marker

Rabbit polyclonal

1:500 (ICC)

Wako

MBP

Myelin basic
protein
(oligodendro
cyte marker)

Rat polyclonal

1:500 (ICC)

In house

2',3'-Cyclic

F. Arthur
McMorris
(477D42A17)

Nucleotide
3'-Phosphodiesterase
CNP

Rabbit polyclonal

1:500 (ICC)

Nogo-A

Oligodendro
cyte marker

Rabbit polyclonal

1:500 (ICC)

Santa Cruz
(sc-25660)

A2B5

Oligodendro
cyte
precursor
cell (OPC)
marker

Mouse monoclonal

1:500 (ICC)

In house
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17028

MAP2

rabbit polyclonal

1:5000 (ICC)

In-house
(VolpicelliDaley et al.,
2011)

Animals
CD1 and C57Bl/6 mice and pregnant rats were purchased from Charles River.
Embryos from pregnant CD1 females were used to generate primary hippocampal
neurons, and mouse pups P0 to P3 from pregnant CD1 females were used to generate
primary astrocyte cultures. P0 to P2 rat pup brains were used to generate primary rat
oligodendrocyte cultures.
Neuronal tau knockout (TauKOn) mice were generated by crossing CAMK2a-Cre
mice (purchased from Jackson laboratories, #027310; Dragatsis and Zeitlin, 2000) with
TauFlox mice (generously provided by the Roberson lab at University of Alabama; see
Figure 4-4B). Due to the expression of Cre in the testes of CAMK2a-Cre mice, male
TauFlox mice were crossed with female CAMK2a-Cre mice to generate the first
generation of TauKOncre;fl/+ heterozygous mice. Then, female TauKOncre;fl/+ from the first
generation were crossed with male TauFlox mice to generate homozygous TauKOn
mice (referred to as TauKOncre;fl/fl), along with littermate controls not expressing Cre
(referred to as Taufl/fl). Additional control mice generated include heterozygous
TauKOncre;fl/+ mice and Cre-only expressing mice (CAMK2a-Cre+). The University of
Pennsylvania’s Institutional Animal Care and Use Committee (IACUC) approved all
animal protocols.
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Table 4-5 Number of mice used all experiments: Number of mice of each genotype
and purpose of each experiment. IHC = immunohistochemistry, IF =
immunofluorescence, WB = western blot, p.i.= post injection
Genotype
IHC/IF WB Injected case 3 months p.i.
6 months p.i.
TauKOncre;fl/fl

TauKOncre;fl/+
TauKOnfl/fl

TauKOncre;+/+

n=3

n=3
n=3

---

n=4

CBD case 1

n=2

---

CBD case 2

n=4

n=5

AD case 1

n=2

---

AD case 2

n=2

n=4

PSP case 1

n=4

n=4

Control case 1

n=4

n=4

---

---

---

CBD case 1

n=2

---

CBD case 2

n=5

n=6

AD case 1

n=3

---

AD case 2

n=2

n=5

PSP case 1

n=4

n=4

Control case 1

n=4

n=4

CBD case 1

n=4

---

AD case 1

n=4

---

n=4
n=4

---

C57Bl/6 (WT)

n=3

n=3

---

---

---

TauKO

n=3

n=3

---

---

---

Stereotaxic Surgery on Mice
Stereotaxic surgery on nonTg mice was performed as previously described
(Narasimhan and Lee, 2017, Narasimhan et al., 2017). The mice were aseptically
inoculated with human brain extracts in the dorsal hippocampus and overlying cortex of
one hemisphere (bregma: -2.5 mm; lateral: +2 mm; depth: -2.4 mm and -1.4 mm from
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the skull). For the hippocampus and cortex injections, each site received 2.5 µl of
inoculum. Concentrations of tau per injection site for AD-tau, CBD-tau and PSP-tau are
described for each figure.

Immunohistochemistry and Immunofluorescence
Injected mice were sacrificed and analyzed via immunohistochemistry (IHC) and
immunofluorescence (IF) as previously described (Iba et al., 2013; Narasimhan et al.,
2017). IHC for various anti-tau primary antibodies was performed or double-labeling IF
was performed with two primary antibodies incubated on tissue sections overnight,
followed by incubation with secondary antibodies conjugated to Alexa fluor (see figure
legends and Table 4.4 for details). IHC stained slides were scanned using the LaminaTM
Multilabel Slide Scanner (PerkinElmer) to obtain images. IF images were acquired using
Nikon Eclipse DSQi1MC microscope.
Quantitative analysis was performed either manually by a blinded reviewer or
using Halo software, with stereological cell counts for AT8-positive neuronal and glial
pathology in brain regions as described in each figure. Semi-quantitative analysis was
performed as previously described (Guo et al., 2016a), with AT8-positive pathology
scored on a scale of 0-3 (0: no pathology; 3: high pathology) at 6 coronal sections
(Bregma 0.98 mm, -2.18 mm, -2.92 mm, -3.52 mm, -4.96 mm and -5.52 mm) for each
mouse. Scores were averaged across all mice at each time point and then imported into
customized software to generate color-coded heatmaps of the spatial distribution of
pathology.
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Western blotting
For cell cultures, samples were extracted as described above and protein
concentration was determined by BCA. For mouse brains, different brain regions were
dissected after cardiac perfusion and frozen at -80°C until extraction. Each brain region
was thawed on ice and homogenized in 5X v/w high-salt RAB buffer (100mL of 10X RAB
containing 1M MES, 10mM EGTA, and 5mM Mg2SO4, 0.75M NaCl, 0.02M NaF) using a
hand-help probe sonicator (QSonica). The homogenates were centrifuged at 100,000xg
for 30 min at 4°C, and the supernatants with soluble tau were analyzed by BCA for total
protein concentration.
Samples were loaded for same total protein on a 10% SDS-PAGE, transferred to
0.2 µm nitrocellulose membranes, and blocked in Odyssey blocking buffer (Li-Cor
Biosciences) or 5% milk diluted in TBS. Blots were incubated in appropriate primary
antibodies overnight as indicated in each figure (see Table 4.4 for details), and then
incubated with IRDye-labeled secondary antibodies and scanned using ODY-2816
Imager.

Experimental design and statistical analysis
For the seeding of primary rat oligodendrocyte and neuron-oligodendrocyte cocultures, n=3 cases of AD, n=3 cases of CBD, and n=1 case of PSP were tested in three
independent experiments, and quantification of IF was performed using HALO. For
western blots of rat oligodendrocyte tau expression, two independent experiments were
performed to extract tau. Data are plotted as mean ± SEM across all experiments of all
cases (see Figure 4-1 for details). One-way ANOVA with Tukey post-hoc test was
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performed comparing all groups with Graph-Pad Prism. P values less than 0.05 were
considered statistically significant.
The number of mice used for all in vivo experiments is described in Table 4.5.
For western blots of TauKOn mouse tau expression, fluorescent antibody signal for each
region was quantified using the LiCor software, and normalized to GAPDH signal. For
quantification of IHC, 9-10 sections per mouse per region were quantified for AT8+ cells
as specified in each figure. Total number of AT8+ cells per mouse per region were
plotted as mean ± SEM. IHC quantification results were analyzed across mice using
one-way ANOVA with Tukey or Bonferroni post-hoc tests with Graph-Pad Prism, with
each statistical test described per figure. P values less than 0.05 were considered
statistically significant.

4.4 RESULTS
Characterization of tau expression in glial cultures
Previously studies have shown rat oligodendrocyte cultures express tau protein
over time (LoPresti, 2002; Seiberlich et al., 2015). Initially, we cultured rat
oligodendrocyte precursor cells (OPCs) in growth factors (PDGF and FGF) for four days,
then differentiated the OPCs at DIV 4 (see Methods). The purity of our cultures began at
~90% oligodendrocytes at DIV 4, and decreasing to ~65% oligodendrocytes, ~30%
astrocytes, and ~1-2% microglia at DIV 26 (Figure 4-1A and C). At DIV 4, the OPCs in
culture express Olig-2 and A2B5 before differentiation as previously described (Figure
4-1A; Back et al., 2006, Ma et al, 2009). After 7 days of differentiation (DIV 11), the
oligodendrocytes matured, decreasing A2B5 expression and increasing expression of
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Figure 4-1: Characterization of glial cell cultures in vitro. A) Immunocytochemistry (ICC) for
markers of oligodendrocytes (Olig-2, A2B5, Nogo-A, CNP, and MBP), astrocytes (GFAP) and
microglia (Iba-1) in rat oligodendrocytes cultured from DIV4 to DIV26. Different oligodendrocyte
markers include Olig-2 (OPCs and mature oligos), A2B5 (OPCs only), Nogo-A (mature
oligodendrocytes), CNP (mature oligodendrocytes), and MBP (mature, myelinating
oligodendrocytes). Scale bar 100 μm. B) Double-labeling ICC for Olig-2 (red) and tau using two
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antibodies: Tau5 (pan-tau antibody, green) or T49 (rodent-tau specific antibody, green), in rat
oligodendrocyte cultures over time. Further double-labeling of oligodendrocyte cultures with MBP,
GFAP, or Iba-1 and T49 shows co-localization of tau in MBP+ oligodendrocytes, but not GFAP+
astrocytes or Iba-1+ microglia. Scale bar 100 μm. C) Quantification on right shows 90% purity of
oligodendrocyte cultures, with 5-6% astrocytes and 4-5% microglia at DIV4 (before
differentiation). After differentiation, some oligodendrocytes die, with about 60-70% remaining at
DIV26, and astrocytes grow more, about 20-30% at DIV26, with microglia also falling off to 1-2%
by DIV26. D) Quantification shows dramatic increase in tau expression after differentiation at
DIV11, stabilizing to ~40% of oligodendrocytes expressing tau by DIV 26. E) Western blot of tau
expression using T49 and Tau5 for rat oligodendrocytes scraped in 1% sarkosyl over time in
culture. Western blot data confirms the increase in tau expression over time, with
oligodendrocytes expressing ~70% tau of CD1 neurons at DIV 21. There is no detectable tau
expression in astrocytes by western blot. F) ICC for GFAP, Olig-2, and Iba-1 in primary mouse
astrocyte cultures show predominance of astrocytes (GFAP) with very few oligodendrocytes
(Olig-2) or microglia (Iba-1). Scale bar 100 μm. G) ICC for GFAP (red, astrocyte marker), Tau5
(green, pan-tau antibody) and DAPI (blue, nuclear marker) shows astrocytes robustly express
GFAP but very little tau in culture. Scale bar 100 μm.

Nogo-A, and myelin markers CNP and MBP (Figure 4-1A). By DIV 26, oligodendrocytes
produced significant amount of myelin, marked by increased MBP expression (Figure 41A).
We found a significant increase in tau expression in our rat oligodendrocyte
cultures after differentiation, from <5% cells expressing tau at DIV 4 to ~40-45% of cells
expressing tau DIV 26 (Figure 4-1B and D). This increase in tau expression was further
confirmed by western blot analysis (Figure 4-1E), with rat oligodendrocytes expressing
~60-70% of CD1 neuron tau expression in culture. Furthermore, we show tau expression
increased as myelination increased in rat oligodendrocyte cultures, with tau protein
colocalizing with myelin marker MBP (Figure 4-1B). Tau is only expressed in
oligodendrocytes in culture at DIV 26, with no colocalization with astrocytic marker
GFAP or microglia marker Iba-1 (Figure 4-1B). We also cultured CD1 mouse astrocytes
separately, and show the astrocytes in these cultures express primarily express GFAP,
with very few Olig-2+ or Iba-1+ cells (Figure 4-1F). In contrast, mouse astrocyte cultures
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did not express detectable levels of tau protein, either by ICC (Figure 4-1G) or western
blot (Figure 4-1E).
Seeding of human tauopathy lysates in glial cultures
Given that rat oligodendrocytes began to express significant levels of tau after
differentiation, we seeded the oligodendrocyte cultures with AD-tau (3 concentrations;
n=3 cases tested), CBD-tau (3 concentrations, n=3 cases testes), and PSP-tau (3
concentrations; case 1) at DIV 11 (7 days after differentiation), and incubated the
cultures for 15 days post-seeding. After extraction of soluble tau in the oligodendrocyte
cultures at DIV 26 with either 4% PFA+1% Triton or cold methanol, ICC was performed
using T49 to mark endogenous tau and Olig-2 to mark oligodendrocytes (Figure 4-2A).
Insoluble T49-positive aggregates formed with all three tauopathy lysates, with PSP-tau
seeding the most aggregates in a dose-dependent manner (Figure 4-2B). AD-tau
seeded a few aggregates per coverslip, and CBD-tau seeded more tau aggregates than
AD-tau, although not statistically significant (Figure 4-2B).
The seeding of tau aggregates in oligodendrocytes with AD-tau was surprising,
given that AD-tau never seeded oligodendroglial tau pathology in vivo. To confirm tau
pathology in our cultures were bona fide aggregates, we confirmed extraction of soluble
tau with dPBS controls with and without extraction (Figure 4-2C). We also found neither
control brain lysate (without tau pathology) nor heparin-induced T40 fibrils seeded any
tau aggregates in cultured oligodendrocytes (Figure 4-2C). The insoluble tau
aggregates formed in myelinating oligodendrocytes; interestingly, the tau aggregates colocalized with MBP, and only partially co-localized with CNP, suggesting tau pathology in
oligodendrocytes initially forms in myelin sheaths (Figure 4-2D). Tau aggregates never
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formed in astrocytes in the oligodendrocyte cultures (no colocalization with GFAP in
Figure 4-2D).
In contrast, CBD-tau does not seed tau aggregates in mouse astrocytes given
their undetectable levels of tau protein (Figure 4-3A top panel). Mouse astrocytes cocultured with CD1 mouse neurons were seeded with CBD-tau, but only neurons
developed tau aggregates, with no tau pathology co-localizing with GFAP in astrocytes,
suggesting the presence of neurons does not facilitate astrocytic tau pathology formation
(Figure 4-3A bottom panel). To determine if astrocytes in culture are capable of
developing tau pathology, we used a viral vector to express 1N4R tau with the P301L
mutation tagged with mCherry (AAV1-T34PL-mCherry) in cultured mouse astrocytes
(Figure 4-3B). Following viral-vector expression, we seeded the astrocytes with AD-tau
(450 ng, n=3 cases tested) or CBD-tau (450 ng, n=3 cases tested), and extracted the
cultures with 1% Triton 15 days post-transduction. ICC for AT8 (S202/T205 phosphotau) and mCherry showed human tau seeded endogenous virally expressed tau
(mCherry-tagged) into phosphorylated, insoluble tau aggregates (Figure 4-3C).
However, there was no difference in seeding of tau aggregates between AD-tau and
CBD-tau, likely due to the high overexpression of tau in the cultures (Figure 4-3C).
These data suggest astrocytes can independently develop tau pathology if they express
significant levels of tau protein.

Characterization of neuronal tau KO (TauKOn) mice
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RNAseq data from Zhang et al., 2016 (brainrnaseq.org) on mouse cortical
neurons, astrocytes, oligodendrocytes, microglia, and endothelial cells showed relative
MAPT expression in these cells types (Figure 4-4A; FKPM>0.1 shows significant
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Figure 4-2: Seeding of rat oligodendrocytes cultures with tauopathy lysates. A) ICC for
Olig-2 (red) and T49 (green) after seeding of rat oligodendrocyte cultures with 3 concentrations of
AD-tau (n=3 cases), CBD-tau (n=3 cases), and PSP-tau (n=1 case). Scale bar 50 μm B)
Quantification of # of T49+ cells for 3 doses of AD-tau, CBD-tau, and PSP-tau (average of n=3-4
experiments with n=3 cases each except n=1 case of PSP). One-way ANOVA with Bonferroni
post-hoc test shows significant differences between PSP-tau and AD-tau/CBD-tau (**p<0.01).
Insoluble T49+ aggregates formed in rat oligodendrocytes seeded with all 3 tauopathy lysates,
although to a much greater extent with PSP-tau than AD-tau or CBD-tau. C) dPBS controls for
seeding experiments show >90% extraction of soluble tau with either 1% Triton or cold methanol,
while normal tau expression at DIV26 is shown without extraction. Neither control brain lysate nor
heparin-induced T40 fibrils (1 ug/coverslip) seeded T49+ aggregates in rat oligodendrocyte
cultures. Scale bar 100 μm D) Top panel: ICC for MBP (red) and T49 (green) shows colocalization of tau aggregates with myelin in rat oligodendrocyte cultures. Middle panel: ICC for
CNP (red) and T49 (green) shows partial co-localization of tau aggregates with CNP enzyme.
Bottom panel: ICC for GFAP (red) and T49 (green) shows no co-localization of tau aggregates
with astrocytic marker GFAP. Scale bar 50 μm.

expression). While neurons have the greatest MAPT expression, myelinating
oligodendrocytes and newly formed oligodendrocytes also express significant levels of
MAPT mRNA (~30% of neurons). Astrocytes express MAPT mRNA to a lesser extent
(~10% of neurons). This data supports the in vitro findings that oligodendrocytes express
a significant amount of tau protein, while astrocytes in culture express a negligible
amount of tau despite significant mRNA expression in vivo.
CAMK2a-Cre mice expressing Cre in forebrain neurons were obtained from
Jackson laboratories (#027310) to generate neuronal tau KO mice (TauKOn; Dragatsis
and Zeitlin, 2000). Next, we obtained TauFlox mice from the Roberson lab at the
University of Alabama, which contained loxP sites around exon 1 of the MAPT gene, for
conditional knockout of tau expression (Figure 4-4B). We crossed female CAMK2a-Cre
mice with male TauFlox mice to generate heterozygous TauKOncre;fl/+ mice, which were
then crossed with male TauFlox mice again to generate the homozygous TauKOncre;fl/fl,
as well as littermate controls (TauKOnfl/fl) (Figure 4-4C).
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TauKOncre;fl/fl mice had significant reduction of tau expression in forebrain regions
of hippocampus and cortex compared to littermate controls and nontransgenic (WT
C57Bl/6) mice (Figure 4-4C; TauKOncre;fl/fl had ~70% reduction of tau compared to
littermate TauKOnfl/fl and WT mice by western blot). Heterozygous TauKOncre;fl/+ had

Figure 4-3: Seeding of mouse astrocyte cultures with tauopathy lysates. A) Top panel:
Seeding of mouse astrocyte cultures with CBD-tau (450 ng/coverslip) did not yield any AT8+
aggregates. Bottom panel: Seeding of neuron-astrocyte co-cultures with CBD-tau (450
ng/coverslip) did not seed AT8+ tau aggregates in astrocytes, although tau aggregates were
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seeded in neurons as previously described (Narasimhan et al., 2017). Scale bar 50 μm B)
Overexpression of tau in mouse astrocyte cultures was achieved using AAV1 virus expressing
T34 (1N4R tau) with P301L mutation tagged with mCherry (MOI 200,000). AAV1-mCherry alone
was used as a control at the same MOI. Viral expression shows robust tau staining by Tau5
antibody, and perfectly co-localizes with mCherry tag. Scale bar 50 μm C) Mouse astrocytes
overexpressing AAV1-T34-mCherry were seeded with either AD-tau (n=3 cases) or CBD-tau (n=3
cases) at 450 ng/coverslip and fixed/extracted with 4% PFA+1% Triton 15 days post-seeding.
Insoluble tau aggregates developed with both AD-tau and CBD-tau, detected by AT8 and
perfectly colocalizing with mCherry, suggesting endogenous tau was seeded by added human
tauopathy lysate. Scale bar 50 μm

intermediate tau expression levels compared to homozygous TauKOncre;fl/fl mice and WT
controls (Figure 4-4C). There were no changes in tau expression in the cerebellum
between TauKOn mice and controls, as expected given forebrain Cre expression. In
contrast, total TauKO mice had no detectable tau expression in any region, suggesting
there is not a complete tau reduction in the TauKOn in forebrain regions (Figure 4-4C).
This could be due to incomplete Cre expression or incomplete Cre excision of the loxP
sites, or due to the remaining glial tau expression in those regions.
To test whether there was residual tau expression in neurons, cell-type specific
tau expression was also analyzed by IHC in the TauKOn mice using mouse-tau specific
antibody R2295 (Guo et al., 2016). Normal tau expression levels were observed
throughout the brain in WT and Taufl/fl mice, while there was a significant reduction in
tau staining in the hippocampus and cortex of TauKOncre;fl/fl mice (Figure 4-4D). In
contrast, TauKO mice had no tau staining in all brain regions (Figure 4-4D). With higher
magnification, we observed most neurons of the hippocampus and cortex had reduced
tau expression in the TauKOncre;fl/fl mice, although there was residual tau expression in
the ventral hilar cells (Figure 4-4D right), which we found also do not express Cre (data
no shown). Surprisingly, we observed significant tau expression in oligodendrocytes of
white matter tracts such as the fimbria in WT, Taufl/fl , and TauKOncre;fl/fl mice, but not in
total TauKO mice, confirming oligodendrocytes express tau protein in vivo. Thus, the
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remaining tau expression in the TauKOn mice was primarily in oligodendrocytes, except
the ventral hilar neurons, which did not express Cre.

Figure 4-4: A) RNAseq data from Zhang et al., (2016) showing MAPT expression in FACS-sorted
cells from mouse cortex (left) (brainrnaseq.org). FKPM (Fragments of each kilobase per parts per
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million) shows significant tau expression in neurons (>0.1 FKPM), oligodendrocytes and
astrocytes in mouse brain. B) Schematic of generation of TauFlox mice using loxP sites around
exon 1 of WT mouse tau gene. After loxP sites are knocked in to tau gene, expression of Cre can
be used to drive cell-specific knockout of tau. C) Western blot analysis of tau expression in
homozygous TauKOncre;fl/fl and heterozygous TauKOncre;fl/+ mice compared to littermate controls
(Taufl/fl), WT mice (C57Bl/6), and whole body TauKO mice using T49 (mouse tau specific mAb) in
the hippocampus (HP), cortex (Ctx), and cerebellum (CBL). GAPDH was used as a loading
control. Quantification of T49 expression on right shows dose-dependent decrease in tau
expression in the HP and Ctx, with ~70% reduction in homozygous TauKOn cre;fl/fl mice, and ~30%
reduction in heterozygous TauKOncre;fl/+ mice, in comparison to littermate controls (Taufl/fl) and WT
mice. There is no change in tau expression in the CBL, given the forebrain expression of
CAMK2a-Cre. In contrast, whole body TauKO mice express no tau in HP, Ctx, or CBL. C) IHC for
R2295 (1:2000 with formic acid antigen retrieval) shows tau expression in all brain regions in WT
and Taufl/fl control mice but reduced tau expression in forebrain regions of the TauKOn cre;fl/fl, with
no tau expression in whole-body TauKO mice. Higher magnification images on right show
significant reduction of tau expression in TauKOncre;fl/fl mice, with some residual expression in the
ventral hilus. Furthermore, there was tau expression in oligodendrocytes of the fimbria in WT,
Taufl/fl, and TauKOncre;fl/fl mice, but not total TauKO mice, confirming tau expression data from 44A. Right: Scale bar 50 μm, Inset 10 μm.

Glial tau pathology forms independently of neuronal tau pathology in vivo
Next, we intracerebrally injected the TauKOn mice with CBD-tau in the
hippocampus and cortex (1 ug/site; n=2 CBD cases), and analyzed the seeding of tau
aggregates 3 months post-injection. We observed a dramatic reduction in neuronal tau
pathology in the TauKOncre;fl/fl mice compared to littermate controls (TauKOnfl/fl), given
the reduction in neuronal tau expression in those regions (Figure 4-5A and C). The
littermate controls showed transmission of neuronal tau aggregates in regions such as
the dorsal and ventral hippocampus and visual cortex (Figure 4-5A), similar to nonTg
mice as we previously reported (Narasimhan et al., 2017), while the TauKOncre;fl/fl mice
had little to almost no tau pathology in those same regions.
Surprisingly, there was no change in the amount of glial tau pathology
(oligodendroglial or astrocytic) in the TauKOncre;fl/fl compared to controls (Figure 4-5B
and C). Both the TauKOncre;fl/fl mice and the littermate controls had oligodendroglial tau
inclusions in white matter tracts such as the fimbria and corpus callosum, and astrocytic
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plaque-like aggregates in the hippocampus, similar to what we reported in nonTg mice
(Figure 4-5B; Narasimhan et al., 2017). The oligodendroglial tau aggregates co-

Figure 4-5: A) Representative images of IHC for AT8 on CBD-tau (n=2 cases) injected
TauKOncre;fl/fl (n=6 mice) and littermate controls (n=7 mice, Taufl/fl) 3 months post-injection.
Littermate controls show significant neuronal tau pathology in the dorsal dentate granule and CA3
cells, visual cortex, and ventral hilar neurons, with significant reduction in neuronal tau pathology
in TauKOn mice. Scale bar 50 μm B) Representative images of IHC for AT8 showing glial tau
pathology in same as mice as in part A. Similar levels of oligodendroglial tau pathology in the
fimbria and corpus callosum were found in both TauKOn and littermate control mice, as well as
similar levels of astrocytic tau pathology in the dorsal and ventral hippocampus. Scale bar 50 μm,

117

Inset 10 μm C) Quantification of number of AT8+ neurons (dorsal and ventral HP, cortex; 10
sections per mouse), oligodendrocytes (fimbria and corpus callosum; 10 sections per mouse),
and astrocytes (dorsal and ventral HP; 5-7 sections per mouse). One-way ANOVA with
Bonferroni post hoc test comparing amount of neuronal, oligodendroglial, and astrocytic tau
aggregates in TauKOn and littermate controls (*p<0.05, **p<0.01, ***p<0.001).

localized with Olig-2, a marker of oligodendrocytes, and the astrocytic plaque-like
aggregates appeared around GFAP-positive astrocytes (Figure 4-6B). Thus, the
reduction in forebrain neuronal tau expression and pathology did not affect the number
or morphology of glial tau pathology in TauKOn mice.
In contrast, TauKOncre;fl/fl mice injected with AD-tau developed little to no
neuronal tau aggregates compared with Taufl/fl control mice injected with AD-tau at 3
months p.i., confirming that reduction in neuronal tau expression significantly reduces
neuronal tau pathology in TauKOn mice (Figure 4-6C). Furthermore, none of the AD-tau
injected TauKOn mice developed any glial tau pathology at 3 months p.i., confirming our
previous finding that glial tau pathology forms in a strain-specific manner (Figure 4-6C;
Narasimhan et al., 2017). We also investigated whether the reduction in neuronal tau
pathology in the TauKOn mice was due to aberrant Cre expression, but found CBD-tau
injected CAMK2a-Cre+ mice (only expressing Cre) had similar levels of neuronal tau
pathology to Taufl/fl control mice (Figure 4-6D).
Spatiotemporal transmission of glial tau pathology in TauKOn mice
We previously reported the spatial transmission of both astrocytic and
oligodendroglial tau aggregates to regions beyond the site of injection in nonTg mice 6
months post-injection of CBD-tau or PSP-tau. In particular, we found astrocytic tau
aggregates spread to the contralateral hippocampus and cortical regions in CBD-
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injected nonTg mice, while oligodendroglial tau inclusions spread from the ipsilateral to
contralateral white matter tracts of the corpus callosum and fimbria. The astrocytic tau

Figure 4-6: Characterization of tau pathology in control mice injected with AD-tau and
CBD-tau A) Double-labeling of oligodendrocyte tau pathology using Olig-2 (green) and AT8 (red)
and astrocyte tau pathology using GFAP (red) and AT8 (green) shows similar morphology of glial
tau pathology in Taufl/fl and TauKOncre;fl/fl mice. Scale bar 50 μm, Inset 20 μm B) AD-tau injected
TauKOncre;fl/fl mice (n=3) showed little to no neuronal tau pathology, while Taufl/fl mice (n=4) had
similar neuronal pathology to nonTg mice at 3 months post-injection. In contrast, there was no
glial tau pathology in either AD-tau injected mouse group. Scale bar 50 μm C) CBD-tau injected
CAMK2a-Cre+ mice alone show similar distribution of neuronal and glial tau pathology to both
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nonTg and Taufl/fl mice, indicating expression of Cre does not affect formation of tau pathology in
mice (n=4 mice). Scale bar 50 μm, Inset 10 μm

pathology in particular had an inverse correlation with neuronal tau pathology,
suggesting the spreading of astrocytic tau aggregates resulted from local release and
uptake from neurons (Narasimhan et al., 2017). However, given our finding that glial tau
pathology is unchanged in the absence of neuronal tau pathology, we hypothesized glial
tau pathology would propagate to distal brain regions in the TauKOncre;fl/fl mice similar to
Taufl/fl control mice.
We confirmed the reduction in neuronal tau pathology in TauKOncre;fl/fl mice
compared to Taufl/fl mice at 6 months p.i. Surprisingly, we show that astrocytic tau
aggregates spread to the contralateral hippocampus and cortical regions in Taufl/fl control
mice, but not in the TauKOncre;fl/fl mice (Figure 4-7A and B). As previously described
(Narasimhan et al., 2017), astrocytic tau pathology formed in regions in which neuronal
tau pathology also formed in Taufl/fl mice; however, since there was no neuronal tau
pathology in the contralateral hippocampus or cortical regions in TauKOncre;fl/fl mice,
there was also no astrocytic tau pathology in those regions (Figure 4-7A and B). Thus,
we found while the initial formation of astrocytic tau pathology does not depend on
neuronal tau pathology, the spreading of astrocytic tau pathology to distal brain regions
does.
In contrast, oligodendroglial tau aggregates spread to contralateral white matter
tracts in both the Taufl/fl and TauKOncre;fl/fl mice, indicating the spatial transmission of
oligodendroglial tau pathology does not depend on neuronal tau pathology (Figure 4-7A
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and B). It is still possible oligodendrocytes use neuronal axons as a conduit to
propagate tau seeds from one side of the brain to the other; however, endogenous tau
expression in those axons is not necessary to seed oligodendrocytes on the
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Figure 4-7: Oligodendroglial, but not astrocytic, tau pathology spatially propagates in the
absence of neuronal tau A) IHC for AT8 of CBD-injected Taufl/fl mice (n=3) and TauKOncre;fl/fl
mice (n=2) both show spreading of oligodendroglial tau aggregates from the ipsilateral to
contralateral side of injection 6 months-post-injection (CC and Fimbria). However, astrocytic tau
pathology only spread from the site of injection in the Taufl/fl mice, while the TauKOncre;fl/fl mice
had no spatial transmission of astrocytic tau pathology. Scale bar 50 μm, Inset 10 μm B)
Quantification of neuronal and glial tau aggregates by IHC for AT8 in the ipsilateral and
contralateral hippocampus and cortex in CBD-injected Taufl/fl and TauKOncre;fl/fl mice. There is a
significant reduction of neuronal tau pathology in all regions in the TauKOn cre;fl/fl mice compared to
controls, similar to 3 months post-injection. In contrast, there is little to no astrocytic tau pathology
in the contralateral hippocampus and cortex of TauKOncre;fl/fl mice compared to controls, while
there are similar amounts of oligodendroglial tau inclusions in the contralateral fimbria and corpus
callosum in both groups of mice. C) Heatmaps of semi-quantitative scores of neuronal tau
pathology on a scale of 0 (gray) to 3 (red) of coronal sections of Tau fl/fl and TauKOncre;fl/fl mice 3
and 6 months post-injection. Astrocytic tau aggregates are coded by red stars (1 star for every 3
astrocytes) and oligodendroglial tau inclusions are coded by purple ovals (1 oval for every 5
oligodendrocytes) on top of the color-coded neuronal heatmaps.

contralateral side. It is also possible oligodendrocytes form their own network across
these tracts and can transmit insoluble tau aggregates via that network.
4.5 DISCUSSION
In conclusion, we investigated whether glial tau pathology formation and
transmission depended on neuronal tau expression using in vitro glial cell cultures and a
novel neuronal tau KO (TauKOn) mouse model. We confirmed our hypothesis that glial
cells can independently form tau aggregates if they express a significant level of
endogenous tau protein: oligodendrocytes in culture increasingly express tau protein
over time, and develop insoluble tau inclusions following seeding with AD-tau, CBD-tau,
or PSP-tau (Figure 4-2). In contrast, astrocytes in culture do not express any tau
protein, and therefore do not develop tau aggregates following seeding with human tau
lysates (Figures 4-1 & 4-3); however, if astrocytes are virally induced to express tau
protein, they can independently develop tau pathology (Figure 4-3). The absence of
astrocytic tau in culture was surprising given the recent finding that astrocytes express a
significant amount of tau mRNA in vivo (Figure 4-4A; Zhang et al., 2014). Two possible
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explanations exist: (1) tau mRNA does not get translated into protein in astrocytes in
vivo; (2) the astrocyte cultures are not representative of astrocytes in vivo, as culturing
astrocytes can change their gene expression profile (Foo et al., 2011).
Furthermore, we developed a new neuronal tau mouse model using the Cre-Flox
system by crossing neuron-expressing CAMK2a-Cre mice to TauFlox mice, the TauKOn
mice. These mice have a dramatic reduction in neuronal tau expression by western blot
and IHC (Figure 4-4), while also maintaining significant tau expression in
oligodendrocytes, confirming the in vitro experiments. Using the TauKOn mice, we
demonstrated that neuronal tau knockdown does not affect the initial formation of tau
aggregates in oligodendrocytes or astrocytes 3 months post-injection of CBD-tau
(Figure 4-5). In fact, the amount, morphology, and distribution of glial tau pathology
remained the same in both TauKOncre;fl/fl mice and littermate controls (TauKOnfl/fl)
following CBD-tau injections (Figures 4-5 to 4-7). The development of glial tau
pathology is still strain-specific as we previously noted (Narasimhan et al., 2017): AD-tau
injections into the TauKOncre;fl/fl mice did not seed any neuronal or glial tau pathology as
expected.
Unexpectedly, while neuronal tau knockdown did not affect the initial formation of
glial tau pathology, it did affect the spatial transmission of glial tau aggregates over time.
The astrocytic tau aggregates did not spread to the contralateral hippocampus or cortex
following CBD-tau injection in the TauKOncre;fl/fl mice compared to TauKOnfl/fl controls
(Figure 4-7). This data indicates the observed spatiotemporal transmission of astrocytic
tau pathology in nonTg mice is due to local spread of neuronal tau aggregates to nearby
astrocytes: in the absence of neuronal tau spreading, there is no astrocytic tau
spreading. This data also confirms our finding that there is an inverse correlation
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between neuronal and astrocytic tau pathology over time, supporting the correlation was
due to direct spreading of tau aggregates from neurons to astrocytes (Narasimhan et al.,
2017).
While it may seem contrary that the initial formation of astrocytic tau inclusions
does not depend on neuronal tau pathology but the spreading of astrocytic tau inclusions
does, there are a few possible explanations. First, it is possible astrocytes do not
express tau protein in vivo (despite expressing tau mRNA; Figure 4-4), and the
astrocytic tau pathology we observe at 3 months post-injection in the TauKOn mice is
due to local spread from oligodendrocytes. While this hypothesis is supported by the
lack of significant tau expression in astrocytes by IHC (Figure 4-4), there is no direct
evidence oligodendrocytes can transmit tau aggregates to astrocytes, particularly given
that the oligodendroglial tau pathology occurs in different regions from the astrocytic tau
pathology (Figure 4-5). It is also possible the remaining tau expression in the ventral
hilar neurons contributes to the astrocytic tau pathology at 3 months post-injection,
although there is a significant reduction (~50%) in the ventral hilar neuron pathology with
no subsequent effect on astrocytic tau pathology (Figure 4-6B).
The most likely explanation is that while astrocytes in vivo do express some
amount of tau protein, there is no astrocyte-to-astrocyte network (a “glial connectome”)
that allows for the propagation of astrocytic tau pathology; instead, the neuronal
connectome allows for the spreading of tau aggregates from neuron to neuron, with
subsequent local transmission of tau pathology to astrocytes. In the absence of neuronal
tau propagation, there is also no astrocytic tau propagation. This data suggests in the
human CBD brain, while the formation of tau pathology in astrocytes in the site of
initiation occurs independently of neuronal tau pathology formation, the subsequent
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development of astrocytic tau aggregates in new brain regions is secondary to neuronal
tau transmission. However, our data appears to contradict a recent study showing
astrocytic tau pathology appears first in new brain regions with the progression of CBD
(Ling et al., 2016). At least one of two possible explanations exist for this discrepancy:
(1) In the human study, it is difficult to capture on a fine timescale the appearance of
neuronal and astrocytic tau pathology; therefore, what appears to be the initial
appearance of astrocytic tau pathology may be secondary to previous neuronal tau
pathology that disappeared by the time of post-mortem study; (2) It is possible astrocytic
tau pathology develops independently of neuronal tau pathology in selectively vulnerable
regions, thereby appearing “first” in new brain regions. Nonetheless, our data still
suggests astrocytic tau pathology cannot propagate on its own, so the initial appearance
of astrocytic tau aggregates in the human brain must be due to some other mechanism.
In contrast, the oligodendroglial tau pathology continued to spread in the
TauKOncre;fl/fl similar to the Taufl/fl controls, along the white matter tracts of the corpus
callosum and fimbria. This finding suggests oligodendroglial tau transmission is not
dependent on neuronal tau propagation, as the TauKOncre;fl/fl have little to no neuronal
tau pathology in many regions (Figure 7). It is possible the oligodendroglial tau
aggregates spread via the axons of neurons in the white matter tracts, using the axons
as conduits for transmission from the ipsilateral to contralateral side of the mouse brain.
Yet, endogenous tau expression in the neuronal axons is not necessary for the
propagation of oligodendroglial-derived tau inclusions. However, it is also possible
oligodendrocytes can transmit tau aggregates to each other without any neuronal
involvement: we now show by the in vitro that tau seeds initially aggregate in the myelin
sheaths of oligodendrocytes, co-localizing with MBP (Figure 2D). The myelin sheaths of
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oligodendrocytes may form their own network, an oligodendroglial connectome, which
creates its own conduit for the transmission of oligodendroglial tau aggregates from one
side of the brain to the other. Future studies will need to investigate the possible role of
myelin sheaths in creating such a network.
The new TauKOn mouse model is the first model to develop glial tau aggregates
in the absence of neuronal tau aggregates without using transgenic mouse models that
overexpress tau in glial cells. Our lab previously demonstrated that overexpression of
human tau in either astrocytes or oligodendrocytes (GFAP-tau and CNP-tau mice,
respectively) results in age-dependent astrocytic or oligodendroglial tau pathology
(Formal et al., 2005; Dabir et al., 2006). However, overexpression of tau does not model
the human disease well, as patients develop tauopathies with normal expression of
human tau levels, as we previously described (Guo et al., 2016a; Narasimhan et al.,
2017). We now show glial tau pathology occurs in a strain-specific manner (CBD-tau and
PSP-tau injections seed glial tau inclusions while AD-tau does not), but without artificial
expression of human tau using transgenic mice. In particular, this model allows us to
conclude that glial cells, especially oligodendrocytes, can independently develop tau
pathology in the absence of neuronal tau, as they do endogenously express tau protein.
It also allows us to investigate the functional role of glial tau pathology independently of
neuronal tau pathology.
Previous studies using the GFAP-tau transgenic mice have shown astrocytic tau
pathology results in mild blood-brain barrier (BBB) disruption, glutamate transporter
impairment, with subsequent neuronal axonal injury and deficits in mice (Forman et al.,
2014; Dabir et al., 2016). Similarly, one study using CNP-tau transgenic mice showed
oligodendroglial tau pathology disrupts myelin sheaths causing myelin atrophy, with
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slower axonal transport and motor deficits (Higuchi et al., 2002, Higuchi et al., 2005).
Some studies have shown just the overexpression of tau either in cell culture
(Yoshiyama et al., 2003; Richter-Landsberg 2008) or in Drosophila models (Colodner et
al., 2010) results in glial or neuron death. Future studies should use our TauKOn mouse
model to elucidate the functional effects of glial tau pathology in the absence of tau
overexpression.
Early studies showed tau expression co-localized with the expression of myelin
protein MBP in rat oligodendrocytes in culture (LoPresti et al., 2001), while further
studies showed tau may be involved in the transport of MBP mRNA along microtubules
to the site of myelination in oligodendrocytes in culture (Sieberlich et al., 2015). This data
supports our findings that initial tau aggregation in oligodendrocytes sin the MBPpositive myelin sheaths, where endogenous tau is involved in MBP transport and
myelination. Future studies will need to investigate the exact mechanism by which
pathological tau seeds are internalized and processed in the myelin sheaths of
oligodendrocytes.
Our study indicates the significance of glial tau pathology in the pathogenesis of
tauopathies. In particular, we show glial tau pathology formation occurs independently of
neuronal tau pathology, suggesting any therapies developed to treat tauopathies should
target both neurons and glia. Until now, most tau-targeted therapies have been tested in
mouse models that only develop neuronal tau aggregates, so future studies should
utilize our nonTg or TauKOn mouse model to test the effect of these therapies on glial
cells. To further understand how oligodendroglial and astrocytic tau aggregates interact
with each other and influence neuronal tau aggregates, the TauFlox mice can be
crossed with glial-specific Cre promoters to selective knockout tau in one glial cell or
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another. Such future studies will demonstrate the full effect of glial tau pathology on the
pathogenesis of tauopathies. Furthermore, the Cre-Flox system can now be used to test
the effects of endogenous tau KO in different neuronal subtypes or brain regions,
addressing novel questions about the pathogenesis of tauopathies.
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CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS
5.1 The versatility of a nonTg mouse model of tauopathy
The limitations of previous mouse models of tauopathy
In this dissertation, I describe a novel mouse model of tauopathy using
intracerebral injections of human tauopathy lysates in nonTg mice. There have been
several tau transgenic mouse models developed over the years that have been widely
used to understand the pathogenesis of tauopathies (Ballatore et al., 2007), including
our lab’s PS19 mouse model that overexpresses the full-length 2N4R tau isoform with
the P301S familial mutation. However, these transgenic mouse models have major
inherent weaknesses that limit their use in understanding the underlying pathogenesis of
tauopathies and developing novel therapies to treat them.
Transgenic mice typically overexpress the human tau protein, which is not
physiological and does not occur in the human brain. Recent studies in amyloid-beta
(Aβ) plaque-bearing mice have shown that several phenotypes of these mice are an
artifact of the overexpression of APP (Saito et al., 2014). Such findings could confound
many of the studies using tau transgenic mice as well. Furthermore, many transgenic
mice also express the mutant tau protein, usually with the P301S or P301L mutation,
which is aggregation-prone (Lee et al., 2001). However, familial cases of tauopathies
harboring these mutations are rare compared to sporadic tauopathies without mutations,
therefore these mice represent only a small subset of patients with tauopathies.
Furthermore, transgenic mice are often used to study the pathogenesis of tau tangles in
AD, when these tau mutations never occur in AD patients. Finally, transgenic mice use
dissimilar promoters with varied regional expression of the transgene, which confounds
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studies investigating the regional distribution and spatial transmission of tau aggregates
(Ballatore et al., 2007).
Therefore, our new mouse model using nonTg mice addresses the limitations of
transgenic mice and provides a new mechanism to study the pathogenesis of sporadic
tauopathies. We can now sequentially extract insoluble tau from postmortem human
tauopathy brains with higher yield and purity than previously reported, and our methods
have been meticulously described for the reproduction of others (Narasimhan and Lee,
2017). Injection of the human tauopathy lysates into nonTg mice shows cell-to-cell
propagation of tau aggregates across the mouse brain, similar to what has been
described for human AD. Furthermore, several neuropathological features that define
the human tauopathies are recapitulated, including the morphologies of tau pathologies
and the brain regions affected by tau aggregation (based on site of injection).
In addition, this mouse model shows certain populations of neurons are
selectively vulnerable to developing tau aggregates: while the hippocampus is
interconnected with many brain regions, only some of them develop tau pathology after
intracerebral injection. In particular, the mossy fiber cells of the ventral hilus were highly
susceptible to tau aggregate formation when all three tauopathy lysates were injected,
and in the two different sites of injection (hippocampus and thalamus). Selective
vulnerability of specific populations of neurons also occurs in human tauopathies: it has
long been reported that large pyramidal neurons with long projections are most
vulnerable in AD, for example (Hof et al., 1990).

Future uses of our novel nonTg mouse model
To better understand why certain populations of neurons are more vulnerable to
developing tau aggregates than others, we can utilize the TauFlox mice described in
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Chapter 4 to selectively knockout tau in specific neurons. Our lab has previously shown
levels of a-synuclein expression determine vulnerability to synuclein pathology and
toxicity (Luna et al., 2018), and similar future studies could be conducted with tau.
Several Cre lines have already been developed to target specific neuronal populations in
the mouse brain (Madisen et al., 2010). For example, since we observe selective
vulnerability of the mossy fiber cells of the ventral hilus, we can use a Calretinin-Cre line
(as these cells are calretinin-positive) to knockout endogenous tau in those particular
cells. Then we can determine how the transmission of tau aggregates changes in the
mouse brain.
Our model could be further used to test disease-modifying factors for tauopathies
that have been previously described in the literature. In AD, amyloid-beta (Aβ) plaques
are a key co-pathology with NFTs; however, the relationship between Aβ and tau in the
pathogenesis of AD was poorly understood. Since we can now seed endogenous mouse
tau using this new model, we used Aβ-plaque bearing transgenic without crossing to tau
transgenic mice to investigate this relationship. We injected AD-tau into Aβ-plaque
bearing mice and showed the plaques create a unique environment that seeds neuritic
tau plaques first, which can then seed tangles in interconnected regions (He et al.,
2017). We also showed that age, the greatest risk factor for developing AD, plays an
important role in the spreading of tau aggregates: older mice injected with AD-tau
exhibited sustained tau pathology from 3 to 6 months post-injection while younger mice
showed a decline over time (Figure 2-4). Future studies will certainly explore other
genetic and environmental factors implicated in AD and other tauopathies.

Addressing the limitations of this new model
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While our new model clearly addresses the drawbacks of previous tau transgenic
mice, it does have its own limitations that must be addressed. The most significant
phenotype this model does not exhibit is neuron loss; none of the injected mice showed
significant neuron loss up to 9 months post-injection (Figure 2-3). There are several
possible reasons why we did not observe significant neurodegeneration in these mice:
(1) It is possible we did not have long enough post-injection intervals, given that
AD and other tauopathies develop over several years in humans. Although tau
tangles have been described even in younger adults in the locus coeruleus, AD
develops over the course of ten to twelve years, suggesting both the spreading of
tau aggregates and the corresponding neuron loss occurs over a long period of
time. Future studies should consider extending the incubation times to 12 to 15
months to assess neuron loss.
(2) One of the biggest factors we have not fully investigated is the impact of
aging on neurodegeneration. Aging is the greatest risk factor for AD, with the risk
of AD doubling every five years after age 65. While we already show that older
mice injected with AD-tau develop more pathology at 6 months post-injection
(Figure 2-4), we do not yet know if this would correspond to neuron loss with
longer incubations times.
(3) An emerging characteristic of all neurodegenerative diseases is the role of the
brain immune system and neuroinflammation. Neuroinflammation has long been
described as a component of AD and other tauopathies, including increased
astrogliosis and microgliosis in post-mortem AD tissue compared to controls.
Recent genome-wide analyses in AD have also revealed genetic risk factors
affecting microglia and neuroinflammation, such as TREM2 variants (Heneka et
al., 2015). The aberrant neuroinflammatory response in neurodegenerative
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diseases is thought to contribute directly to neurodegeneration, as studies have
shown activated microglia and astrocytes result in neuron death (Heneka et al.,
2015). However, my model currently does not recapitulate the neuroinflammation
observed in tauopathies; future studies investigating the role of immune factors,
such as TREM2 variants, are already underway using our model. We
hypothesize in the setting of neuroinflammation, greater neuron loss would be
observed using this model.
(4) It is possible this model will never show significant neuron loss: in the prion
field, mutant prion protein will propagate pathology in nonTg mice, but without
neuron loss (Hill et al., 2000). It has been shown this is due to a lower prion “titer”
or amount of prion seeds propagated in the nonTg mouse brain; however, longer
incubation times resulted in higher prion titers and eventual clinical disease in
nonTg mice (Hill et al., 2000). We have already shown with our model a minimum
concentration of 1 μg of AD-tau per site of injection is necessary to propagate
significant pathology in nonTg mice, suggesting even higher tau “titers” are
necessary for neurodegeneration.
A second limitation of our nonTg mouse model is that the adult mouse brain only
expresses the 4R tau isoforms, while the human brain expresses all six isoforms of tau.
However, we have now developed in parallel a second mouse model, called the 6htau
mice, which express all six isoforms of human tau (on mouse tau KO background). We
have shown we can use the similar paradigm of injecting human tauopathy brain-derived
lysates into the 6htau mice to investigate the isoform selectivity, in addition to tau strain
properties (He et al, manuscript in preparation).

5.2 The unique properties of tau strains
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A comparison of prion and tau strains
Since the discovery of the prion protein as the primary transmissible agent in
prion diseases, it has been thought a similar mechanism may underlie other
neurodegenerative diseases (Prusiner, 1982). Now after a decade of research, many
studies from our lab and others have demonstrated that tau behaves similarly to the
prion protein (Table 1.1). We have now shown pathological tau aggregates, like prion
aggregates, can propagate from neuron-to-neuron in vitro and in vivo, with misfolded tau
templating normal soluble tau to form larger insoluble fibrils (Figure 1-1).
Prion diseases also have phenotypic diversity, with each prion disease
presenting with different clinical symptoms and neuropathological findings, similar to the
heterogeneity of tauopathies. Specific prion strains have different potencies, incubation
periods, brain regions affected, and neuropathological lesions in mouse models. We
have now demonstrated insoluble tau fibrils can form distinct structural conformations, or
strains, similar to prion strains, which underlie the diversity of prion diseases and
tauopathies (Figure 3-1; Taniguchi-Watanabe et al., 2016; Sanders et al., 2014). These
tau strains also have different potencies, different rates of propagation, and
neuropathological features (including different cell-type specificities), similar to prion
strains. Interestingly, human tau strains do not affect distinct brain regions in our mouse
model, unlike prion strains; instead, we showed the site of initiation of tau pathology, not
the strain, defines which brain networks are affected. Furthermore, our lab has even
shown tau strains can be serially passaged in a mouse brain, with injection of insoluble
tau from one mouse brain into a naïve mouse brain, recapitulating the human
neuropathology, a phenomenon long-described in the prion literature (He et al,
manuscript preparation).
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Despite numerous similarities between the tau and prion proteins, one key
difference remains: the prion protein is an infectious agent that can transmit from
organism to organism, such as bovine spongiform encephalopathy (also known as mad
cow disease) (Collinge and Clarke, 2007). However, no such inter-organism
transmission has been demonstrated for tauopathies. There was a recent study that
suggested patients who develeoped iatrogenic Creutzfeld-Jakob disease (CJD, a prion
disease) after receiving cadaveric human growth hormone (c-hGH) also had amyloid
deposition in the brain at younger ages than the typical onset of AD (Jaunmuktane et al.,
2015). However, the number of patients with any amyloid deposition was small, and
there was no established link between the receipt of c-hGH and amyloid plaques.
Furthermore, a study from our lab several years prior had the complete opposite
findings, with no evidence of increased amyloid plaques in patients receiving c-hGH
(Irwin et al., 2013). Nonetheless, neither of these studies showed any transmission of
tau pathology, indicating tau does not transmit from human to human. This is an
important distinction between tau and prion protein that must be considered as tau
transmission studies are disseminated to the public.

Determining the biochemical and biophysical properties of tau strains
One of the big questions raised by this dissertation is what properties define a
tau strain? Previous studies have shown that insoluble tau aggregates have different
banding patterns following limited proteolysis, and the core of the insoluble tau fibril
differs between tauopathies with mass spectrometry (Sanders et al 2014; TanaguchiWatanabe et al 2016). Those results suggested that tau fibrils may form distinct
structural conformations, or strains. We have now demonstrated insoluble tau from
different tauopathies have different stabilities in a strong denaturing reagent (GuHCl;
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Figure 3-1), a biochemical assay commonly used to distinguish prion strains. However,
all of these experiments thus far only indirectly shown tau fibrils can form unique
structural conformations. There are additional properties of tau fibrils that must
investigated to fully define each unique strain, such as isoform composition, posttranslational modifications, and the 3-D structure.
It has long been known each tauopathy incorporates a different combination of
tau isoforms in the insoluble tau aggregates (Lee et al., 2001). AD-tau tangles contain all
six isoforms of tau, including both 3R and 4R tau; in contrast, CBD and PSP only include
the 4R tau isoforms, while Pick’s disease only incorporates the 3R tau isoforms.
However, the underlying mechanism of isoform specificity in these diseases is still
unknown. Studies have shown 4R tau is more prone to aggregation than 3R tau, and 3R
tau can inhibit the fibrillization of 4R tau in vitro (Adams et al., 2010). While one study
showed 4R tau can only seed 4R tau aggregates (and the same for 3R tau), it was
conducted with heparin in vitro (Dinkel et al., 2011). In contrast, we showed when
seeding AD-tau fibrils, the 3R and 4R tau isoforms incorporate randomly in vitro, so 4R
can seed either 3R or 4R (and vice versa) (Guo et al., 2016). Nonetheless, we have only
recently begun to understand why different tau isoforms aggregate in the human
disease.
Using the 6htau mouse model, we have now shown AD-tau will seed both 3R
and 4R in vivo, while CBD-tau and PSP-tau will only seed 4R tau, and Pick’s (PiD-tau)
will only seed 3R tau (He et al, manuscript in preparation). This data now shows
insoluble tau aggregates from each of these diseases will preferentially seed one set of
tau isoforms based on the original fibril composition. Yet, this data also brings up the
question: do tau isoforms alone account for all the biochemical differences between tau
strains?
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There is some controversy in the literature about whether differences in tau
isoforms can be defined as unique tau strains when the primary amino acid sequence
differs between isoforms. However, according to the prion literature, the primary
sequence of a protein does not define the strain property; in other words, if a strain can
be passaged into different primary sequences but still maintain its biochemical and
phenotypic properties, it is considered a unique strain (Collinge and Clarke, 2007). I
have already illustrated AD-tau, CBD-tau, and PSP-tau can be seeded into adult nonTg
mouse brain, which is only 4R tau, and yet recapitulate the same phenotypic properties
of the original human tauopathies (Chapter 3).
Furthermore, our new study using 6htau mice demonstrates that the differential
isoform recruitment of each tauopathy is not based on the original isoform composition:
we show when AD-tau is seeded into nonTg mice and then passaged into 6htau mice, it
will still seed both 3R and 4R tau, despite the tau seeds now only containing 4R mouse
tau (He et al, manuscript in preparation). We conclude that because the isoform
recruitment is a property that can be maintained even with serial passaging through
different primary sequences, human tau fibrils do fit the definition of a true strain.
Moreover, while isoform composition is one biochemical difference between different tau
strains, it does not fully define the properties of each tau strain. Therefore, there must be
additional biochemical or structural features that distinguish tau strains.
One potential biochemical feature that could define unique strains is the posttranslational modifications (PTMs) of tau fibrils. The PTMs of tau protein have been
highly studied, both for physiological tau and in the context of disease, as described in
Chapter 1. There are ~40 phosphorylation sites identified on the tau protein, some of
which are only found in disease (Brunden et al., 2009). The most well studied sites
congregate around the microtubule-binding domain, and have been shown to reduce
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microtubule binding affinity and may also enhance aggregation (Brunden et al., 2009).
Other PTMs associated with tau aggregation in diseased brains are acetylation, Oglycosylation, sumoylation, ubiquitination, and nitration (Brunden et al., 2009). The
spectrum of PTMs in normal, endogenous mouse tau has also been thoroughly
characterized (Morris et al., 2015).
However, differences in PTMs between human tauopathies could also exist,
thereby defining new tau strains based on the pattern of PTMs. In the prion field,
differences in PTMs of the prion protein define diverse protein conformations (AguilarCalvo et al., 2017). Therefore, it is quite possible certain PTMs on tau aggregates also
contribute to the different fibril conformations. Thus far, there has been no study directly
comparing the PTMs from one tau strain versus another strain. One of the technical
challenges has been purifying sufficient quantities of insoluble tau aggregates from each
of the tauopathies to perform mass spectrometry analysis to differentiate PTMs for each
strain. However, with our new method of extraction of tau aggregates from human
tauopathy brains (Narasimhan and Lee, 2017), coupled with new techniques in
quantitative mass spectrometry for distinguishing PTMs (i.e., FLEXITau; Mair et al.,
2016), we can begin to identify unique PTMs for each strain. Then, each of those PTMs
can be further studied using our in vitro and in vivo models (described in Chapters 2 and
3) to determine which PTMs define certain tau strain properties.
Nonetheless, all of the potential future studies described above will only indirectly
address whether tau fibrils actually form different structural conformations. In order to
directly visualize the structure of tau fibrils in each of these tauopathies, more complex
techniques like cryo-EM will need to be utilized. Recent breakthroughs in cryo-EM
technology have now defined the tau fibril structure of AD-tau (Fitzpatrick et al., 2017).
This study published for the first time a high-resolution structure of tau fibrils from AD
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human brain. They showed two different conformations of AD-tau, the primary paired
helical filament (PHF), as well as straight filaments, both with filament cores defined by
two identical protofilaments of residues 306 to 378 of tau protein, suggesting
conformational diversity even within a single tauopathy. A new study now shows
insoluble tau from Pick’s disease forms a different structural conformation than AD-tau,
already confirming true distinct conformations or strains of tau exist in human brain
(Falcon et al., 2018). Future studies can utilize the new cryo-EM technology, along with
our new purification protocol of tau fibrils from other tauopathy brains, to characterize
specific structural differences between tau strains.

The biological mechanisms of tau strain formation
Thus far, I have described different biochemical and biophysical studies that
could be performed to identify a unique tau strain that defines each tauopathy. However,
this is based on the assumption that each tauopathy contains only one unique strain,
which is unlikely to be true, particularly given the insights from the prion literature. It is
more likely that, since tau is an intrinsically disordered protein that can acquire multiple
different conformations, there is an ensemble of different tau fibril conformations that
exist at any given time. It is hypothesized from the prion literature that there is a
dominant tau strain, which is thermodynamically favored to emerge as the primary strain
among this ensemble of different tau conformations (Collinge and Clarke, 2007).
However, it is also possible there are several tau strains within this ensemble that
propagate tau aggregates and may even define specific properties: for example, there
may be one strain responsible for neuronal tau pathology and another for glial tau
pathology (see Chapter 5.3 below). Until more detailed biophysical studies are
conducted to determine all the structural conformations within the insoluble tau
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aggregates derived from human brain, we will not know how many such tau strains exist
in each tauopathy. In particular, recent cryo-EM studies create an average structural
conformation from many different tau fibrils, and are therefore not able to fully
differentiate multiple strains within a single preparation (Fitzpatrick et al., 2017). It will
also be critical to faithfully propagate these human tau strains using recombinant tau
fibrils to investigate how dominant tau strains emerge and how they dictate specific
phenotypes.
To add further complexity, it is also possible for tau strains to evolve or “mutate,”
either as they propagate through one diseased brain or as they are serially passaged in
mouse models like our own. In the prion field, such mutation has been described with
serial passaging of prion strains: prion strain conformations sometimes change as they
are passaged from one species to another, either due to differences in primary
sequence between the seed and host prion protein, or due to other cellular or genetic
factors (Collinge and Clarke, 2007). This evolution of tau strains could also occur, due to
the new environment now thermodynamically favoring a different dominant strain from
the ensemble, or due to an actual conversion of the original dominant strain to a new
conformation. It is even possible that with inoculation of human tau strains into a nonTg
mouse brain, we are changing the original strain conformation: however, since the
neuropathological features in our mouse model mirrors the human disease, we are still
likely preserving some, if not all, of the tau strain conformations necessary for disease
propagation.
If tau strains really can evolve, it is then also possible they evolve as they
propagate throughout a single human brain, with the dominant or ensemble tau
conformations changing as the seeds enter new cell types in a different brain region. Our
data with a single PSP case shows that tau strains extracted from different brain regions
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all had the same properties in our mouse model: they had the same potencies and celltype specificities as the strain from the frontal cortex. We hypothesized that in certain
PSP cases, a dominant tau strain propagates throughout the human brain rapidly, and
therefore does not mutate as it spreads. However, it is still conceivable that for other
PSP cases or other tauopathies, such evolution can occur within a single human brain.
Since the human post-mortem tissue we selected for our study was mostly from endstage disease, we are only observing a snapshot of tau strains at the end of their
evolution. Future studies investigating early to late-stage tauopathies, and from different
brain regions, will determine whether tau strain conformations can mutate over time.
What selective forces determine how a dominant tau strain emerges and how it
may evolve over time? There are certainly genetic modifiers that could influence the
development of different tau strains for each tauopathy. While many genetic variants
increasing the risk of AD affect amyloid-beta processing or deposition (Scheuner et al.,
1996), there are other rare variants that have also been implicated in tau pathogenesis,
such as TREM2 mutations (Leyns et al., 2017; Bemiller et al., 2017). Similarly, the
H1/H2 haplotype in the MAPT gene confers risk for CBD and PSP, and other variants in
genes such as STX6, EIF2AK3, SOS1 and MOBP increase risk for PSP and/or CBD
(Hoglinger et al., 2011). Some of these variants have been shown to increase MAPT
expression, while others play some role in tau aggregation and pathogenesis.
Certain variants may also contribute to the transmission of the tau strains:
currently the rare TREM2 variants increasing the risk of AD are being investigated for
their role in cell-to-cell propagation of tau pathology. In addition, we have identified
one variant in valosin-containing protein (VCP) that results in a tauopathy phenotype;
pathological tau extracted from this VCP case spreads in a different pattern than AD 141

tau in our nonTg mouse model (Darwich et al, unpublished data). It is quite possible
some of these variants or other genetic/epigenetic factors also contribute to the
formation of distinct tau strains in each of these diseases. In addition, it is unknown
how mutations in the MAPT gene itself affects the structural conformation of tau
fibrils, so future studies using human brains from familial FTDP-17 cases should be
used to study those conformations.
Our data already suggests the cellular environment may be critical to the rise of
certain dominant strains. We showed in Chapter 3 that different tau strains do not dictate
specific brain regions that are affected by tau pathology. Instead, we show where the tau
pathology initiates then determines how the aggregates spread along anatomically
connected networks. This data suggests that there are unique sites of initiation for each
tauopathy, which thereby results in different brain regions affected in the human disease.
Staging data using human post-mortem brains have shown there are different sites of
initiation for AD, CBD, and PSP (Braak and Braak 1991; Ling et al., 2016; Williams et al.,
2015). Furthermore, a different study from our lab investigating α-synuclein strains has
indicated the oligodendrocyte cellular environment actually creates a highly potent glial
cytoplasmic inclusion (GCI) strain found in multiple system atrophy (Peng et al., 2018).
This data is one of the first pieces of evidence to demonstrate how the cellular milieu
may be critical in favoring certain strains that have specific properties. Moreover, it also
indicates tau aggregates formed in neurons versus glia may have different
conformations and thereby explain some of the selectivity for each cell type (see
Chapter 5.3 below).
Future studies should investigate whether unique cellular environments
contribute to tau strain formation. In particular, these studies should determine what
142

components of the cellular environment are important in creating thermodynamically
favorable environments for particular dominant strains. In the prion field, certain prion
strains are cleaved by cellular proteases, thereby preventing further seeded fibrillization;
if there are similar factors affecting tau cleavage, certain cell types would cleave some
tau strains and not others (Collinge and Clarke, 2007). There are other proteins already
implicated in the misfolding (or refolding) of tau, such as Hsp chaperones, whose
expression levels in different cell types could create unique cellular environments
favorable for tau aggregation.
The protein quality control system is also highly studied for its role in tauopathy
pathogenesis; the role of the ubiquitin/proteasome, lysosome, and autophagy pathways
in preventing tau misfolding and their failure in neurodegenerative disease has mostly
been investigated to identify therapeutic targets (McClellan et al., 2005). However, it is
also possible these systems contribute to how the tau protein misfolds and forms
different structural conformations. In order to study which cellular factors affect the
emergence of unique tau strains, we will need to first isolate and study the specific celltypes in the initiation site of each tauopathy. With the advent of single-cell sequencing
techniques to interrogate different subsets of neuronal populations, such studies are
more promising in the near future.
Finally, there are many environmental factors that increase the risk for AD and
other tauopathies, including toxic pollutants, dietary factors (possible affecting the
microbiome), physical exercise, and other comorbid diseases (Mattson, 2004). It is still
unclear how most of these factors confer risk or protect from the development of
neurodegenerative disease, but it would be interesting to test how they would affect tau
strain formation or propagation. These studies could utilize our mouse model and
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determine if any of these factors change the phenotypic properties of one or more
human tau strains following injection into mouse brain.

5.3 Insights into the role of glial tau pathology in tauopathies
While the first half of this dissertation describes the development of novel
methods and mouse models to study the properties of human tau strains, the second
half focuses on a poorly studied component of tauopathies: glial tau pathology. Glial tau
pathology has long been described in the tauopathy literature, with glial tau aggregates
being a major component of several tauopathies, including CBD, PSP, Pick’s, GGT, and
ARTAG. In GGT and some cases of CBD and PSP, glial tau pathology is the most
prominent pathology observed in post-mortem human brain tissue (Ahmed et al., 2011).
However, the mechanisms of glial tau pathology formation have been poorly understood
until now.
It was long thought tau was only expressed in neurons, although a growing body
of literature now suggests tau is also expressed in glial cells (Kahlson and Colodner,
2015). In rat oligodendrocytes in culture, tau protein is involved in early axonal contact,
microtubule stabilization during process formation, and myelination (Kahlson and
Colodner, 2015). There is less evidence for tau expression in astrocytes, although recent
RNAseq data suggests there is significant MAPT mRNA expression, albeit at a much
lower level than neurons or oligodendrocytes (Zhang et al., 2014; Zhang et al., 2016). It
is unclear if the MAPT mRNA gets translated into tau protein in astrocytes, as we could
not detect any tau protein expression in cultured astrocytes (Figure 4.1).
Despite the evidence for tau expression in glial cells, especially
oligodendrocytes, it was hypothesized that glial cells acquired tau aggregates via some
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mechanism of uptake from neurons. With the recent body of literature supporting the
prion-like transmission of tau aggregates in neurons, many hypothesized that this
transmission of tau pathology could also occur from neurons to glia. However, until this
dissertation, there was no method to test whether tau aggregates form independently or
via transmission from neurons to glial cells.
Using the CreFlox model system, we developed a novel neuronal tau KO mouse
model, now dubbed the TauKOn mice. Based upon the methods developed in Chapter
3, we injected CBD-tau into the hippocampus/cortex of the TauKOn mice to show initially
at three months, glial tau pathology forms independently of neuronal tau pathology
(Figure 4.5). However, the subsequent spreading of glial tau pathology has a unique
relationship to neuronal tau pathology. Astrocytic tau pathology did not spread from the
initial site of injection in the TauKOn mice, suggesting astrocytes cannot independently
transmit tau aggregates in the absence of neuronal tau transmission. In contrast,
oligodendroglial tau aggregates continued to spread from the ipsilateral to contralateral
side of injection in the TauKOn mice, showing oligodendroglial tau transmission can
occur in the absence of neuronal tau transmission. Overall, the data reveals unique
relationships between neuronal and glial tau pathology in tauopathies.
There is a great diversity of astrocytic tau pathology in tauopathies, ranging from
tufted astrocytes (PSP) to astrocytic plaques (CBD), to thorn-shaped astrocytes
(ARTAG) and globular astrocytic inclusions (GGT) (Kahlson and Colodner, 2015).
However, it has been unclear what accounts for this heterogeneity, although some
studies have suggested different astrocyte subtypes could give rise to different tau
morphologies (Kahlson and Colodner, 2015). Our data shows astrocytic tau
morphologies can be recapitulated in a strain-specific manner, suggesting the structural
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properties of tau strains from different tauopathies determines the variation in astrocytic
tau pathology (Figure 3-3).
While the differences in astrocytic tau morphologies have been carefully
characterized, thus far no clear mechanism of astrocytic tau aggregate formation has
been described. Initially, it was thought astrocytes become reactive and develop tau
pathology in response to neuron tau pathology and degeneration. One study showed
thorn-shaped astrocytic tau pathology occurs in reactive astrocytes in ARTAG (Ikeda et
al., 1985). However, another study showed tufted astrocytes in PSP do not correlate with
the extent of neuron tangles, neuron loss, or reactive astrogliosis, suggesting astrocytic
tau pathology is an independent degenerative process and not a reactive process (Togo
and Dickson 2002). Taken together, it appears some forms of astrocytic tau pathology
may be a reactive process while others are an independent degenerative process. In this
dissertation, we show that astrocytic tau aggregates can initially form in the absence of
neuronal tau expression or pathology, suggesting the formation of astrocytic tau
pathology is independent from neuronal tau pathology (Figure 4-5). However, the
spreading of astrocytic tau pathology only occurs in the context of neuronal tau
pathology, suggesting the appearance of astrocytic tau aggregates in new regions is a
reactive process secondary to the transmission of neuronal tau.
This raises the question of whether astrocytes truly express their own
endogenous tau or if the initial formation of astrocytic tau pathology in TauKOn mice
comes from another cell type. In particular, we cannot rule out whether astrocytic tau
pathology arises from oligodendroglial tau pathology, although the two types of
pathology occur in spatially distinct regions (Figure 4-5). The only way to determine
exactly how astrocytes develop tau pathology would be to knockout endogenous tau in
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astrocytes. Future studies can utilize the TauFlox mice and cross them to GFAP-Cre
mice for astrocyte-specific knockout of tau to test this hypothesis.
In contrast, oligodendrocytes clearly express their own endogenous tau, and can
both form and spread tau pathology without neuronal tau pathology. Ultrastructural
studies of oligodendroglial tau pathology in agyrophilic threads have shown tau
aggregates form in the inner and outer loops of myelinating oligodendrocytes, showing
that the extensive white matter pathology observed in some tauopathies at least partly
occurs in oligodendroglial processes (Arima et al., 1997). Furthermore, the close
proximity of tau aggregates to myelin sheaths in oligodendrocytes suggests a
relationship between myelination and initial tau aggregate seeding. We showed in our rat
oligodendrocyte culture model that tau pathology co-localizes with myelin marker MBP,
further confirming this hypothesis (Figure 4-3).
In the TauKOn mouse model, oligodendrocytes develop tau pathology in white
matter tracts such as the fimbria and corpus callosum in the absence of neuronal tau
pathology. In particular, oligodendroglial tau aggregates continued to spread across
these white matter tracts from 3 to 6 months post-injection of CBD-tau, even in the
absence of neuronal tau pathology. While the exact mechanism of this spreading is still
unknown, since oligodendroglial tau pathology co-localizes with MBP, it is possible
oligodendrocytes can transmit small pathological seeds via myelin sheaths across these
white matter tracts. It is also possible that even in the absence of neuronal tau
expression or pathology, small pathological seeds can travel via neuronal axons and
seed endogenous tau in oligodendrocytes on the other side. Future studies should use
EM to identify ultrastructurally the location of tau seeds in the TauKOn mice, particularly
if there are seeds inside neuronal axons or myelin sheaths.
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Strain-specificity of neuronal and glial tau pathology
While we now have a much clearer understanding of the relationship between
neuronal and glial tau pathology in vivo, the larger question that remains is: how do tau
strains determine cell-type specificity? In other words, why does AD-tau only seed in
neurons, while CBD-tau and PSP-tau can seed in neurons, oligodendrocytes, and
astrocytes? There are several possible hypotheses that could explain how different tau
strains could dictate tau pathology in one cell type over another: (1) entry into the cell;
(2) seeding of endogenous tau in the cell; (3) refolding/degradation of tau aggregates in
the cell.
(1) One possible mechanism by which to achieve cell-type specificity is to select
for different strains at the point of entry into the cell. For example, it is
possible there are different receptors that bind to specific tau strains, or
different mechanisms of endocytosis for one tau strain versus another.
Studies have shown tau seeds are internalized primarily by bulk endocytosis
(Frost et al., 2009; Guo and Lee, 2011); however newer studies have
identified a couple of receptors tau aggregates bind to before being
internalized (Holmes et al., 2013; Falcon et al., 2017 JBC; Guo and Lee,
2011). Yet, no study has described different receptors binding to different tau
strains, although now with our in vitro primary neuron model, we can assess
the mechanisms of tau strain internalization.
(2) If it is possible for all tau strains to enter every cell, then another possible
mechanism for cell-type specificity is mismatch of conformations of tau seeds
and endogenous tau in each cell type. In the prion literature, there is a well148

documented species barrier, whereby certain prion strains from one species
cannot seed prions from another species because the conformations
between the two strains are too different (Collinge and Clarke, 2007).
Similarly, there may be a cell-specific barrier, where endogenous tau in
neurons and glia may acquire different conformations as the misfold, and
there is a barrier between misfolded tau strains in one cell type versus
another. Therefore, while AD-tau seeds derived primarily from neurons may
enter glial cells, they may not be able to efficiently template the endogenous
tau in glial cells, thus resulting in cell-type specificity. In order to test this
hypothesis, we would need to isolate insoluble tau aggregates from regions
with purely neuronal tau pathology and purely glial tau pathology to compare
the structural conformations between the tau strains. If we can also
successfully propagate tau strains from each cell type using recombinant tau,
we can determine if there is a conformational seeding barrier between one
cell type and another.
(3) A third possible mechanism for cell-type specificity of tau strains is different
rates of cleavage or degradation of misfolded tau in each cell type. While all
tau strains may enter and seed endogenous tau in every cell, it is possible
that there are different protein quality control mechanisms in neurons,
astrocytes, and oligodendrocytes so certain strains get degraded more
quickly in one cell type. For example, AD-tau may be more easily degraded in
astrocytes and oligodendrocytes than neurons, so only neuronal pathology
persists, while CBD-tau and PSP-tau are not as easily degraded and develop
insoluble tau aggregates in all cell types. Additionally, some studies have
shown the role of different Hsps in oligodendroglial tau inclusion formation,
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suggesting there are different protein clearance mechanisms in each cell type
(Richter-Landsberg and Bauer 2004). If we can successfully label tau fibrils
from each strain with fluorescent tags, in conjunction with membraneimpermeable fluorescent quenchers developed in our lab, we can track how
different tau strains get internalized and possibly degraded in neuronal versus
glial cell culture models (Karpowicz et al., 2017).
The functional consequences of glial tau pathology
Although the extent and morphology of astrocytic and oligodendroglial tau
aggregates has been extensively studied in tauopathies, the functional consequence of
glial tau aggregation is still poorly understood. Oligodendroglial tau pathology has a
potential detrimental role in human tauopathies, although this has not been extensively
studied. Oligodendrocytes express tau normally, and tau expression is involved in MBP
transport and differentiation of oligodendrocytes into myelinating cells. When tau
expression is increased or decreased from its normal balance, there are impairments in
MBP transport and myelination (Richter-Landsberg and Bauer 2004). Furthermore,
oligodendrocyte tau inclusions have been shown to disrupt myelin sheath maintenance
(Kahlson and Colodner 2015). In GGT, oligodendroglial globular inclusions have been
associated with loss of MBP and myelin disruption (Rohan et al., 2016). However, the
effect of oligodendroglial tau inclusions on clinical symptoms or disease progression will
be an important future study from this work.
Similarly, it is unclear what detrimental effects astrocytic tau pathology has on the
progression of human tauopathies. Astrocytic tau aggregates have been shown to
correlate with specific clinical symptoms such as aphasia, movement disorders, and
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psychiatric symptoms in ARTAG (Kovacs et al., 2017). In contrast, incidental astrocytic
tau pathology in CBD with no clinical symptoms has also been described, obscuring the
role of tau aggregates in astrocytes in clinical disease. Future human studies will need to
carefully investigate neuronal and glial tau pathology to determine their individual effects
on clinical symptoms and disease progression in tauopathies.
While it has been challenging to determine the functional effects of glial tau
pathology in humans, a few studies described in Chapter 4 have examined the effect of
glial tau pathology using mouse models. Mice overexpressing human wild-type or
mutant tau under the astrocytic promoter GFAP (GFAP-tau) developed age-dependent
astroglial tau inclusions; in addition, they also had mild blood-brain-barrier (BBB)
disruption and glutamate transporter function, indicating a detrimental effect to
astrocytes (Format et al., 2005, Dabir et a., 2006). Likewise, mice overexpressing wildtype human tau in oligodendrocytes under the CNP promoter (CNP-tau) had myelin
disruption (Higuchi et al., 2005). Other transgenic mice overexpressing human tau
formed tau pathology in astrocytes and oligodendrocytes before neurons, with
subsequent motor deficits, gliodegeneration, and myelin disruption (Higuchi et al., 2002).
In addition to deleterious effects on the glial cells themselves, overexpression of
tau in astrocytes or oligodendrocytes may cause neuronal deficits and degeneration.
Overexpression of tau in cultured astrocytes results in cytoskeletal collapse and cell
death, while overexpression of tau in cultured oligodendrocytes results in
oligodendrocyte degeneration (Yoshiyama et al., 2003; Richter-Landsberg 2008)
Overexpression of tau in astrocytes results in neuron death in Drosophila (Colodner and
Feany, 2010), and age-dependent neuron axonal injury and motor deficits in GFAP-tau
mice, suggesting astrocytic tau accumulation also had secondary harmful effects in
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neurons. Similarly, overexpression of tau in oligodendrocytes leads to subsequent
axonal degeneration (CNP-tau mice), and neuron death (Colodner and Feany, 2010).
There is also an interaction between neuronal and glial tau pathology, as overexpression
of tau in neurons or both neurons and glia resulted in neuronal and glial degeneration
(Colodner and Feany, 2010). Taken together, these data indicate, at least in transgenic
mouse models that overexpress tau, glial tau pathology can have severe detrimental
consequences in the mouse brain.
However, as described earlier in this chapter, transgenic mouse models have
several important limitations, so future studies should use the TauKOn mouse model
that develops glial tau pathology without overexpression of tau in glial cells to investigate
functional effects. To further investigate the individual roles of astrocytes and
oligodendrocytes in the formation of glial tau pathology, a future study should also use
astrocyte-specific Cre mice (GFAP-Cre) and oligodendrocyte-specific Cre mice (PLPCre) to knockout tau in those respective cell types. These mice can help us further
understand both the normal function of tau in these cell types, as well as the interaction
between neurons, astrocytes, and oligodendrocytes in the progression of tau pathology.

5.4 The clinical and therapeutic significance of tau strains
The utility of tau strains in the diagnosis of tauopathies
In this dissertation thus far, I have described how tau strains may underlie the
molecular pathogenesis of tauopathies, and our advances in understanding the basic
biology of human tau strains by developing novel models. While understanding the basic
mechanisms of disease pathogenesis is fascinating for its own sake, ultimately our goal
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is to use the information gathered to inform clinical practice. So how can tau strains play
a role in the clinical diagnosis of tauopathies?
One key finding from our studies is the vast diversity of human tau strains, not
just between different tauopathies, but also within a single tauopathy like PSP. PSP has
now been characterized as a diverse clinical disease, with several different subtypes that
can be hard to differentiate clinically because of varied symptoms from patient to patient
(Williams et al., 2009). In particular, it is difficult to diagnose PSP if the classical
constellation of symptoms including vertical gaze palsy of Richardson’s syndrome is not
present. Furthermore, each subtype has a different clinical prognosis, and progression of
the disease can vary greatly for each PSP patient (Williams et al., 2009). However, in
Chapter 3, we described how different PSP brains contain unique tau strains whose
heterogeneous properties are represented in the seeding of primary neuron cultures
(Figure 3.2). In particular, we identified a potent tau strain in the frontal cortex of PSP
brains with abundant cortical tau pathology; these cases represent a rare subtype of
PSP in which tau pathology progresses quickly throughout the brain. Thus, using the
techniques described in Chapter 3, we can identify the different tau strains found in each
subtype of PSP to better classify PSP brains post-mortem. Yet, post-mortem
classification of PSP or other tauopathies using diverse tau strains is not sufficient to
help patients who currently suffer with the disease. Therefore, we need to co-opt
methods of identifying tau strains to clinical diagnosis, and thereby apply a type of
personalized medicine to patients with tauopathies.
Currently, diagnosis of tauopathies primarily consists of a clinical diagnosis, with
a trained neurologist assessing the patient or family’s self-reported symptoms and
specific signs identified on the neurological exam. However, the accuracy of clinical
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diagnosis when compared to neuropathological confirmation can range anywhere
between 50 to 80%, with higher rates for AD and lowest rates for CBD (Beach et al.,
2012). In particular, overlapping symptoms between CBD and PSP or atypical
presentations of AD make diagnosis based on purely clinical signs and symptoms
challenging.
In response to this challenge, several biomarkers have been developed to assist
in the diagnosis of AD in particular. Most patients undergo a brain MRI to look for medial
temporal lobe atrophy, particularly hippocampal atrophy, or reduced cortical thickness in
advanced disease (Galasko and Shaw, 2017). Lumbar punctures to analyze CSF
biomarkers are also used more routinely, with low Aβ1-42 and high total tau and phosphotau levels indicative of AD. Finally, with the new advent of PET imaging of Aβ, patients
with high amyloid-plaque burden can be identified for the diagnosis of AD, or low plaque
burden for exclusion (Galasko and Shaw 2017).
While these biomarkers are more commonly used now in clinical diagnosis of
AD, their utility in the diagnosis of FTLD-tau is less clear. While grey matter atrophy on
MRI can be used to differentiate FTLD from AD or normal controls, it cannot differentiate
between FTLD subtypes. Likewise, while CSF biomarkers of tau and Aβ can be used to
distinguish between AD and FTLD, no specific tau/phospho-tau levels have been clearly
linked to one FTLD subtype versus another (Meeter et al., 2018).
However, now the discovery of different human tau strains allows for finer
biomarker testing, particularly with CSF analysis. For example, real-time quakinginduced conversion (RT-QuIC), which uses human CSF samples to seed recombinant
prion protein, has been used to distinguish different prion strains (Cramm et al., 2016).
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Furthermore, ultrasensitive detection of small amounts of prion strains from CSF
samples is also being developed (Bieschke et al., 2000). If such ultrasensitive
techniques could be coupled with conformational-selective antibodies for the different
human brain-derived tau strains, we could differentiate one tau strain from another to
specifically diagnose each subtype of FTLD.
A new biomarker that is being actively developed is tau-PET imaging; several
different tau PET ligands have been investigated and some can identify AD-tau with
fairly high sensitivity and specificity (Meeter et al., 2018). However, one of the key issues
with tau PET ligands is that they do not bind to all tau forms equally: there is differential
binding of some ligands to 3R versus 4R tau aggregates, and more recent evidence
suggests some ligands bind better to neuronal versus glial tau pathology (Meeter et al.,
2017). This data further supports the idea of different tau strains in each of these
diseases, as some PET ligands may bind better to one structural conformation of tau
versus another. If these ligands are further tested for clinical use, a broader
understanding of tau strains is necessary to determine which strains bind which ligands,
and whether some ligands can be developed to bind multiple strains. Thus, tau PET
imaging will have high utility for both AD and FTLD clinical diagnosis.
Addressing tau strains in the development of therapeutics for tauopathies
While understanding the biology of tau strains can aid in the diagnosis of
tauopathies, the more pressing clinical application is in developing novel therapeutics for
these devastating diseases. The current landscape of therapeutics for AD and other
tauopathies has shifted to include: (1) modulating tau phosphorylation; (2) inhibiting tau
fibrillization/increasing tau degradation; and (3) tau immunotherapy (Khanna et al.,
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2016). However, without a deeper understanding of the tau strains involved in these
human diseases, there will be many challenges in pursuing these lines of therapeutic
development.
First, as discussed earlier in this chapter, one of the differences between tau
strains could be different PTMs; thus, targeting specific phosphorylation sites may only
affect some tau aggregates and not others, even within one tauopathy and certainly
between different tauopathies. Second, if there are different mechanisms of formation of
unique tau strains, based upon distinct cellular environments, inhibiting the fibrillization
of one strain using one pathway will not affect the aggregation of other strains. Similarly,
tau strains may have different rates of degradation, through different protein clearance
pathways, so which pathway to target becomes less clear. Finally, as monoclonal tau
antibodies are developed for passive immunotherapy in AD and other tauopathies, the
question of conformational selectivity arises: would these antibodies bind to and target
all tau conformations or only a subset? We recently showed we could develop
conformational-selective antibodies for AD-tau by immunizing mice with the AD-tau
derived in Chapter 1; these antibodies only recognize tau aggregates in AD and not the
other tauopathies (Gibbons et al., 2017). In the future, we will either need to develop
anti-tau antibodies for each tau strain for more “personalized” immunotherapy options, or
develop anti-tau antibodies that can recognize multiple conformations of tau aggregates.
Furthermore, any new therapeutics developed for tauopathies other than AD
should also be evaluated for their effects on glial tau pathology. Given that tau
aggregates form independently in neurons versus glia, the resulting drugs will also need
to target each cell type independently. In particular, since we still do not fully understand
the functional consequence of glial tau pathology in the human disease, reducing tau
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aggregates in glial cells may or may not be beneficial for the patient. Even if it is
beneficial, until glial cell biology is investigated more thoroughly, we will not know the
differential effects of drugs targeting neurons or glial cells. Fortunately, our new TauKOn
mouse model only develops glial tau pathology, which can be used to test any new
therapies for glial cell specificity.
This discussion of the development of novel therapeutics targeting tau assumes
any therapies that are discovered will be tested for all tauopathies, not just AD. While
there is a huge therapeutic need to find new treatments for AD, given that it is the most
common neurodegenerative disease, the other tauopathies can be equally debilitating
albeit less common. In particular, CBD and PSP have an earlier age of onset and much
shorter clinical duration, affecting people in the prime of their life. Thus far, research into
AD has also been informative for other tauopathies; however, all of the work described in
this dissertation demonstrates how tau strains differentiate these diseases, calling into
question the relevance of research in AD to the other tauopathies. However, as we
further study the properties of tau strains, we can use what we learn about the
dissimilarities between tauopathies to find unifying factors. Thus, as novel therapies are
developed, they can impact the lives of a larger number of patients living with these
devastating diseases.
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